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Abstract 
The definite hemodynamic diagnosis of pulmonary hypertension (PH) requires 
direct measurement of the pulmonary artery pressure by right heart 
catheterisation. As right heart catheterisation is an invasive test with a small risk 
of associated morbidity and mortality, diagnostic algorithms have been devised 
that combines clinical history and examination, cardio- respiratory assessment by 
non-imaging techniques and subsequently imaging techniques in patients 
suspected of having PH. The aim of these initial investigations is to establish a 
tentative diagnosis of PH, help identify the underlying aetiology and to provide 
information regarding disease severity and determine response to treatment. 
Although PH is a disease of the pulmonary vasculature, it is the subsequent right 
ventricular (RV) failure that is the main cause of morbidity and mortality in PH 
patient. Thus, RV is the most widely studied of the chambers in PH, however focus 
has started to move to the left ventricle (LV). Although a disease of the pulmonary 
circulation and the RV, there is now evidence demonstrating LV abnormalities in 
PH. Further to this, the atrial chambers offer valuable information when 
measuring cardiac function as well as in identifying the aetiology of PH. Small 
animal (rodent) models are increasingly used to identify pathophysiology as well 
as therapies for PH with the intention of translating the findings to humans. 
Accurate monitoring of disease in rodents with emphasis on ventricular function 
and the ability to monitor the disease state without killing the animal is needed.  
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1.1 Definition and haemodynamic classification of 
pulmonary hypertension.  
Pulmonary hypertension (PH) is defined in guidelines as a resting mean pulmonary 
artery pressure (mPAP) ≥ 25mmHg measured at right heart catheterisation, 
resulting from a variety of conditions that can affect the pulmonary circulation 
(1). However, there are recent proposals to change the haemodynamic definition 
of PH and this will be discussed later in this chapter (2, 3). There is a progressive 
increase in pulmonary vascular resistance (PVR), which causes right ventricular 
(RV) failure and premature death. The term “primary pulmonary hypertension” 
was first reported in 1951 in a study of 39 patients with PH (4). However, the first 
description of the disease probably happened in 1891 by Ernst Von Romberg who 
described an autopsy as pulmonary arterial sclerosis (5). The 1st world symposium 
on PH organised by the World Health Organisation (WHO) in Geneva in 1973 was 
devoted to primary PH, few years after an outbreak related to the anorexigen 
Aminorex (6). In 1961, a report from the WHO expert committee on cor-pulmonale 
stated that mPAP does not normally exceed 15 mmHg in a healthy subject in 
supine position, however, in the World Symposium it was recognised the upper 
limit of normal mPAP was 25 mmHg. This was arbitrarily defined but this 
conservative cut-off value was used to discriminate patients with primary PH from 
severe PH due to other causes including lung diseases. This definition remained 
unchanged during the subsequent World Symposia from 1998 to 2013 at least in 
part to preclude potential over diagnosis and over treatment of PH (3).  
In the first definition of the disease in 1973 in Geneva, the disease was classified 
as primary, secondary and associated PH (6). Since then subsequent world 
symposia have developed a more comprehensive clinical classification system 
based on 5 main groups of PH. Clinical classification as proposed at the 6th World 
Symposium on PH is summarised in Table 1.1 (3). The studies included in this thesis 
were conducted in patients with pulmonary arterial hypertension (PAH, Group 1 
PH) unless otherwise stated.     
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Table 1.1 Clinical classification of pulmonary hypertension 
 
1 PAH 
 1.1 Idiopathic PAH 
 1.2 Heritable PAH 
 1.3 Drug- and toxin-induced PAH  
 1.4 PAH associated with: 
  1.4.1 Connective tissue disease 
  1.4.2 HIV infection 
  1.4.3 Portal hypertension 
  1.4.4 Congenital heart disease 
  1.4.5 Schistosomiasis 
 1.5 PAH long-term responders to calcium channel blockers 
 1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement  
 1.7 Persistent PH of the newborn syndrome 
2 PH due to left heart disease 
 2.1 PH due to heart failure with preserved LVEF 
 2.2 PH due to heart failure with reduced LVEF 
 2.3 Valvular heart disease 
 2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH 
3 PH due to lung diseases and/or hypoxia 
 3.1 Obstructive lung disease 
 3.2 Restrictive lung disease 
 3.3 Other lung disease with mixed restrictive/obstructive pattern 
 3.4 Hypoxia without lung disease 
 3.5 Developmental lung disorders 
4 PH due to pulmonary artery obstructions  
 4.1 Chronic thromboembolic PH 
 4.2 Other pulmonary artery obstructions 
5 PH with unclear and/or multifactorial mechanisms  
 5.1 Haematological disorders 
 5.2 Systemic and metabolic disorders 
 5.3 Others 
 5.4 Complex congenital heart disease 
 
Modified from Simonneau et al (3). The clinical classification of PH is intended to categorise PH to 5 
groups of clinical conditions according to clinical presentation, pathological findings, hemodynamic 
characteristics, and treatment strategy. 1 - pulmonary arterial hypertension, 2 - pulmonary 
hypertension due to left heart disease, 3 - pulmonary hypertension due to lung diseases and/or 
hypoxia, 4 - chronic thromboembolic pulmonary hypertension and other pulmonary artery 
obstructions, and 5 - pulmonary hypertension with unclear and/or multifactorial mechanisms. 
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1.1.1 Right heart catheterisation  
Right heart catheterisation is the gold standard for diagnosis of PH. Apart from 
mPAP other haemodynamic measurements are taken during right heart 
catheterisation to characterise the pulmonary vasculature (7).  
1. Cardiac output – cardiac output is usually measured by thermodilution or 
the estimated oxygen uptake Fick method.  
2. Pulmonary Artery Wedge Pressure (PAWP) also known as pulmonary artery 
occlusion pressure and pulmonary capillary wedge pressure – this is 
measured by wedging the catheter in a branch of the pulmonary artery and 
inflating the balloon to a wedge position and reflects the pressure of the 
left atrium (LA). Elevated PAWP >15 mmHg is suggestive of left sided 
cardiac disease.  
3. Pulmonary Vascular Resistance (PVR) – this is calculated by (mPAP – PAWP) 
/ CO 
1.1.2 Upper limit of normal pulmonary artery pressure 
As mentioned in chapter 1.1, the existing haemodynamic definition of PH had been 
based on a relatively arbitrary figure of mPAP ≥ 25 mmHg. However, in 2009 Kovacs 
et al analysed all available data obtained by right heart catheterisation in healthy 
individuals to determine the normal values of mPAP (8). In a large dataset of 1187 
healthy subjects mPAP at rest was 14.0 ± 3.3 mmHg; this value was independent 
of ethnicity and gender, and was not significantly affected by age and posture.  
Considering this value of 14 mmHg, two standard deviations would suggest mPAP 
> 20 mmHg as above the upper limit of normal. This haemodynamic definition is, 
therefore, no longer arbitrary, but based on a scientific approach. Thus, the most 
recent World Symposium of PH has proposed to reconsider the haemodynamic 
definition of PH to mPAP > 20mm Hg. However, they also recognised an isolated 
mPAP > 20 mmHg is not sufficient to define PH as this level of pressure rise could 
be due to an increase in cardiac output and PAWP. The task force has therefore 
proposed including a PVR ≥ 3 Wood Units (WU) into the definition of pre-capillary 
PH associated with mPAP > 20 mmHg, irrespective of aetiology (2, 3). However, 
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as most of the research included in our thesis predates this recent proposal, we 
have considered mPAP ≥ 25 mmHg as indicative of PH for the purpose of this thesis. 
1.1.3  Idiopathic pulmonary arterial hypertension 
Idiopathic pulmonary arterial hypertension (IPAH) is a rare disease causing 
progressive pulmonary vasoconstriction, leading to RV failure and death. It is 
diagnosed after exclusion of other causes of PAH (group 1 PH) as shown in Table 
1.1 (9). The annual incidence of IPAH has been estimated at 1-3.3 cases per million 
per year. Progressive shortness of breath is the common presentation and 
exertional chest pain, pre-syncope and syncope may occur. With further decline 
in RV function, leg swelling can occur. IPAH is often diagnosed at an advanced 
stage in terms of symptom burden as well as haemodynamic severity.  
1.2 Treatment  
The treatment of PAH has significantly advanced in recent years. Five different 
classes of drugs are now available targeting 3 pathways i.e., Endothelin receptor 
antagonists, Phosphodiesterase 5 inhibitors, Soluble Guanylate Cyclase inhibitors, 
Prostacyclin analogues and Prostacyclin receptor antagonists. Studies have shown 
evidence that various combinations of these drugs to improve morbidity and 
survival in patients with PAH (10). In patients with left sided heart disease or lung 
disease causing PH (group 2 and group 3), the use of pulmonary vasodilator 
treatment has not shown to be safe or effective. For chronic thromboembolic PH 
(CTEPH) pulmonary endarterectomy (PEA) is the treatment of choice (11). In 
patients with inoperable CTEPH, Riociguat has proven efficacious (12). Other 
interventional options, including balloon pulmonary angioplasty has become a 
treatment option for these patients (13). Existing pharmaceutical treatment 
options for PH are shown in Figure 1.1. 
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Figure 1-1 Evolution of current treatment options for patients with pulmonary arterial 
hypertension. 
Modified from Gaine et al (10). Five different classes of drugs are now available i.e., Endothelin 
receptor antagonists, Phosphodiesterase 5 inhibitors, Soluble Guanylate Cyclase inhibitors, 
Prostacyclin analogues and Prostacyclin receptor antagonists. Studies have shown various 
combinations of these drugs to improve morbidity and survival in patients with PAH. 
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1.3 Non-invasive imaging in PH 
The hemodynamic diagnosis of PH requires direct measurement of the pulmonary 
artery pressure by right heart catheterisation using a Swan-Ganz catheter. As right 
heart catheterisation is an invasive test with a small risk of associated morbidity 
and mortality, diagnostic algorithms have been devised that combines clinical 
history and examination, cardio- respiratory assessment by non-imaging 
techniques and subsequently imaging techniques in patients suspected of having 
PH (7, 14). The aim of these initial investigations is to establish a tentative 
diagnosis of PH.  These imaging investigations also help to identify the underlying 
aetiology. Subsequently, guidelines recommend that the diagnosis of PH to be 
confirmed by right heart catheterisation. The initial tests will provide information 
regarding disease severity and will be used to monitor disease progression as well 
as response to treatment. Advanced imaging techniques may also help us to 
understand the cellular and molecular mechanisms responsible for the 
pathophysiology of PH in both the pulmonary circulation and the RV (15).   
While it is noted that the RV is the most widely studied of the chambers in PH, 
focus has started to move to the left ventricle (LV).  Although a disease of the 
pulmonary circulation and the RV, there is now evidence demonstrating LV 
abnormalities in PH (16, 17). Further to this, the atrial chambers offer valuable 
information when measuring cardiac function as well as in identifying the 
aetiology of PH (18). Small animal (rodent) models are increasingly used to 
identify pathophysiology as well as therapies for PH with the intention of 
translating the findings to humans (19). Accurate monitoring of disease in rodents 
with emphasis on ventricular function and the ability to monitor the disease state 
without killing the animal is needed.  
The existing literature on imaging of the pulmonary circulation and the RV, 
particularly focusing on cardiac MRI (CMR) will be reviewed in the introduction of 
this thesis. Subsequently the rationale of the work undertaken in this thesis will 
be discussed. The introduction will also discuss the shifting of focus from the RV 
to the left heart and the importance of non-invasive imaging techniques in 
translational medicine. Finally, the aims and hypothesis of this thesis are 
introduced.  
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1.4 Echocardiography 
 
1.4.1 Morphological assessment of the right heart and pulmonary 
circulation 
Two-dimensional echocardiography using a subcostal or an apical 4-chamber view 
has been used to determine variables of RV morphology in patients with PH.  Both 
RV end diastolic volume (RVEDV) and RV end diastolic volume indexed to body 
surface area (RVEDVI) have shown to correlate with mPAP (20, 21). However, RV 
volume calculation by two-dimensional echocardiography is extremely challenging 
due to the retrosternal location of the RV as well as it’s heavily trabeculated 
border. Measurements of RV free wall thickness and RV mass are also less practical 
due to the complex RV shape. The systolic and the diastolic positioning of the 
inter-ventricular septum (IVS) can be used to differentiate RV dilatation secondary 
to RV pressure overload from RV dilatation due to RV volume overload. In RV 
pressure overload the leftward IVS displacement is maximum at end-systole while 
RV volume overload due to increased RV preload resulted in predominantly end-
diastolic IVS displacement (22). LV eccentricity index is the ratio of the length of 
two perpendicular minor axis diameters, which are obtained at both end-systole 
and end-diastole. One of these bisected and was perpendicular to the IVS. Ryan 
et al demonstrated that this index was 1.0 in normal subjects while it was greater 
than 1.0 in both end-systole and end-diastole in RV pressure overload.  In RV 
volume overload the index was significantly increased at end-diastole, and 
approximately 1.0 at end-systole (23).  
1.4.2 Haemodynamic assessment of the right heart and the 
pulmonary circulation 
From the velocity of blood driving through a cardiac orifice, pressure is calculated 
using the modified Bernoulli equation (pressure gradient, ∆P = 4V2 mmHg). From 
the apical 4-chamber view, tricuspid valve regurgitant jet velocity is used to 
calculate the tricuspid regurgitant pressure gradient (TRPG). From this, systolic 
pulmonary artery pressure (sPAP) can be calculated using the equation sPAP = 
TRPG + right atrial pressure (RAP) (24).  RV systolic pressure (RVSP) is equivalent 
to sPAP assuming that there is no RV outflow tract stenosis. Right atrial pressure 
is required to calculate sPAP from TRPG.  Inferior vena cava (IVC) diameter of 
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more than 1 cm and an IVC area of more than 2 cm2 measured by echocardiography 
was a sensitive and a specific measure of raised RAP (8mm Hg) (25). Kicher et al 
suggested the percentage collapse of IVC during inspiration and expiration (caval 
index) as a predictor of RAP (caval index < 50% indicate RA pressure ≥  10 mm Hg) 
(26).  
1.4.3 Echocardiography definition of PH  
Pulmonary hypertension has an invasive haemodynamic definition of mPAP of ≥ 25 
mmHg during right heart catheterisation. Various attempts have been made to 
define PH based on non-invasive echocardiographic findings. Thus, these studies 
focused on finding the upper limit of normal sPAP or TRPG by echocardiography. 
In a study of 53 healthy people, TRPG ranged from 12.6 to 29.3 mmHg. The study 
authors concluded that TRPG of 30 mmHg should be considered the upper limit of 
normal (27). In a large database analysis of the Massachusetts General Hospital, 
among 3790 normal subjects, the estimated upper 95% limit for sPAP was 37.2 
mmHg (RAP = 10mmHg). A sPAP > 40 mmHg was found in 6% of those >50 years old 
and 5% of those with a BMI > 30 kg/m2 (28). Syyed et al demonstrated a relationship 
between sPAP measured by echocardiography and right heart catheterisation 
derived mPAP. This linear relationship (sPAP = 1.5 * mPAP + 0.46) was maintained 
following changes in activity and posture (29).  
The European Society of Cardiology and European Respiratory Society guidelines 
suggest grading the probability of PH based on tricuspid regurgitant velocity (and 
TRPG) and on the presence of additional echocardiographic variables. The 
probability of PH may be determined as high, intermediate or low probability and 
when interpreted in a clinical context can be used to decide on the need for right 
heart catheterisation(30).  
1.4.4 Pulsatile pulmonary haemodynamics 
Doppler techniques studying the flow velocity patterns of the RV outflow tract 
have been used to identify patients with PH. Kitabake et al identified 
characteristic abnormalities in the pulmonary valve motion in PH including rapid 
opening slope in systole and mid-systolic semi-closure of the pulmonary valve. In 
patients with PH, the flow velocity pattern demonstrated a rapid acceleration 
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reaching a peak level sooner than the normal cohort. Mid systolic notching due to 
a secondary slower rise during deceleration was also observed. They observed that 
the time to peak flow (AcT) and the ratio AcT/RVET (Right ventricular ejection 
time) decreased with rising pulmonary artery pressure (31). However ACT was also 
longer in patients with low cardiac index, congenital heart disease (32, 33) and 
shorter in patients with high body surface area and proximal pulmonary emboli 
(34, 35).  
1.4.5 Prognostic staging and follow up 
Echocardiographic evidence of pericardial effusion, right atrial enlargement and 
septal displacement during diastole predicted adverse events in patients with PH 
and these are important in terms of prognosis in these patients (36). The Tei index 
or the myocardial performance index is a strong predictor of clinical status and 
survival in patients with PH. The Tei index is relatively unaffected by heart rate, 
RV pressure, RV dilatation or tricuspid regurgitation. The index is calculated using 
tissue Doppler recordings and is defined as (A-B)/B where A is the time interval 
between the end and onset of the trans-tricuspid flow and B is the right ventricular 
ejection time (RVET). The A interval includes the isovolumetric contraction time 
(IVCT), isovolumetric relaxation time (IVRT) and the RVET, thus the Tei index can 
also be expressed by the formula (IVCT + IVRT) /RVET (37). Using animal studies, 
Cheung et al demonstrated that the Tei index was significantly affected by 
changes in preload and afterload (38). 
Tricuspid annular systolic plane excursion (TAPSE) is the most commonly used 
echocardiography derived prognostic indicator in PH. The RV contraction 
predominantly occurs on a longitudinal plane. Thus the displacement of the 
tricuspid annulus towards the RV apex is reflective of RV contraction, thus RV 
ejection fraction. TAPSE has shown to be highly reproducible and practical (39, 
40). Fofia et al demonstrated that a TAPSE of less than 1.8 cm was associated with 
greater RV systolic dysfunction and right heart remodelling. A high TAPSE of 1.8 
cm or more predicted survival with a 1 and 2-year survival rates of 94% and 88% 
compared to 60% and 50% in the low TAPSE group (41). In a study of 59 patients 
with IPAH, the group with TAPSE ≤ 15 mm and a left ventricular eccentricity index 
≥1.7 had the highest adverse event rates (42). It is important to note that TAPSE 
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could be pseudo-normalised in significant volume loading as seen in left to right 
shunting or severe functional TR.  
1.4.6 Differential diagnosis 
Echocardiography may also aid in identifying the cause of PH including left heart 
disease, congenital cardiac diseases and valvular heart diseases. It may also help 
in identifying alternative causes of RV dilatation including RV arrhythmogenic 
dysplasia and RV infarction (43).  
1.4.7 3D Echocardiography 
RV measurements by 2-dimensional echocardiography are difficult due to its 
complex shape.  3-dimensional echocardiography (3D Echo) has been used 
frequently in the volumetry of the LV.  Grapsa et al measured RVEDV and end-
systolic volumes (RVESV), stroke volume and RV mass and compared these findings 
with CMR. Although CMR showed less inter-observer variability for some measures, 
RV volume and mass were similar for CMR and 3D echo in PH patients (44). In 
patients with dilated RV, 3D echocardiography has the disadvantage of suboptimal 
images, and the resulting exclusion of the RV free wall from the imaging has led 
to inaccurate volumes. As an alternative to this, Bhave et al suggested using a 
“knowledge-based reconstruction” method for 3D modelling of the RV 
endocardium from 2D images. This involved acquiring 2D images localised in 3D 
space by a magnetic field generator located under the patient and a magnetic 
field sensor, then using a reconstruction algorithm to construct a 3D model. This 
is based on identifying specific landmarks and a reconstructing algorithm using 
these landmarks to fit sub regions of the RV to hearts in a database of patients 
with similar pathology. These provided valuable and accurate RV volumes, which 
compared well with CMR, but larger studies are required (45). 
1.5 Chest radiography 
Plain chest radiography (Chest X-ray) is inexpensive, widely available and in 
combination with echocardiography provide the first clue to the presence of PH. 
Enlargement of pulmonary arteries, cardiac enlargement, particularly the right 
sided chambers and rapid tapering of the pulmonary vessels as they extend to the 
periphery are all chest X-ray features of PH. There is also peripheral pruning 
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(reduction of the size of intrapulmonary vessels) (46). Transverse diameter of the 
proximal inter-lobar pulmonary artery on posterior-anterior chest radiograph that 
exceeds 16 mm in men and 15 mm in women is a useful measurement for 
enlargement of the central pulmonary arteries, likely to be due to PAH in the 
absence of a left-to-right shunt (47).  
Kanemoto et al reviewed 59 chest radiographs in patients with “primary PH”. They 
compared five measured values between normal control and primary PH group. 
DPA/ (T/2), which is an indicator of the degree of protrusion of the main 
pulmonary artery, where DPA is the width of the main pulmonary artery from the 
midline and T is the thoracic diameter (divided by half thoracic diameter to 
eliminate differences) was significantly higher in the primary PH group. The 
average width of the descending branch of the right pulmonary artery (dPA) was 
more than twice that of the control group (12.1 to 25.1). The PL/T index (The 
point of union of the external border of the upper lobe artery with the pars 
interlobaris = point L, the sum of horizontal distances of the right and left L to 
the midline = pulmonary lobar diameter, PL) was increased in the “primary PH” 
population (48). Previously Lupi et al had suggested that the PL/T index as a 
radiological index suggesting PAH (49). The normal values for the width of the 
descending branch of the right pulmonary artery has been reported as 9-13 mm 
by Schwedel et al (50) 9-16 mm by Simon et al (51) and 9-16 mm for men and 9-
15 mm for women by  Chang et al (52).  
In CTEPH apart from features of peripheral oligaemia there may be asymmetry of 
hilar vessels when thrombosis occurs in central pulmonary arteries. Woodruff et 
al reviewed 22 chest radiographs of patients with CTEPH (53). Cardiac 
enlargement was defined by a cardiothoracic ratio of more than 0.5 and RV 
enlargement was defined by a retrosternal cardiac silhouette height greater than 
one-third the distance between the anterior cardiophrenic sulcus and the angle of 
Louis. All the patients in both operative and non-operative groups had abnormal 
chest radiographs. Nineteen patients had cardiomegaly and 13 of these had 
predominantly RV enlargement. A value of 0.23 for the ratio of the diameter of 
the main PA to the diameter of the left hemithorax was considered normal in a 
previous study and all but one patient had a higher ratio in this study. Twelve 
patients had enlarged right descending pulmonary arteries (16 mm for men and 15 
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mm for women). Specific areas of diminished vascularity were found in about two 
third of the patients and these were confirmed by pulmonary angiography. 
Findings of an abnormal chest radiograph in this study and in a further study by 
Tilkian et al (54) were in contrast to previous studies by Moser et al (55) and 
Benotti et al (56) who concluded most patients with CTEPH have normal chest 
radiographs.  
The aforementioned characteristic chest X-ray findings are only likely to be visible 
in severe disease limiting the use in diagnosing early or mild PH. Chest X-ray will 
also provide valuable information regarding the cause of PH during the diagnostic 
workup including parenchymal lung disease and left heart disease (24).  
1.6 Ventilation perfusion scintigraphy 
Ventilation Perfusion scintigraphy (V/Q scan) is recommended in the diagnostic 
workup of PH. Its main role is in distinguishing CTEPH from other types of PH (57, 
58). Acute or chronic pulmonary embolism results in a characteristic wedge-
shaped defect on the perfusion scan that corresponds to the thrombotic occlusion 
and the normal ventilation images produce the V/Q mismatch.  
Worsley et al demonstrated that a high probability V/Q scan had sensitivity and 
specificity of 96 % and 94 % respectively in detecting CTEPH and when high and 
immediate probability scans were combined the sensitivity was 100% at the 
expense of reduced specificity of 86%. None of the patients with a low probability 
scan had CTEPH (59). In a larger study of 227 patients by Tunariu et al, when only 
high probability scans were considered as suggestive of CTEPH the sensitivity was 
96% with a specificity of 95%. When both high and intermediate probability scans 
were considered suggestive of CTEPH the specificity fell to 90% (57). These and a 
number of other studies demonstrate that V/Q scanning is a highly sensitive test 
for suspected CTEPH. Grouping intermediate probability results with low 
probability results provide a highly sensitive and specific investigation in the 
diagnosis of CTEPH. However mismatched defects at V/Q scanning maybe seen in 
patients with IPAH presumably due to thrombosis in situ (58). An abnormal 
perfusion scan similarly can be observed in large vessel vasculitis (60), fibrosing 
mediastinitis (61), pulmonary artery sarcoma (62) and pulmonary veno-occlusive 
disease (63).  
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Multi-detector CT pulmonary angiography (CTPA) has replaced V/ Q scanning as 
the investigation of choice in the diagnosis of acute pulmonary embolism. 
However, the role of CTPA in detecting CTEPH is variable. Pitton et al showed 
multi-detector CTPA to have a sensitivity of 70.4% for segmental and 63.6% for 
sub-segmental branches when compared to pulmonary digital subtraction 
angiography (DSA) (64). The retrospective review by Tunariu et al confirmed that 
normal V/Q scintigraphy excluded CTEPH whereas normal CTPA did not (57). In 
the CTEPH group in this study, CTPA was reported as showing features suggestive 
of CTEPH in 40 of the 78 patients with a false negative report in 38 of the 78 
(sensitivity 51%). A CTPA report was considered as suggestive of CTEPH, if it stated 
visualisation of the thrombus, calcified thrombus, recanalization, sudden change 
of vessel calibre, strictures, post-stenotic dilatation, webs or perfusion 
abnormalities. The presence of mosaicism was also noted but its presence alone 
without other features was not considered diagnostic of CTPEH.  
On planar imaging, the detection of perfusion defects is dependent on camera 
position and the anatomical location of the defects, thus there is the potential 
that a defect can be masked if superimposed over normal lung. Single – photon 
emission computed tomography or SPECT scanning overcomes this by producing 
three-dimensional imaging data. Soler et al demonstrated higher sensitivity of 
SPECT scanning with minimal change to specificity in CTEPH patients (65).  
1.7 Computed Tomography (CT) 
There have been significant advances in CT scanning in recent years. There have 
been advances in contrast enhancement, post-processing power and sub 
millimetre thick slices. CT scanning is usually performed as part of the early 
diagnostic assessment in patients presenting with shortness of breath or atypical 
chest pain. CT scanning has the advantage of not just imaging the lung 
parenchyma but the heart,mediastinal structures and the pulmonary arteries in 
patients presenting with PH. CT scanning aids identifying parenchymal 
abnormalities that can occur sometimes in the presence of normal spirometry, CT 
pulmonary angiography will help assessing the pulmonary vasculature in PH 
patients. Other imaging biomarkers including RV to LV ratio, left atrial size and 
PA size are also derived from CT. CT will also aid in the classification of PH into 
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WHO groups (66).  Due to repeated exposure to radiation, CT scanning is not 
routinely used in monitoring disease progression and response to treatment.  
1.7.1 The main pulmonary artery (Main PA) 
There have been various studies examining the reliability of the diameter of the 
main PA being a non-invasive surrogate of PH. The intra-pericardial main PA 
cannot be measured by plain chest radiography. However, it can be measured by 
CT. A diameter of the main PA of more than 28.6 mm predicted PH in an early 
study of 32 patients. The best estimate of PA pressure was given by the calculated 
cross sectional area of main and inter-lobar arteries normalised to body surface 
area (67).  
Ng et al measured the main PA diameters at a defined level, where the right 
pulmonary artery is in continuity with the main PA and sweep across the midline. 
The ratio of the main PA to the ascending aorta as well as main PA alone were 
related to mPAP (68). In younger patients (<50), mPAP correlated more with the 
ratio than the dimeter of the main PA alone. This is probably due to a gradual 
increase in the diameter of the aorta with advancing age. Another advantage of 
using the ratio of the main PA: aorta is the degree of internal normalisation with 
the lack of dependence on body surface area and gender, as both influence the 
pulmonary artery and aortic diameters to an equal degree. In another study where 
the main PA was measured at the widest portion of the main pulmonary artery 
within 3 cm from the bifurcation, PA diameter of ≥29 mm had a sensitivity of 87%, 
a specificity of 89% and a positive predictive value of 0.97 for predicting PH. 
Mahammedi et al attempted to establish the best method to measure the main 
PA by CT in suspected PH (69). The most reproducible method with the least inter-
observer variability was the method in which the axial diameter of the main PA 
was measured along the line that originates from the centre of the adjacent aorta 
and passes perpendicular to the long axis of the main PA at the level of PA 
bifurcation.  A main PA diameter of > 31.5 mm demonstrated sensitivity and 
specificity 52% and 90% respectively. A main PA: aorta of > 1 was 71% sensitive 
and 76% specific for PH. Truong et al used the transverse axial diameter of the 
main PA and the ascending aorta at the level of the bifurcation of the right PA. 
They established a 90th percentile sex-specific cut-off value for main PA for men 
of 29mm and women of 27mm and found an association with dyspnoea using the 
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aforementioned cut-off values. Interestingly they did not find an association with 
dyspnoea when using a 90th percentile cut off value of 0.9 or commonly used value 
of 1.0 for the pulmonary artery: aorta ratio (70).  
As noted above, there is a large variation both in terms of the methodology and 
the reported cut-off diameter of the main PA on CT when determining dilatation.  
1.7.2 Beyond the main pulmonary artery 
The studies that measures the calibre of right and left PA and the right inter-lobar 
artery did not appear to offer an advantage over main PA measurements on the 
strength of correlation with right heart catheter derived mPAP. In a study by Tan 
et al, they looked at CT determined measurements of main PA, right and left PA 
and the ratio between segmental arteries and their corresponding bronchi (ABR). 
An ABR of more than 1:1 in three of four lobes were higher in the PH population 
compared to the control group (65% vs 22 %). The apical segmental arteries and 
the bronchi of the upper lobes and the posterior basal segmental arteries and the 
bronchi of the lower lobes were chosen for this study (71).  It is important to note 
that solitary segmental artery enlargement may be seen in normal subjects as well 
as patients with regional lung abnormalities such as pulmonary fibrosis. In this 
study the combination of a main PA diameter of or more than 29 mm and an ABR 
of more than 1:1 in three or four lobes was the most specific finding for the 
presence of PH (specificity 100%). 
Hypertrophy of the bronchial arteries is a well-recognised radiological feature on 
conventional angiography and CT pulmonary angiography (CTPA) in patients with 
CTEPH. Although the mechanism of bronchial artery hypertrophy is not completely 
understood, their role is thought to be to maintain the viability of the lung 
parenchyma after pulmonary artery occlusion. Hypertrophied bronchial arteries 
are easily identified on CT and are usually not visualised in normal individuals. 
Remi-Jardin et al defined bronchial artery hypertrophy as a curvilinear 
mediastinal vessel of more than 1.5 mm diameter, which is seen along the course 
of the proximal bronchial tree. In an earlier study of patients with primary PH and 
CTEPH, they suggested that visualisation of bronchopulmonary collaterals and 
demonstration of bronchopulmonary collateral flow were a distinguishing feature 
of CTEPH from those with primary PH. However, more recent studies have 
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demonstrated bronchial artery hypertrophy to occur in patients with IPAH as well 
as Eisenmenger’s syndrome (72). 
A study by Shimizu et al showed that in CTEPH patients the cross-sectional area 
of bronchial arteries correlates to the extent of central pulmonary thrombus. 
When they grouped the CTEPH patients into main, lobar and segmental type based 
on the most proximal location of thrombi, they did not find any significant 
difference between the total area of bronchial arteries in segmental type CTPEH 
and PAH patients. The cross sectional area of bronchial arteries did not have a 
significant correlation with mPAP or PVR but their presence predicted a better 
post-surgical outcome (73).  
1.7.3 Cardiac signs 
ECG gated CT can be used to obtain information regarding ventricular function 
and to detect congenital cardiac abnormalities.  However, conventional CT 
provide information about the heart that can be used in the diagnostic workup in 
patients suspected of having PH. An axial RV to LV ratio of more than 1:1 at the 
mid ventricular level is indicative of RV enlargement. There may be paradoxical 
bulging of the IVS towards the LV, although this is better appreciated in cine 
review of ECG gated studies. When CT features of PH are associated with left 
sided cardiac chamber enlargement, pulmonary venous dilation and interlobular 
septal thickening, this is suggestive of pulmonary venous hypertension with a 
possible left heart cause. Thickening and calcification of the mitral valve leaflets 
with associated left atrial enlargement, which is suggestive of mitral valve disease 
and aortic valve calcification, and LV hypertrophy suggestive of aortic valve 
disease can be identified on conventional CT. Left atrial myxomas, by interfering 
with mitral valve function and pulmonary vein drainage can occasionally present 
with PH and can be identified as a well-defined intra-cavity mass with low 
attenuation (74-76). 
The presence of contrast in the IVC or hepatic veins during first pass contrast 
enhanced chest CT is associated with tricuspid regurgitation. The extent of 
contrast reflux was associated with PA pressures measured at right heart 
catheterisation as well as the severity of tricuspid regurgitation by 
echocardiography (77). It is important to note that although this is a specific sign 
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of TR, the specificity decreases at higher contrast injection rates of greater than 
3ml/sec (78). 
Pericardial effusions are common in patients with severe PH and this was 
demonstrated in a multicentre trial of patients with severe PH on prostacyclin. 
The 1-year mortality in patients with small or moderate effusions was three times 
that of patients with trace or no effusions. The presence of an effusion also 
correlated with right atrial size, severity of tricuspid regurgitation and reduced 6-
minute walk test (79). On CT pericardial effusions create an infilling of the space 
between the main pulmonary artery and ascending aorta which is known as the 
“bikini bottom sign”. 
1.7.4 Lung parenchyma 
Mosaicism of the lung parenchyma is characterised by sharply demarcated areas 
of heterogeneous attenuation that predominantly conform to the boundaries of 
the secondary pulmonary lobules. In the context of PH this is most commonly seen 
in patients with CTEPH. In CTEPH, mosaicism corresponds to V/Q mismatch. The 
darker areas represent hypoperfusion while the higher attenuation areas 
correspond to normal or hyperperfusion. However mosaicism is not specific for 
CTEPH and can be seen in patients with small airways diseases as well as 
infiltrative lung diseases (80). In small airways disease expiratory HRCT 
demonstrate air trapping which caused an increase in the conspicuity of the 
mosaic pattern. It was initially thought that this could be used to differentiate 
CTEPH from small airways disease but studies have reported air trapping as well 
as bronchial dilatation in patients with CTEPH (81, 82). 
1.7.5 CT in chronic thromboembolic pulmonary hypertension 
Contrary to the findings in acute pulmonary emboli, which result in a concavity 
within the contrast material on angiography, CTEPH may lead to a complete vessel 
cut off which appears as a convex margin of contrast material on CTPA. In a 
complete obstruction the distal vessel diameter will be decreased, and the 
pulmonary artery diameter may be increased at the site of the thrombus. In a 
partial obstruction CTPA findings include abrupt vessel narrowing, irregularity of 
the intimal surface contour and intravascular bands and webs. Bands are thin 
39 
 
structures attached to the vessel wall that can be up to 20 mm in length with a 
free mid portion. Webs are a descriptive term for a complex network of bands. 
These features seen in pulmonary angiography represent organising thrombi. 
Chronic organising thrombi can rarely be calcified (83). Pulmonary artery diameter 
may be increased with a raised main PA to ascending aorta ratio as described 
earlier in the section 1.6.1. The RV undergoes hypertrophy and subsequently 
dilates with RV failure. There may be displacement of the IVS towards the LV 
during systole. The reflux of contrast material to the inferior vena cava or hepatic 
veins maybe observed which would indicate tricuspid regurgitation. Bronchial 
artery hypertrophy as well as enlarged non-bronchial systemic arteries are more 
common in patients with CTEPH compared to other forms. The key parenchymal 
imaging feature of CTEPH is mosaic attenuation pattern of the lung parenchyma. 
Pulmonary infarcts may be visible especially at the lower parts of the lung as 
wedge shaped or linear, peripheral, irregular densities (84). They are due to 
occlusion of segmental and smaller pulmonary arteries and occur commonly in 
peripheral type CTEPH.  
The morbidity and mortality from Pulmonary Endarterecomy (PEA) has fallen 
significantly over the last few years. Several studies have concentrated on imaging 
features that help predict surgical success in patients undergoing PEA. In a study 
by Bergin et al CTPA evidence of extensive central vessel disease and limited small 
vessel involvement predicted a favourable post-surgical outcome (85). In a study 
by Shimizu et al the total area of bronchial arteries correlated to the central 
extent of thrombi and also predicted the gas exchange improvement after PEA 
suggesting that these patients had a lower proportion of distal vascular disease 
(73). The presence of peripheral sub pleural densities, which reflect pulmonary 
infarcts commonly seen in peripheral type CTEPH demonstrated a positive 
correlation with postoperative PVR, which may lead to a poor postoperative 
outcome. 
1.7.6 CT in pulmonary veno-occlusive disease 
Pulmonary veno-occlusive disease (PVOD) is a rare cause of PH where there is 
involvement of the post- capillary vasculature. It is difficult to make this diagnosis 
in vivo and a histopathological diagnosis using open surgical biopsy is usually 
contraindicated in these patients due to general frailty of this patient group.  Two 
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studies that retrospectively identified fifteen and eight patients with PVOD, 
studied the radiological features that would assist non-invasive CT assessment in 
these patients (86, 87). The most common CT findings were septal lines, ground 
glass opacities particularly with a centrilobular distribution and lymphadenopathy. 
In the absence of other causes of PH; e.g.; CTEPH and left sided heart disease, 
adenopathy was highly specific for PVOD. Normal left sided cardiac chambers and 
normal PAWP allows distinction of PVOD from pulmonary venous hypertension. 
1.8 Cardiac Magnetic Resonance imaging 
1.8.1 Ventricular volume, structure and function 
Although PAH is a disease of the pulmonary vasculature, it is the subsequent RV 
failure that is the main cause of morbidity and mortality in patients with PAH. 
Plain chest radiography and CT scanning do provide some information about RV 
structure; however, they do not give information regarding RV function. Although 
echocardiography is widely available RV volume and function calculation by two-
dimensional echocardiography is extremely challenging due to the retrosternal 
location of the RV as well as the heavily trabeculated border (section 1.3). 
Cardiac magnetic resonance imaging (CMR) is a non-invasive imaging tool and 
provides high-resolution 3D images of the heart (15). Short axis stacks are used to 
reconstruct a 3D image of the RV and LV and ventricular volumes and wall mass 
can be measured covering the entire cardiac cycle. Endocardial and epicardial 
contours are drawn at end-diastole and end-systole during post processing of 
images and ventricular volumes are calculated using the “Simpsons rule”, which 
takes the sum of individual slice volumes and the inter-slice gap into account. 
From the volume changes of the RV over time, systolic and diastolic function can 
be derived. New software solutions with semi-automatic analysis have resulted in 
decreased post processing times. The inter-study reproducibility and accuracy of 
CMR measurements using a semiautomatic analysis have been validated in several 
reports (88, 89). Velocity encoded cine CMR images are used to quantify PA flow. 
The aorta flow can be measured in the same plane and the ratio of pulmonary 
artery: aorta flow (Qp: Qs) and vice versa can be used to assess intra-cardiac 
shunts. Beerbaum et al concluded that the calculation of Qp: Qs by CMR to be 
quick, safe and reliable in children with cardiac defects (90). 
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The ability to determine RV systolic function by conventional echocardiography 
based on volume calculations is limited. Although contrast-enhanced 3D 
echocardiography has become available recently and has shown to be useful in 
assessing RV mass and RV ejection fraction, CMR remains the gold standard(44). A 
large number of studies using CMR imaging in patients with PAH have been 
published. Many CMR measures have shown to be strongly predictive of mortality 
and survival thus offering potential for monitoring and assessing response to 
treatment.  
Of these, Stroke volume (SV) is recognised as a key MR prognostic measure in PAH 
patients. Van Wolferen et al investigated the prognostic significance of a variety 
of LV and RV structural and functional measurements in patients with IPAH (91, 
92). They showed that a low SV at baseline is a predictor of poor prognosis. They 
also showed that SV rather than cardiac index to have a stronger correlation with 
prognosis in these patients, possibly explained by the fact that there may be 
compensatory increase in heart rate which will flaw the relationship between 
cardiac output and prognosis. The results in this study also suggested that a 
decrease in SV during treatment to be an indicator of treatment failure. Although 
results were comparable when SV were measured by CMR or with the Fick method, 
CMR underestimated SV. This is probably explained by turbulent blood flow 
patterns observed in the main PA. This was evident both at baseline as well as 
follow up. In a large single centre cohort of patients with systemic sclerosis 
associated PH, stroke volume index (SVI) was a strong predictor of survival. There 
was two-fold increased risk of mortality in patients with a SVI of > 30ml/m2 (93). 
Van Wolferen et al evaluated 111 patients at baseline and at 1 year follow up to 
identify a minimally important difference in SV in patients with PH. They used 
both an anchor based method (using 6 minute walk distance as anchor) and a 
distribution-based method and showed a 10 ml change in stroke volume during 
follow up should be considered as clinically relevant (94).   
Right ventricular ejection fraction (RVEF) is also an important prognostic factor in 
patients with PH and is poorly derived by conventional echocardiography. A study 
in a large group of WHO group 1 patients with PAH, RVEF measured at baseline 
was a better predictor of mortality compared to PVR (95). They showed, in 
patients who are on PAH targeted therapy that RV function can deteriorate despite 
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reduction in PVR, which occurred in 25% of the patients. They showed that the 
deterioration of RVEF was associated with poor outcome independent of any 
changes of PVR. They hypothesized that the deterioration in RVEF could be 
explained by pulmonary pressures and subsequently ventricular wall tension that 
was unaltered after medical treatment despite a fall in PVR. This study 
emphasized the importance of monitoring RV function during the course of the 
disease.  
RV end diastolic volume is another predictor of prognosis in PAH.  Kaplan-Meier 
survival analysis in a study by Van Wolferen et al demonstrated that patients with 
a RVEDVI of  < 84ml/m2 at diagnosis had a significantly better survival compared 
to those with a RVEDVI of 84 ml/m2 or more (91). A further study by Yamada et al 
showed that an increased RVEDVI predicted both hospitalisation and mortality in 
patients with IPAH but couldn’t establish a significant difference between the 
aforementioned two groups in the previous study (96). 
Swift et al identified patients with PAH undergoing MRI from the ASPIRE registry 
and determined the value of CMR metrics for mortality prediction in PAH (97). 
They confirmed the independent prognostic value of CMR measurements reflecting 
RV volume and proximal pulmonary vasculature in a large cohort of PAH patients. 
A model combining MRI measurements of RVESV and PA relative area change in 
combination with clinical data including age, sex, WHO functional class and the 
presence of underlying connective tissue disease improved the prognostication in 
PAH. In this study RVESV rather than RVEDV was independently prognostic in PAH 
patients and the authors suggested that loss of RV systolic function may explain 
the greater prognostic importance.   
In a study by Mauritz et al, CMR defined geometric changes during the 
development of RV failure (98). They identified certain CMR derived geometric 
characteristics that defined non-survivors (survival less than 5 years) at the 
beginning of the study and at 1 year follow up. They identified that the RV 
longitudinal shortening (distance change between end-diastole and end-systole of 
the tricuspid annulus to apex distance) and transverse shortening (change 
between end-diastole and end-systole of the RV free wall to septal distance) are 
already reduced at baseline in non-survivors, that transverse shortening further 
declines over time while longitudinal shortening and RV free wall motion stay the 
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same. They demonstrated that the end stage decline in RV function is due to 
progressive leftward septal displacement rather than further changes in RV free 
wall transverse or longitudinal displacement. The authors concluded that although 
there is a parallel decline in longitudinal and transverse shortening during 
progressive RV failure, a floor effect is reached for longitudinal shortening. As 
transverse shortening incorporates both free wall and septal motion, it could be 
used as a variable of monitoring RV failure. They identified that the RV fractional 
area change (RVFAC) which combines the effect of both transverse and 
longitudinal shortening (RVFAC = 100 × [(RVED area – RVES area) / RVED area] to 
correlate well with RVEF. The study showed that a decline in RVFAC to be an 
accurate measure of RV failure in patients with severe PAH.  
In a multicentre study prospectively assessing the use of CMR before and during 
PAH disease specific treatment, Peacock et al demonstrated the importance of 
including both right sided and left sided variables when determining cardiac 
function (99). In this EURO-MR study they highlighted that LV end-diastolic volume 
(LVEDV) to be more closely related to SV than RV end-diastolic volume. The 
authors suggested that poor LV output in PH patients was due to poor LV filling 
which was a consequence of prolonged RV contraction time. This contributed to a 
decreased stroke volume thus LVEDV reflected both the stroke volume and RV 
contraction time.  
1.8.2 Phase contrast CMR 
Blood flow of the main PA can be measured with phase contrast imaging using 
velocity encoded gradients. Various measurements such as average velocity, peak 
velocity, anterograde and retrograde flow can be determined. Sanz et al 
demonstrated that average velocity of the blood flow in the pulmonary artery to 
correlate with invasive pressure measurements (sPAP r= -0.76, mPAP r = -0.73) 
and PVR index (r=-0.86) (100). Average velocity with a cut off value of 11.7cm/sec 
was 92.9% sensitive and 82.4% specific to detect PH. Mousseaux et al 
demonstrated good correlations between right heart catheter measurements and 
CMR velocity encoded image derived flow measurements, enabling distinction of 
individuals with high PVR from normal PVR (101).  Relative onset of time (ROT) of 
retrograde flow in the main PA (relative to cardiac cycle duration) were 
determined in a study by Helderman et al, consisting of 38 PAH patients (102). A 
44 
 
ROT of 0.25 distinguished PAH patients from non-PAH patients, demonstrating that 
early onset of retrograde flow to be characteristic of PAH.  
1.8.3 Pulmonary artery stiffness and pulsatility 
Pulmonary arterial elasticity is an important factor determining the relationship 
between the RV and the PA, RV – PA coupling. A study was conducted to evaluate 
pulmonary arterial stiffness in patients with PH, exercise induced PH and no PH. 
Various indices of PA stiffness were studied. These included 1. Relative change in 
lumen area during cardiac cycle (pulsatility), 2. Absolute change in lumen area for 
a given pressure (compliance), 3. Change in volume associated with a given 
pressure (capacitance), 4. Relative change in lumen area for a given pressure 
(distensibility), 5. Pressure change driving a relative increase in lumen area 
(elastic modulus) and 6. Slope of function between distending arterial pressure 
and arterial distension (stiffness index beta). Patients with exercise induced PH 
had lower median compliance and capacitance than patients with no PH. The 
aforementioned different measures of PA stiffness showed significant correlation 
with PA pressures (r2 = 0.27 to 0.73). They showed that reduced PA pulsatility of 
< 40% to detect the presence of PH with a sensitivity of 93% and a specificity of 
63%. The authors concluded that PA stiffness occur early in PH even when overt 
pressure elevations are not present at rest (103).  
 
1.8.4 RV - PA coupling 
The gold standard measure of RV systolic functional adaptation to changes in 
afterload is to measure end-systolic elastance (Ees), which is derived by dividing 
end-systolic pressure (ESP) by end-systolic volume (ESV), corrected for arterial 
elastance (Ea) (stroke volume/ ESP). This load independent measure of RV – PA 
coupling defines matching of RV contractility to afterload. Although this requires 
instantaneous measurements of RV pressure and volume which is not practical, 
this can be simplified for pressure and expressed either as a SV/ ESV ratio (the 
volume method) or simplified for volume and expressed as RV maximum pressure 
divided by mPAP minus 1 (the pressure method). In a study of 140 treatment naïve 
patients by Brewis et al, RV – PA coupling measurements by volume method 
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(SV/ESV) predicted outcome, however there were no added benefits of RV-PA 
coupling measurements by the pressure method (104). 
An alternative descriptor of coupling has been analysed by echocardiography 
(105).  In a study of 459 patients with heart failure, TAPSE/PASP ratio was used as 
a measure of RV and pulmonary arterial coupling. The group with the lowest ratio, 
that is low TAPSE with high PASP, had greater risk of adverse events and most 
impaired clinical function. Although the authors termed this study ventriculo-
arterial coupling, their measurements did not calculate elastance within the 
ventricle or pulmonary vasculature.  
1.9 Non-invasive assessment of haemodynamics with 
CMR 
As discussed in the Echocardiography section, the ability to non-invasively 
estimate pulmonary pressure is a key objective of imaging techniques. Systolic 
pulmonary artery pressure can be estimated with echocardiography using the 
tricuspid regurgitant jet velocity. Various CMR studies have assessed estimation 
of both mPAP and PVR with CMR metrics in PH(106, 107). In a study by Swift et 
al, mPAP was accurately estimated using a statistical model involving VMI and 
IVS angle.  
1.10 Strain 
Myocardial strain measures the degree of deformation of a myocardial segment 
from its initial length. If the initial length is termed L0 and the maximum length 
L, strain can be determined by the following formula (108). Strain = (L – L0) / L0 
There are two main definitions of strain.  
1. Lagrangian strain – the displacement is calculated at a fixed material point 
in the myocardium. The deforming myocardium is used as a reference.  
2. Eulerian strain – tissue strain at a specific location in space, so spatial 
coordinates are fixed, but material points keep changing.  
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Strain imaging that is discussed in this thesis is based on the analysis of Lagrangian 
strain.  
1.10.1 Cardiac deformation / strain by echocardiography 
In echocardiography strain has been assessed by Doppler imaging and speckle 
tracking. Doppler imaging requires identification of a “region of interest” in the 
myocardial wall and mapping changes in the velocity of this “region of interest” 
through the cardiac cycle. In recent years, this process has become superseded by 
the speckle tracking method. From strain, strain rate can be calculated by ΔL/Δt.  
Whereas strain is a measurement from baseline, the rate can be measured 
continuously throughout the cardiac cycle.  Peak systolic measurements of strain 
and strain rate are typically reported in studies looking at strain as a measure of 
cardiac function however, early and late diastolic peak values can be derived 
providing insight into diastolic function.   
1.10.2 Speckle tracking echocardiography 
Speckle is the term given to the greyscale pixilation pattern created by the 
reflection of sound waves at an interface.  The imperfection of a surface creates 
a unique reflection and therefore fingerprint of pixels at that region. This pixel 
fingerprint can subsequently be tracked across the cardiac cycle.  By tracking 
many pixels across a “region of interest”, the deformation of the tracked structure 
can be measured, thus strain can be calculated along the entire “region of 
interest” (15). Unlike Doppler imaging, speckle tracking is not dependent on 
angle. Although measurement of deformation can be made in three planes, 
longitudinally, circumferentially and radially, imaging the latter two in the RV by 
two-dimensional imaging is challenging.  Developments in 3D echocardiography 
assists with this limitation.  Longitudinal strain of the RV free wall is the right 
ventricular measurement often reported in the literature.  
1.10.3 RV strain and RV dyssynchrony in PH by 
echocardiography 
Strain analysis of the LV in post myocardial infarction hearts through speckle 
tracking has been reported since 2004 and LV strain analysis by echocardiography 
is well established (109, 110). The use of speckle tracking echocardiography to 
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analyse strain has been validated by sonomicrometry and MRI tagging (111, 112). 
Rajdev et al demonstrated reduced strain in RV and LV free walls and the IVS in 
PH using tissue Doppler imaging (113, 114). They did, however report inter-
observer variabilities between 11.2% and 26.6% +/- 30.9, and intra-observer 
variability of 13.6 to 18.2% +/-13.   In another study Borges et al demonstrated 
significant changes in RV strain pre-treatment and post-treatment in PH patients, 
using both Doppler imaging and speckle tracking(114). Both tissue Doppler 
measurements and speckle tracking showed significance between groups, 
although were not compared against each other.  
Peak systolic longitudinal strain of the RV has become established as a measure of 
RV function in PH.  Filusch et al used tissue Doppler imaging to measure peak 
systolic strain and strain rate of the RV free wall in controls and patients with 
IPAH.   They demonstrated that RV strain and strain rate measurements to 
correlate with known markers of disease severity including PVR, cardiac output, 
TAPSE, Tei Index, NT-proBNP and 6 minute walk (115). Although, this implies that 
strain could be used as a continuous variable of cardiac function, in current 
guidelines, a value less than -20% (i.e. smaller measure of strain) is accepted as a 
cut-off measure of impairment (116). Sachedev et al studied a patient group with 
PAH and demonstrated impaired RV free wall peak systolic longitudinal strain and 
strain rates (average strain -15.5% and strain rate -0.80 s-1.) (117).  Comparing 
patients with a strain less than -12.5% compared to patients with a strain more 
than -20%, showed 4-year mortality of 93% versus 39% respectively.  Regarding 
strain rate, a value less than -0.7s-1 was associated with worsened disease 
progression and mortality. Haeck et al also looked at peak systolic longitudinal 
strain of the RV in a PH group (118).  They found the group with a strain value less 
than -19% was associated with an impaired survival over a 5-year period of 55%.  
They also identified a higher WHO functional class, increased diuretic use, larger 
RV areas with reduced RVFAC and lower TAPSE in this group. 
Global strain assessments of the RV, including measurement of the IVS and free 
wall, have also been studied (119-121).  In a group of PH and control subjects, 
global peak systolic RV longitudinal strain was reduced in the PH group, -15.6% 
versus -23.8% (119). In another PAH group, a global peak RV longitudinal strain 
less than -15.5% was associated with reduced event free time and total survival 
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(121). In 2015 Park and Kusunose also looked at global RV longitudinal strain and 
isolated free wall strain pre and post treatment (120). They showed improvement 
in longitudinal strain measurements and moderate correlation with change in 
strain and mPAP.  More recently a study looking at longitudinal RV free wall strain 
against other echocardiogram parameters and pulmonary pressures showed a 
strain value of -19.26% was diagnostic of mPAP ≥ 45mmHg with a sensitivity of 
83.9% and a specificity of 73.4% (122).  
Cardiac function assessment by strain recording across the cardiac cycle allows 
assessment of intra-ventricular dyssynchrony (123). Dyssynchrony is usually 
calculated by taking the standard deviation of time to peak strain measured across 
a chosen number of cardiac chamber segments. The higher the standard deviation, 
the greater the dyssynchrony. Haeck et al demonstrated worse RV intra-
ventricular dyssynchrony to be associated with worse clinical function. They also 
suggested the presence of ventricular interdependence (124).  Badagliacca et al 
also demonstrated the association of RV dyssynchrony with worse WHO functional 
class, six-minute walk distance, RV remodelling and impaired RV haemodynamics 
(125, 126).  
1.10.4 CMR to assess myocardial deformation 
Cardiac MRI is the gold standard for assessing biventricular structure and function. 
Recently there has been significant focus on using CMR to assess myocardial 
deformation. Various techniques have been used based on techniques that focus 
on image acquisition or techniques that focus on post processing methods. These 
techniques are summarised in the Table 1.2 below.  
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Table 1.2 Cardiac Magnetic Resonance Imaging techniques of assessing myocardial 
deformation.  
 
CMR technique Mechanism 
Image acquisition 
method 
 
  CMR tagging Tracks magnetization tags 
  PVM (Phase 
Velocity Mapping) 
Encodes myocardial velocity, in the three 
directions, in the phase of the signal 
  DENSE 
(Displacement 
Encoded with 
Stimulated 
Echoes) 
Encodes tissue displacement into the phase of an 
image 
  SENC (Strain 
nc ded Imaging) 
Uses magnetization tags parallel to the image 
plane combined with out-of-plane phase-encoding 
gradients Post-processing method 
 
  CMR-FT (Feature 
tracking) or tissue 
tracking) 
Tracks features in the image and recognizes them 
in the successive image of the sequence 
 
Various CMR techniques for the assessment of myocardial strain are summarised. Myocardial 
tagging, PVM, DENSE and SENC are image acquisition methods while CMR-FT focuses on post 
processing.   
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1.10.5 RV strain by CMR imaging 
The application of tagging in the evaluation of RV had been limited by the 
relatively thin RV wall. To overcome this challenge Shehata et al developed a fast 
strain-encoded (SENC) imaging, to allow direct measurement of regional function 
by using a free-breathing single heart beat real time acquisition. They measured 
biventricular segmental peak systolic longitudinal strain as well as LV 
circumferential and RV tangential strains in patients with PAH and controls. 
Longitudinal contractility of the RV was reduced at the basal, mid and apical levels 
and tangential contractility was reduced at mid-ventricular level. Longitudinal 
contractility of the RV positively correlated with mPAP and PVR (r=0.62 and r=0.77 
respectively). Interestingly in a subgroup of patients with normal RV function 
(measured by RVEF), significantly reduced RV strain was noted in septal as well as 
free wall regions (127). 
1.10.6 Feature tracking CMR imaging 
The advantage of feature tracking is that the post processing technique can be 
applied to routinely acquired CMR images without the need for additional imaging 
acquisition.  The basis for CMR-FT is identifying certain features in an image and 
tracking these features in the successive images of the sequence. It is based on 
defining small square windows, centred around a feature, on a first image and 
searching the “as-much-as-possible similar” greyscale pattern on the following 
image (128). The endocardial and epicardial borders will be defined manually and 
CMR-FT software automatic border tracking will track these during the cardiac 
cycle. CMR-FT will estimate global longitudinal strain from two cine images while 
circumferential and radial strains are derived from the short-axis cine images.  
The main limitation of CMR-FT is artefacts due to through-plane motion, as 
features moving out of plane cannot be tracked (128). CMR-FT was developed for 
two-dimensional images; however, this technology can be applied to track 3D 
regions. Furthermore, CMR-FT is based on the assumption that the deformation is 
derived from the myocardium and that the blood motion does not interfere with 
it. However, blood motion can affect the tracking close to the endocardial regions, 
where unrealistic results may be noticed. Finally, CMR-FT is limited by the pixel 
size; displacement of less than the pixel size may not be detected.  
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In a study by de Siqueira et al using CMR-FT, peak RV global longitudinal and 
circumferential strain and strain rates were quantified from standard CMR cine 
images. Patients were classified into three groups (no PH, PH with normal RVEF 
and PH with reduced RVEF). All RV strain and strain rate values were reduced in 
the PH group with reduced RVEF. After adjustment for six clinically meaningful 
covariates, RV global longitudinal strain (p = 0.026), RV global longitudinal strain 
rate (p = 0.04), and RV global circumferential strain rate (p = 0.01) were associated 
with a poor outcome (death, lung transplantation, worsening functional class) 
(129).  
1.10.7 Left ventricular myocardium and strain 
The LV myocardium is organized into three layers.  
1. Subendocardial layer – fibres are orientated longitudinally from base to 
apex.  
2. Midwall layer – fibres are orientated circumferentially. 
3. Subepicardial layer – fibres are orientated longitudinally from apex to base.  
Due to this complex architecture, LV deformation in systole is along different 
directions determining longitudinal shortening, circumferential shortening, radial 
thickening and torsion (128). Longitudinal strain represents the longitudinal 
shortening from base to apex and is expressed as a negative value. Circumferential 
strain represents myocardial shortening along the circular perimeter on a short 
axis view and is expressed as a negative value. Radial strain represents the radially 
directed myocardial fibres deformation towards the centre of the LV cavity and 
indicates LV thickening and thinning during the cardiac cycle. As there is 
thickening of the myocardium in this direction during systole, this is expressed as 
a positive value. LV torsion is created by the clockwise and counter-clockwise 
rotation of the ventricular base and apex respectively in relative to a stationary 
mid myocardial reference point. Strain rate (longitudinal, circumferential and 
radial) represent the rate at which myocardial deformation occur. The complex 
LV fibre architecture and LV deformation is shown in Figure 1-2.  
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Figure 1-2 Myocardial deformation of the left ventricle 
Modified from Scetteia et al (128) with permission. LV deformation in systole is along different 
directions determining longitudinal shortening (L), circumferential shortening (C), radial thickening 
(R) and torsion. This is due to the fact that the LV myocardium is organised into three layers. LV 
torsion is not shown but is created by the clockwise and counter-clockwise rotation of the ventricular 
base and apex respectively in relative to a stationary mid myocardial reference point. 
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1.10.8 Torsion of the LV  
During LV systole, when viewed from the apex, the apical segment rotates in an 
anti-clockwise direction, while the basal segment rotates clockwise, which is 
known as torsion of the LV.  Puwanant et al demonstrated an impaired torsion in 
PH compared to controls, 9.6o vs. 14.9o but preserved untwisting rates (130).  They 
suggested that raised RV pressure, causing septal flattening and bowing into the 
LV, impairs the ability of the LV to torque.  While LV torsion continues to be 
studied in other conditions, there is limited additional data regarding 
echocardiography assessment of torsion in PH.  The advent of 3D imaging should 
assist further in the analysis of torsion in this setting. 
1.11 Myocardial tissue characterisation and 
myocardial perfusion by CMR  
The advantage of CMR is the ability to achieve high resolution imaging of the heart 
in multiple orientations without using radiation. Recently, there has been 
significant focus on non-invasive myocardial tissue characterisation. Longitudinal 
relaxation time (T1) and Transverse relaxation time (T2) are central properties of 
tissues and reflect their molecular make up (131, 132). Tissue T1 relaxation time 
is defined as the time when longitudinal proton magnetization recovers 63% of its 
equilibrium value. Late Gadolinium Enhancement (LGE, delayed cardiac 
enhancement, DCE) is the gold standard for determination of myocardial fibrosis. 
This is based on the difference in distribution of contrast between normal and 
fibrotic myocardium. The areas of fibrosis demonstrated a shorter T1 time than 
adjacent normal tissue. Conventionally this method is performed using inversion 
recovery gradient-echo sequences 10-15 minutes after gadolinium contrast 
injection. Retention of contrast within the extracellular space results in 
shortening of the inversion time (T1) and hyper-enhancement relative to normal 
myocardium (on T1 weighted MRI images) (Figure 1-3). Ischemic scar usually 
results in delayed enhancement in a sub-endocardial or transmural distribution 
consistent with the perfusion territories of epicardial coronary arteries, while non-
ischemic fibrosis tends to be irregular and intramural or subepicardial in 
distribution. The main limiting factor when using LGE is that fibrotic process is 
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often a diffuse process thus lacking the normal non-fibrotic myocardium for 
reference. To ameliorate this issue, T1 mapping has been developed to quantify 
diffuse, non-ischemic myocardial fibrosis, as it does not rely on contrasting signal 
intensity.  
1.11.1 Late gadolinium enhancement 
Blyth et al used contrast enhanced CMR imaging to determine the presence of LGE 
in PH (133). They hypothesised that myocardial abnormalities may exist in patients 
with PH, that they could be identified by contrast enhanced CMR imaging and that 
the severity of the contrast enhancement would relate to the severity of PH. LGE 
was present in almost all patients with PH and the extent of contrast enhancement 
was associated with RV volumes, RV function as well as mPAP derived at right 
heart catheterisation. The authors also found LGE to be associated with IVS bowing 
and concluded that this may provide a novel marker for occult septal 
abnormalities directly relating to the haemodynamic stress experienced by these 
patients. McCann et al found similar results with the extent of LGE related to RV 
function and RV stroke volume. In two other patients who had post mortem 
histological analysis of the RV insertion points, fibrosis was present suggesting this 
may be the causal mechanism, however there was also evidence of interstitial 
space expansion and a small increase in fat which may have contributed to LGE. 
In a study by Freed et al, patients with RV insertion point LGE had larger RV 
volume index, lower RVEF and higher mPAP and LGE was a predictor for adverse 
outcomes (p=0.026) in this population (134). In a study by Swift et al, LGE at the 
RV insertion points was suggestive of the presence of PH, however, after 
multivariable analysis, septal LGE was not associated with an increase in overall 
mortality(135).  
In a study by Shehata et al, LGE at RV insertion points were observed in almost all 
patients with PH and LGE was associated with pulmonary haemodynamics, 
reduced RV function and reduced eccentricity index (127). Reduced longitudinal 
strain of the basal anterior septal insertion point was independently associated 
with LGE although the same was not observed for the posterior insertion point. 
The authors suggested that the two insertion regions may behave differently as 
they are part of anatomically and functionally distinct regions i.e. RV outflow and 
inflow tracts. 
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1.11.2 T1 mapping techniques 
There have been numerous T1 based techniques for quantification of fibrosis. The 
modified Look Locker inversion recovery (MOLLI) technique was designed to 
overcome the limitations caused by motion and prolonged acquisition time (136). 
Specifics included an ability to acquire data within one breath-hold at a 
designated time within the cardiac cycle and the capability of merging images 
from multiple Look Locker experiments at different consecutive inversion times 
into one data set. MOLLI sequencing employs a balanced steady-state free 
precession (SSFP) readout to achieve a higher signal to noise ratio with a narrow 
image acquisition period of less than 200 ms in end-diastole to minimize motion 
artefact. In a later study Messroghli et al demonstrated high reproducibility of 
this technique (137). Piechnik et al introduced a shortened MOLLI sequence 
(ShMOLLI) that generated immediate, high-resolution myocardial T1-maps in a 
short breath-hold with high precision. Other prototype vendor specific sequences 
are in development including a modified Look-Locker FIESTA technique using 
saturation-recovery imaging, saturation-recovery single shot acquisition (SASHA), 
and saturation pulse prepared heart-rate-independent inversion recovery, which 
consists of a combination of saturation and inversion pulses (131). 
1.11.3 T1 mapping methodology 
Typically, a series of short axis images are acquired pre contrast and 
approximately 12 minutes’ post gadolinium contrast with between 6 and 12 
consecutively longer inversion times depending on the protocol. Image acquisition 
is usually performed with ECG gating with breath holding at end-inspiration. 
During post processing, standard basal, mid-ventricular and/or apical slices are 
selected and can be further divided into conventional myocardial segments (or 
discrete regions of interest) and blood-pool for analysis if desired. A curve fitting 
technique is employed to reconstruct the consecutively acquired images into one 
data set from which a T1 map of voxels is generated.  
The signal intensity of each voxel directly represents the T1 relaxation time of the 
corresponding myocardial tissue. An exponential recovery curve of signal 
intensities at the different inversion times is then created for each designated 
region of interest (slice or segment) to determine the myocardial T1 relaxation 
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time. These can be averaged to extrapolate T1 as an index of diffuse fibrosis, 
where shorter T1 time and higher signal intensity correspond to increased 
gadolinium contrast accumulation within the extracellular matrix. Standardization 
of myocardial T1 values to non-myocardial tissue (blood) assists in minimizing the 
dynamic features of gadolinium contrast. The ratio of myocardial to blood post-
contrast T1 values is expressed as the partition coefficient. By preceding post-
contrast T1 mapping with pre-contrast T1 mapping, myocardial extra-cellular 
volume (ECV) can similarly be derived. This pseudo-equilibrium technique employs 
the reciprocals of myocardial and blood T1 values pre- and post-contrast and then 
adjusts for haematocrit to correct for the blood contrast volume of distribution. 
This ECV is expressed as a percentage of the total myocardial extracellular space. 
Gadolinium equilibrium between blood and myocardium must be achieved prior 
to image acquisition to enable accurate estimation of ECV. Typically, this occurs 
from 8.5 minutes’ post contrast injection, after which ECV differences between 
time-points are minimal. A larger ECV represents increased contrast accumulation 
in an expanded extra cellular matrix (131). 
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Figure 1-3 Normal and fibrotic myocardium pre and post gadolinium contrast injection 
From Jellis et al (131) with permission. Normal myocardium (top) and fibrotic myocardium (bottom) 
pre and post injection of Gadolinium contrast. By preceding post-contrast T1 mapping with pre-
contrast T1 mapping, myocardial extra-cellular volume (ECV) can be derived. This pseudo-
equilibrium technique employs the reciprocals of myocardial and blood T1 values pre- and post-
contrast and then adjusts for haematocrit to correct for the blood contrast volume of distribution. This 
ECV is expressed as a percentage of the total myocardial extracellular space.  
  
58 
 
1.11.4 T1 mapping in PH  
Sprujit et al used CMR T1 mapping for myocardial tissue characterisation in IPAH, 
connective tissue disease associated PH and CTEPH (138). They used regions of 
interest in the RV and LV free wall, interventricular septum and the RV insertion 
points. In PH patients, native T1-values of the RV insertion regions were 
significantly higher than the native T1-values of the RV free wall, LV free wall and 
interventricular septum. They showed that the T1 values at the RV insertion 
regions were significantly related to disease severity. Saunders et al also used 
regions of interest in the IVS, LV free wall and RV insertion points during T1 
mapping assessment. Elevated myocardial native T1 was found to a similar extent 
in PH patient subgroups and was independently associated with IVS angle. The 
authors did not find an additive value of native T1 mapping in the diagnostic and 
prognostic evaluation of PH patients (139). In another study by Reiter et al using 
CMR imaging, LV global, segmental and ventricular insertion point T1 times were 
evaluated manually and corrected for blood T1. AHA segmentation was used to 
segment the LV myocardium including RV insertion points. Septal, lateral and 
global T1 times were significantly higher in PH than in non PH subjects (132).  
Although identification of raised native T1 times has been used to identify 
myocardial histological changes this has been limited due to 
1. The need for visual assessment of the insertion points (Sprujt et al, 
Saunders et al) or, 
2. The existing AHA segmentation of the LV fails to isolate the regions of RV 
insertion for analysis (Reiter et al) 
Ana García-Álvarez et al used an experimental pig model of PH to assess the 
association between native myocardial T1 values and ECV with haemodynamics 
and RV performance (140). Native T1 values and ECV values were higher at RV 
insertion points in the experimental model animals compared to controls and also 
showed significant correlations with haemodynamics and RV-PA coupling. 
Interestingly ECV values were increased before overt RV dysfunction, which may 
offer a potential for early detection of PH. In another study, Homsi et al used 
mapping techniques and strain imaging to explore the mechanism of myocardial 
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changes in PH (141). They demonstrated higher T1 and ECV values in PAH and also 
showed impairment of LV longitudinal strain. However, there was no change in LV 
ejection fraction (LVEF). They hypothesised that due to longstanding LV under-
filling, there may be LV myocardial fibrosis and LV atrophy despite preserved 
LVEF.  
1.11.5 Myocardial perfusion 
Myocardial perfusion imaging using CMR enables monitoring passage of contrast 
through the lung. This is dependent on pulmonary pressures, PVR and cardiac 
output. Pulmonary transit time (PTT) describes the transit time of contrast 
between RV and LV while LV full width at half maximum (FWHM) and LV time to 
peak (TTP) contains information regarding bolus dispersion in the left ventricle. 
Skrok et al demonstrated PH patients to have a longer PTT, FWHM and TTP 
compared to healthy controls (142). These myocardial perfusion variables 
associated with mPAP and cardiac index. There is increased RV workload and RV 
hypertrophy in PH due to increased RV afterload. This demands in increased RV 
myocardial perfusion. However, there may be a reduction in systolic flow in the 
right coronary artery in PAH. Therefore, reduced myocardial perfusion reserve 
may contribute to further RV dysfunction and RV failure. In a study by Vogel-
Claussen et al, who evaluated biventricular myocardial perfusion with 
biventricular function and pulmonary haemodynamics in PH patients by adenosine 
stress perfusion MR imaging showed that, myocardial perfusion reserve indices 
were lower in PH compared to non PH controls (143). Myocardial perfusion indices 
inversely correlated with RV workload and RVEF, concluding that reduced 
myocardial perfusion reserve may contribute to RV dysfunction.   
1.12 Positron emission tomography (PET) 
There is evidence that inflammation and immune dysregulation may play a role in 
IPAH. Elevated levels of pro-inflammatory cytokines have been found in the serum 
of IPAH patients. 18F-FDG PET have been extensively used in oncology to identify 
primary and metastatic tumour cells and a similar increased glycolytic metabolism 
has been seen in endothelial cells derived from IPAH-transplant patients. Hagan 
et al demonstrated higher FDG uptake in the lung parenchyma and the RV in IPAH 
patients compared to patients with CTEPH and controls (144). They suggested 
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using FDG uptake as a surrogate marker of cellular metabolism and immune 
activation as underlying mechanism of the disease. Another study by Can et al 
demonstrated that increased FDG uptake in RV myocardium was associated with 
elevated systolic PAP (145). The myocardial FDG uptake also correlated with pre-
existing prognostic markers including elevated BNP and reduced exercise capacity. 
In another study Wang et al evaluated gated 18F-FDG PET for the assessment of 
right ventricular volume and function in patients with PH and compared it to 
Cardiac MR and Cardiac CT data (146). Right ventricular end-diastolic and end-
systolic volumes and RV ejection fraction were calculated. They determined 18F-
FDG uptake as RV corrected standardized uptake value (SUV) and the ratio of RV 
to LV corrected standardized uptake value (corrected SUV R/L). Their study 
demonstrated that gated PET correlated well with CMR in assessing RV volume and 
function, however gated PET underestimated RVESV and RVEDV while 
overestimating RVEF when compared to CMR. They also found statistically 
significant negative correlation between RV SUV and RVEF by CMR as well as 
corrected SUV R/L. This study demonstrated that 18F-FDG gated PET could be used 
in the simultaneous assessment of RV function as well as RV metabolism. 
Previously Bokhari et al had suggested that perfusion and metabolic PET imaging 
using N-NH(3) and 18F-FDG respectively to be a feasible modality to quantify RV 
blood flow and metabolism. The RV free wall myocardial glucose uptake 
correlated well with mPAP suggesting the possibility that this could be used as a 
novel early biomarker in patients with PAH (147).  
1.13 Right and left ventricular Interaction 
Although PAH is a disease of the pulmonary vasculature, it is the subsequent RV 
failure that is the main cause of morbidity and mortality in patients with PAH. 
Thus, CMR studies measuring myocardial deformation and myocardial tissue 
characterisation in patients with PH have been focused on the RV.  
Frank Starling mechanism or the Starling’s Law of the heart explains the ability of 
the heart to change its force of contraction and therefore stroke volume in 
response to changes in venous return (148). An increase in venous return increases 
the end-diastolic volume (ventricular filling) and therefore ventricular preload. 
This causes the initial stretching of cardiac myocytes prior to contraction. Myocyte 
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stretch causes an increase in sarcomere length, which causes an increase in 
myocyte force generation. This enables the heart to eject the additional volume 
of venous return causing an increase in stroke volume. In mechanical terms, 
increasing preload increases the active tension developed by the muscle fibre and 
increases the velocity of fibre shortening at a given afterload and inotropic state. 
Although other mechanisms may be involved, increasing the sarcomere length 
increases Troponin C calcium sensitivity, which increases the rate of cross bridge 
attachment and detachment and the amount of tension developed by the muscle 
fibre, increasing contractile force. This is termed length dependent activation.  
Under normal conditions the impact of the RV on LV function is negligible. 
However ventricular independency plays an important role when the RV is pressure 
loaded as in PH. Ventricular interdependency can be affected both by parallel and 
series interaction (149). Leftward septal bowing hampers filling of the LV due to 
parallel interaction. Lowered RV stroke volume causes a decrease in LV filling due 
to series interaction. There is also the anatomical consideration that both these 
chambers are enclosed within a space limited pericardium. The primary reason 
for the leftward paradoxical motion of the IVS is due to the prolonged RV 
contraction time compared to the LV contraction time. Doppler echocardiography 
studies had demonstrated that the post systolic isovolumetric time is prolonged in 
severe PAH (149, 150). This hampers early diastolic LV filling. (RV contraction 
continues while the LV is already in diastole).  
Because of the ventricular interdependency, measures of ventricular interaction 
are clinically useful to measure disease state as they contain information on the 
stroke volume as well as wall tension. As mentioned in the chapter earlier, several 
large studies have demonstrated that LV volume parameters to have important 
prognostic information in addition to RV function and volumes (99). Parameters 
that incorporate post systolic isovolumetric time such as the myocardial 
performance index have also shown to be of clinical relevance (37). Under filling 
of the LV may also bring the LV myocytes into an atrophic state. This is of 
importance as unloading the RV and improving LV preload might induce LV failure. 
Re-setting ventricular interdependency by means of pacing has also been explored 
in small cohorts of patients (151, 152). The importance of the LV in PH is 
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underlined by the fact that SV is closely related to LV but not RV end diastolic 
volume (16). 
1.14 Left atrium 
Left atrial function is increasingly studied and is known to have a significant role 
in the prognosis and risk stratification in different cardiac diseases. The principal 
role of the LA is to module left ventricular filling by three basic functions (153).  
1. Reservoir function – collection of pulmonary venous return during LV systole 
2. Conduit function – passage of blood to the LV during early ventricular 
diastole 
3. Booster pump function – during late diastole augmentation of LV filling.  
When assessing atrial function, it is important to recognise that there is significant 
interplay that exist between atrial function and ventricular performance during 
the cardiac cycle (153). This is discussed in detail in chapter 2.   
LA function is most often assessed by echocardiography using volumetric analysis, 
spectral Doppler analysis or by tissue Doppler analysis. Subsequently Kowallick et 
al demonstrate CMR–FT to be reliable quantifier of LA longitudinal strain and strain 
rate from standard SSFP cine images. They also demonstrated that CMR- FT to 
discriminate between patients with impaired LV relaxation and healthy controls 
(154).  
1.14.1 Left atrial area / volume measurement by CMR in PH 
Pulmonary hypertension due to heart failure with preserved ejection fraction 
(HFpEF) is venous in origin and causes dilatation of the left atrium. Thus, 
determination of the LA size is primary used to exclude PH due to left sided 
cardiac dysfunction (group 2 PH) in the diagnostic workup of PH. In a study by 
Crawley et al, they determined LA size using a standard 2 and 4 chamber CMR 
views using the biplane area – length method. Left atrial volume was significantly 
lower in patients with IPAH compared to patients with HFpEF. Using an LA volume 
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threshold of 43 ml/m2 as the cutoff, they could distinguish IPAH from HFpEF with 
97% sensitivity and 100% specificity (18). 
1.14.2 Left atrial function 
Abnormal LA function in patients with left heart disease is relatively well 
explored. In the above study by Kowallick et al, they demonstrated significantly 
decreased passive strain in patients with HFpEF and hypertrophic cardiomyopathy 
(HCM) corresponding to reduced conduit function (154). As atrial conduit function 
is closely related to LV compliance the authors suggested that this represented 
impaired LV relaxation. In the same study, total strain and peak positive strain 
rate which correspond to atrial reservoir function were decreased in HCM and 
HFpEF which might indicate impaired atrial compliance. They also showed 
increased active strain and peak late negative strain rate corresponding to booster 
pump function in HCM while decreased in HFpEF. They hypothesised that this may 
represent an initial increase in LA booster pump at early stages of impairment of 
LV relaxation followed by progressive decompensation of global LA performance. 
This was also demonstrated in a study by Murata et al using 3D echocardiography 
to study LA function (155).  
Although PAH is defined, in-part by normal LV filling pressures, aforementioned 
series and parallel interactions from the RV to the LV affect LV performance. Thus, 
due to the direct interplay between LV and LA, study of LA function is of interest 
to further explore the ventricular interdependence in PAH.  
1.15 Small animal CMR 
Small animal (rodent) models are increasingly used to identify pathophysiology as 
well as therapies for PAH with the intention of translating the findings to humans 
(19). Accurate monitoring of disease in rodents with emphasis on ventricular 
function and with the ability to monitor the disease state without killing the 
animal is needed. This is particularly important as some models are expensive to 
create.  
Various rodent models to recapitulate human PAH have been produced. 
Taraseviciene-Stewart et al described the Sugen-hypoxia (SuHx) rat model in 2001 
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(156). Based on the fact that vascular endothelial growth factor (VEGF) is an 
important maintenance and differentiating factor for vascular endothelial cells, 
they designed an experiment to inhibit VEGF signalling in rats exposed to chronic 
hypoxia and normoxia. They showed that a selective VEGF receptor-2 (VEGFR-2) 
inhibitor, SU5416 (Sugen) to cause mild PH and pulmonary vascular remodelling in 
rats exposed to normoxia. However, in rats exposed to chronic hypoxia, Sugen 
caused severe PH associated with pulmonary arterial endothelial cell 
proliferation. The VEGFR-2 blockade caused endothelial cell apoptosis, which 
under chronic hypoxic conditions triggered luminal obliterative endothelial cell 
proliferation in the pulmonary circulation. In 2010, Abe et al showed that SuHx 
rats demonstrated evidence of severe pulmonary arteriopathy including 
concentric neo-intimal and complex plexiform-like lesions which closely resemble 
plexiform lesions seen in humans (157). Subsequently, other groups have 
attempted to characterize hemodynamics in a SuHx model beyond right heart 
catheterization alone (158-161).  
Our group has a proven track record using CMR imaging to evaluate RV function in 
humans with PAH (99, 104, 133). The same non-invasive and repeatable 
measurements would be of great advantage for the study of rodent models to 
allow a detailed understanding of bi-ventricular structural and functional changes 
that occur, to enhance efficacy in translational medicine. 
1.16 Hypothesis and aims of the thesis 
Although right heart catheterisation is the gold standard in the diagnosis of 
pulmonary hypertension, imaging methods play an important role in the diagnostic 
process, in measuring response to treatment and determining prognosis. These 
non-invasive investigations provide more information about RV function than 
acquired from right heart catheterisation. At present there are few imaging 
methods, which assist in the understanding of the molecular and cellular processes 
occurring in the RV and pulmonary circulation in patients with PH. However, 
advances in imaging techniques such as PET imaging will provide insight into the 
basic pathobiology of pulmonary vascular remodelling and RV dysfunction.  
In the past, the RV has been the most widely studied of the cardiac chambers in 
PH, but now the focus has started to move towards the left ventricle (LV) (section 
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1.11). Although a disease of the pulmonary circulation and the RV, there is now 
evidence demonstrating LV abnormalities in PH. Furthermore, the atrial chambers 
offer valuable information when measuring cardiac function as well as in 
identifying the aetiology of PH (section 1.12). Small animal (rodent) models are 
increasingly used to identify pathophysiology as well as therapies for PAH with the 
intention of translating the findings to humans. Accurate monitoring of disease in 
rodents with emphasis on ventricular function and with the ability to monitor the 
disease state without killing the animal is needed (section1.13). 
The overall aim of the thesis was to determine if CMR could be used to address 
contemporary issues in the assessment of patients with PAH. 
1. To explore LV mechanics including longitudinal, circumferential and radial 
myocardial deformation and LV intra-ventricular synchrony in patients with 
PAH and to identify the importance of LV mechanics in the disease 
progression, prognostication and survival in patients with PAH. (chapter 3) 
2. To explore LA strain in PAH and to identify whether LA function assessment 
beyond LA volume will provide additional / incremental information about 
disease severity in patients with PAH. (chapter 4)  
3. To identify a novel segmentation of the LV that isolate RV insertion regions 
of the IVS during native T1 mapping that will provide additional prognostic 
information about the LV myocardial changes in PAH. The existing AHA 
segmentation of the LV fails to isolate the RV insertion region for analysis. 
(chapter 5) 
Small animal (rodent) models are increasingly used to identify pathophysiology 
as well as therapies for PAH with the intention of translating the findings to 
humans. The intention is to translate the findings from animal studies to 
humans. However, monitoring of the disease in small animals is done by cardiac 
catheterisation. Accurate monitoring of disease in small animals with emphasis 
on ventricular function and with the ability to monitor the disease state 
without killing the animal is needed.  
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4. To explore the feasibility of CMR to study longitudinal cardiac changes in a 
small animal model of PH and to discuss the suitability of a small animal 
model for translational studies of the mechanisms of RV dysfunction in PAH.  
(chapter 6)  
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 Material and Methods  
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2.1 Scottish pulmonary vascular unit 
All patients recruited for the studies in this thesis were attending the Scottish 
pulmonary vascular unit (SPVU). The SPVU was founded in 1990 and is the tertiary 
referral centre for patients suspected of PH in Scotland (162).  Apart from 
diagnosis, SPVU is the tertiary centre in Scotland for the ongoing management of 
all adult patients with PAH. Scotland has a population of 5.4 million (2018) of 
whom approximately 4.5 million are adults of age 16 years or over and therefore 
served by the SPVU (163). The National Audit of PH gathers data from all 8 
specialised PH centres in the United Kingdom, seven of which treat adult patients 
and one paediatric centre. The most recent data from this audit from 2018 shows 
that the SPVU managed 474 patients with PH in the preceding year (164).  
2.2 WHO functional class 
WHO functional class (WHO-FC) has been used since 1998 and is well established 
in the functional assessment of PH patients (165). It was modified from the New 
York Heart Association classification which describes the functional impact of 
heart failure. WHO FC classification is summarised in table 2.1.  
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Table 2.1 WHO functional class classification of PH.  
 
 
From Barst et al (165). WHO functional class has been used in the functional assessment of PH 
patients describing the impact of PH on limitation of physical activity.  
  
Class I 
Patients with pulmonary hypertension but without resulting 
limitation of physical activity. Ordinary physical activity does not 
cause undue dyspnoea or fatigue, chest pain or near syncope. 
Class II 
Patients with pulmonary hypertension resulting in a slight 
limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity causes undue dyspnoea or fatigue, chest 
pain or near syncope. 
Class III 
Patients with pulmonary hypertension resulting in marked 
limitation of physical activity. They are comfortable at rest. Less 
than ordinary activity causes undue dyspnoea or fatigue, chest pain 
or near syncope. 
Class IV 
Patients with pulmonary hypertension with inability to carry out 
any physical activity without symptoms. These patients manifest 
signs of right heart failure. Dyspnoea and/or fatigue may even be 
present at rest. Discomfort is increased by any physical activity. 
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2.3 Patient recruitment and assessment 
We retrospectively identified all patients who were referred to the SPVU between 
2010 to 2017 for investigations of PH and underwent right heart catheterisation 
and CMR.  Patients underwent multidisciplinary evaluation including non-invasive 
diagnostic tests and right heart catheterisation during a four to five-day diagnostic 
admission. Patients underwent non-invasive measurements and CMR within 72 
hours from right heart catheterisation and gave informed written consent to 
undergo these procedures. An additional group of healthy volunteers with no 
known history of arrhythmias, ischaemic heart disease and lung disease were used 
as controls in the LV / LA strain studies. The study protocols were approved by 
the local research ethics committee. All patients had either been assessed first in 
an out-patient pulmonary vascular clinic and offered diagnostic admission for 
further assessment or admitted directly for assessment following faxed or 
telephone referral from other hospitals within Scotland.  
2.4 Non-invasive assessment 
During the diagnostic admission, all patients underwent a series of investigations 
as part of the diagnostic algorithm for PH. These included blood investigations 
including autoantibodies and blood borne virus testing, arterial blood gas analysis, 
NT pro BNP level, pulmonary function testing, cardio pulmonary exercise testing, 
6-minute walk test, transthoracic echocardiography, chest radiography, CTPA, 
High resolution CT of thorax and V/Q scanning. These investigations were 
performed at the Golden Jubilee National Hospital unless they had been 
performed recently at a referring hospital. Patients also had their WHO FC 
assessed in accordance to current guidelines (30).  
2.5 Right heart catheterisation 
Right heart catheterisation was performed at the cardiac catheterisation lab at 
the Golden Jubilee National Hospital during the diagnostic admission. This was 
done during free breathing in the supine position with a 7 F quadruple lumen, flow 
directed balloon tipped Swan–Ganz catheter using the internal jugular approach. 
To facilitate this, an 8F introducer sheath was inserted in the internal jugular vein 
under ultrasound guidance. Pre-medication or sedation was not routinely used. 
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The external pressure transducer was zeroed at mid-thoracic line with the patient 
in the supine position, halfway between the anterior sternum and the bed surface, 
representing the level of the LA. Measurements were recorded in this supine 
position and were determined at the end of normal expiration. Right atrial 
pressure, mPAP, sPAP and diastolic pulmonary artery pressures (dPAP), PAWP 
were obtained. PAWP was obtained by catheter in the wedge position and the 
balloon inflated, reflecting the pressure of the LA. Cardiac output (CO) by 
thermodilution and PVR was determined by the following [PVR = (mPAP-PAWP)/ 
CO]. Mixed venous Saturations (SvO2, pulmonary artery oxygen saturations) were 
measured during right heart catheterisation. Systemic blood pressure, heart rate 
and oxygen saturations were monitored during right heart catheterisation. 
If the initial non-invasive tests and the right heart catheterisation results were 
suggestive of IPAH, pulmonary vasoreactivity testing was performed. This was 
performed by inhalation of Nitric Oxide (40 ppm) for 5 mins. A positive 
vasoreactivity was defined as a reduction in mPAP ≥ 10 mmHg to absolute value 
of < 40 mmHg without a drop in cardiac output measured by thermodilution. If the 
non-invasive imaging (CTPA and V/Q scanning) was suggestive of chronic 
thromboembolic disease, conventional pulmonary angiography was also 
performed.  
2.6 Cardiac Magnetic Resonance imaging 
2.6.1 Patient preparation and positioning  
Cardiac MRI scanning was done prior to right heart catheterisation during the 
diagnostic assessment in these patients. CMR imaging was performed in the supine 
position on a 1.5T MRI scanner (Avanto, Siemens, Erlangen, Germany). Patients 
signed a safety questionnaire prior to entering the scanning room. This was to 
ensure there was no contraindication to performing CMR. Patients were asked to 
lie supine on a CMR examination table. Patients had continuous ECG monitoring 
via monitoring pads. The phased array chest coil was placed on the patient’s chest 
and this was secured with a Velcro strap. Patients were also supplied with an 
emergency buzzer. The centre of the chest coil, approximating the position of the 
heart, was defined by a laser pointer attached to the magnet’s inner 
circumference at the 12 o’clock position. This reference point was obtained to 
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allow the patient to be moved within the bore of the magnet, to the point where 
their heart was at the centre of the main magnetic field. Once the patient was 
moved inside the bore of the magnet the scanning door was closed. Image 
acquisition was commenced with direct communication between the CMR 
radiographer and patient.  
Steady State precession sequences (True FISP) were used to generate the initial 
axial scout images in the coronal, transverse and sagittal planes which helped 
localising the heart within the thoracic cavity. They were used for planning the 
subsequent cine images. Vertical long axis (VLA) and Horizontal long axis (HLA) 
cine were acquired based on the initial scout images. The HLA cine was then used 
to plan a series of short axis (SA) cine images, intersecting the atrioventricular 
valve roots. Images were acquired during end-expiratory breath holds. The SA 
imaging plane was then propagated towards the cardiac apex, covering both 
ventricles with 6-mm SA imaging slices, separated by a 2-mm inter-slice gap.  
Imaging parameters, which were standardised for all subjects, included: TR 
(repetition time)/ TE (echo time) 3.2-3.9/0.6-2 ms, flip angle 45-90, slice 
thickness 6 mm, temporal resolution 33-45 ms, spatial resolution 1.5-2 mm.  
2.6.2 CMR image analysis 
All CMR images were analysed by the author using the Medis suite analysis software 
(Medis medical imaging systems, Leiden, Netherlands). Individual scans were 
anonymised and analysed by the author who was blinded to the identity and 
haemodynamic results of any given subject at the time of analysis. RV and LV 
volumes [RVEDV, RVESV, LV end-diastolic volume (LVEDV), and LV end-systolic 
volume (LVESV)] were determined by manual planimetry of selected short axis 
images, as described previously. Particular methodological points of note included 
the deliberate inclusion of trabeculations and papillary muscles in all analyses, as 
discussed by previous authors (166, 167). Right and left ventricular stroke volume 
(RVSV and LVSV), ejection fraction (RVEF and LVEF), and mass (RVM and LVM) were 
determined as previously described. RV mass was determined as RV free wall 
mass, the IVS was considered part of the LV. Ventricular Mass index (VMI) was 
determined as RV Mass: LV Mass. For analyses, RV and LV variables were index to 
body surface area (BSA). 
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2.7 Strain 
The concept of strain as a measure of myocardial deformation was introduced in 
section 1.8. The LV myocardium is organized into three layers.  
1. Sub-endocardial layer – fibres are orientated longitudinally from base to 
apex.  
2. Mid–wall layer – fibres are orientated circumferentially. 
3. Sub-epicardial layer – fibres are orientated longitudinally from apex to 
base.  
Due to this complex architecture, LV deformation in systole is along different 
directions: longitudinal shortening, circumferential shortening, radial thickening 
and torsion. Myocardial strain measures the degree of deformation of a myocardial 
segment from its initial length. If the initial length is termed L0 and the maximum 
length L, strain can be determined by the following formula.  
Strain = L – L0 / L0 
There are two main definitions of strain.  
1. Lagrangian strain – the displacements calculated at a fixed material point 
in the myocardium using the deforming myocardium as a reference.  
2. Eulerian strain – tissue strain at a specific location in space, so spatial 
coordinates are fixed, but material points keep changing.  
The cardiac imaging that is discussed in this thesis is based on the analysis of 
Lagrangian strain.  As mentioned above, due to the different directions of the 
myocardium deformation, longitudinal, circumferential and radial strain and 
strain rate can be calculated.  
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2.7.1 LV Strain 
Feature tracking CMR was performed using dedicated software (QStrain, Medis 
medical imaging Systems, Netherlands). The 4-chamber view was used to 
calculate LV longitudinal strain (EllLV). LV short axis circumferential (EccLV) and 
radial strains (ErrLV) were derived from a mid-ventricular short axis view 
containing both papillary muscles. The horizontal long-axis SSFP cine series was 
used to identify the slice closest to the true mid cavity at end diastole (equidistant 
between apex and ring). The RV upper septal insertion of the LV was manually 
defined to allow accurate segmentation according to AHA segmentation template. 
Endocardial values were calculated for longitudinal and circumferential strain. 
(Figure 2-1) Global as well as segmental peak systolic longitudinal, radial and 
circumferential strain and strain rates were derived. To minimize variability, user 
adjustments after the first attempt at tracking were kept to a minimum. However, 
as with any deformation technique, inaccuracies can arise, because the boundary 
between the trabecular and compact portions of the wall may shift as the blood 
spaces between the trabeculae close during systole. This can result in an 
artefactual, apparent inward motion of the endocardial contour. If this was 
deemed to be a significant problem, the cine series was re-tracked with manual 
contouring using an end-systolic frame. Tracking was repeated for three times. 
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Figure 2-1 Feature tracking CMR 4-chamber image and a short axis image 
CMR feature tracking was performed using dedicated software (Qstrain, Medis medical imaging 
systems, Leiden, Netherlands). Four chamber long axis view (A) was used to calculate LV 
longitudinal strain (EllLV). A mid-ventricular short axis slice (B) was used to calculate LV 
circumferential strain (EccLV). Radial strain (EccLV) was also calculated from the mid-ventricle short 
axis slice. The horizontal long-axis SSFP cine series was used to identify the slice closest to the true 
mid cavity at end diastole (equidistant between apex and ring). (Author’s own image)   
A B 
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2.7.2 LV intra-ventricular dyssynchrony 
The strain software tracks 48 tissue segments throughout the cardiac cycle in 
radial, circumferential and longitudinal directions. The following dyssynchrony 
indices were calculated. 1) Radial dyssynchrony - Standard deviation of the time 
to peak (TTP-SD6) radial strain of six mid ventricular myocardial segments given 
as a percentage of the length of the cardiac cycle. 2) Circumferential 
dyssynchrony - Standard deviation of the time to peak circumferential strain of 
six mid ventricular myocardial segments given as a percentage of the length of 
the cardiac cycle. 3) Longitudinal dyssynchrony - Standard deviation of the time 
to peak of seven (TTP-SD7) longitudinal myocardial segments given as a 
percentage of the length of the cardiac cycle (168). (Figure 2-2)   
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Figure 2-2 Assessment of intra-ventricular dyssynchrony 
Dyssynchrony was calculated from the standard deviation of the time to peak of six 
(radial/circumferential) or seven (longitudinal) myocardial segments and was given as a percentage 
of the length of the cardiac cycle. The figure demonstrates the circumferential strain curves (yellow 
arrow) of six myocardial segments. (Author’s own image) 
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2.8 Left atrial strain 
Left atrial myocardial feature tracking was performed using dedicated software 
(Qstrain, Medis medical imaging systems, Leiden, Netherlands). LA endocardial 
borders were manually traced using the 2-chamber and 4-chamber views using a 
point and click approach when the LA was at its minimum volume after atrial 
contraction. The atrial endocardial border surface was manually delineated, and 
the automated tracking algorithm was applied. Subsequently this was visually 
reviewed to ensure accurate tracking of the atrium. In case of insufficient 
automated border tracking, manual adjustments were made to the initial contour 
and the algorithm was reapplied. If the tracking quality was not sufficient, e.g. 
due to the presence of pulmonary veins or left atrial appendage, the 
corresponding segment was excluded from the analysis. Tracking was repeated for 
three times in both the 2 and 4-chamber view. LA longitudinal strain and SR results 
were averaged across all three repetitions in both views.  
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Figure 2-3 LA myocardial feature tracking using a 2-chamber and 4-chamber view  
Left atrial endocardial borders were manually traced using the 4-chamber (top row) and 4-chamber  
(bottom row) views using a point and click approach when the LA was at its minimum volume after 
atrial contraction. The atrial endocardial border surface was manually delineated and the automated 
tracking algorithm was applied. Subsequently this was visually reviewed to ensure accurate tracking 
of the atrium. (Image provided by Chongmiao Yang)  
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Three aspects of atrial function were analysed: 
1. Total strain, the sum of passive and active strain (εs, corresponding to atrial 
reservoir function).  
2. Passive strain (εe, corresponding to atrial conduit function) 
3. Active strain (εa, corresponding to atrial contractile booster pump function)  
Accordingly, three strain rate parameters were evaluated:  
1. Peak positive strain rate (SRs, corresponding to atrial reservoir function),  
2. Peak early negative strain rate (SRe, corresponding to atrial conduit 
function)  
3. Peak late negative strain rate (Sra, corresponding to atrial contractile 
booster pump function) 
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Figure 2-4 Left atrial strain and strain rate profiles. 
Left atrial function compromises reservoir, conduit and contractile booster pump function. Total strain 
(εs) and peak positive strain rate (SRs) correspond to reservoir function. Passive strain (εe) and peak 
early negative strain rate (Sre) correspond to conduit function. Active strain (εa) and peak late 
negative strain rate (Sra) correspond to contractile booster pump function. Profile A demonstrates 
strain, while profile B demonstrates corresponding strain rate. (Image provided by  Chongmiao Yang) 
  
A 
B 
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2.9 T1 mapping CMR 
T1 maps were acquired using a MOLLI (Modified Look-Locker Inversion Recovery) 
sequence on a mid-ventricular short axis plane with a trigger delay to coincide 
with systole. T1 maps were generated from the individual motion corrected T1 
relaxation images using dedicated software (Qmap, Medis medical imaging 
systems, Leiden, Netherlands). The LV was segmented using our modified AHA 
segmentation carefully excluding blood pool, papillary muscles and trabeculae. 
Segment 6 was drawn with the inferior RV insertion point at its centre. Segment 
4 and Segment 6 were defined as anterior and inferior RV insertion segments 
respectively. These two segments were combined to form the RV insertion region. 
Segments 1, 2 and 3 represented the LV lateral wall. Segment 5 was defined as 
the septal segment. (Figure 2-5) Definition of regions with the new myocardial 
segmentation using a modified AHA model is summarised in Table 2.2. 
In the validation cohort, subjects underwent native and post contrast T1 mapping. 
ECV values were calculated from T1 maps acquired pre and post contrast 
calibrated by blood haematocrit. ECV value was calculated as ECV = (1-
hematocrit) (1/T1 myocardium post contrast – 1/T1 myocardium pre contrast) 
(1/T1 blood post contrast – 1/ T1 blood pre contrast) (169).  
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Figure 2-5 Cardiac Magnetic Resonance mid ventricular slice T1 map of a patient with 
pulmonary arterial hypertension 
Cardiac MR native T1 map of the PAH patient demonstrating raised native T1 at right ventricular 
insertion points (arrows). The image A) uses traditional AHA segmentation and image B) 
demonstrates the novel segmentation proposed which encompasses the two insertion points into 
segments S4 and S6. T1 maps were generated from the individual motion corrected T1 relaxation 
images. The LV was segmented using our modified AHA technique carefully excluding blood pool, 
papillary muscles and trabeculae. Segment 6 was drawn with the inferior RV insertion point at its 
centre. Segment 4 and Segment 6 were defined as anterior and inferior RV insertion segments 
respectively. These two segments were combined to form the RV insertion region. Segments 1, 2 
and 3 represented the LV lateral wall. Segment 5 was defined as the septal segment. (Author’s own 
image)  
A B 
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Table 2.2 Definition of regions with the new myocardial segmentation using a modified AHA 
model. 
 
 
 
The LV was segmented using our modified AHA segmentation carefully excluding blood pool, 
papillary muscles and trabeculae. Segment 6 was drawn with the inferior RV insertion point at its 
centre. Segment 4 and Segment 6 were defined as anterior and inferior RV insertion segments 
respectively. These two segments were combined to form the RV insertion region of the 
interventricular septum. Segments 1, 2 and 3 represented the LV lateral wall. Segment 5 was defined 
as the septal segment. 
  
Segments Definition 
4 and 6 Right ventricular insertion region 
(anterior and inferior segment 
respectively) 
1, 2 and 3 LV lateral wall 
5 Septal segment 
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2.9.1 Diagnosis, commencement of treatment and follow up  
A multidisciplinary team (MDT) meeting is held at the end of the diagnostic 
admission. The MDT is attended by the pulmonary vascular consultants, consultant 
radiologists, pulmonary vascular research fellows, clinical nurse specialists and 
clinical trials nurses. For each patient undergoing assessment the relevant clinical 
history, examination findings, imaging, non-invasive investigations and pulmonary 
haemodynamics were reviewed. A diagnosis was then made in accordance with 
current PH guidelines and agreed by the MDT (30). If a diagnosis of PAH or CTEPH 
was made, then the patient was offered PAH specific treatment in accordance 
with the current clinical guidelines.  If disease-targeted therapy was commenced 
following the diagnostic admission, then the patient was reviewed in an out-
patient clinic after approximately 3-4 months, 6 months, 9 months and 12 months 
of treatment. Assessment at out-patient follow-up clinics involved history taking 
and examination, documentation of WHO FC, and a repeat 6-minute walk test was 
performed. Routine blood investigations and NT-ProBNP was performed at each 
visit. 
2.10 CMR in a Sugen-hypoxia rat model of PH 
All experimental procedures were carried out in accordance with the United 
Kingdom Animal Procedures Act (1986) and with the US NIH publication No. 85-23, 
revised 1996, and ethical approval was also granted by the University of Glasgow 
Ethics Committee. Rodents were housed in a 12-hour light dark cycle with access 
to food and water ad libitum. Male Sprague Dawley rats (three weeks) (n=32) were 
divided into two groups (n=16 in each group). Group 1) Sugen-hypoxia - a single 
dose of subcutaneous Sugen-5416 (Sigma, UK) suspended in vehicle (20mg/kg)), 
before being placed in a hypobaric chamber (atmospheric pressure 550 mbar) for 
2 weeks and then placed in normal room pressure (1013 mbar) for 3 weeks whilst 
PH developed. Group 2) Normoxia maintained at normal room pressure for 5 
weeks. In each group (n=16) half the animals entered the CMR arm of the study 
(n=8) while the other half underwent right heart catheterization for hemodynamic 
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assessment (n=8). Animals were assessed at five weeks and eight weeks from the 
beginning of the study (170). A detailed study design is discussed in chapter 6.   
2.10.1  Small animal CMR imaging.  
CMR imaging was performed in a Bruker Biospec 7-T/30-cm (Bruker Biospin, 
Ettlingen, Germany) system with a gradient coil insert (400 mT/m). Using a 72mm 
transmit birdcage resonator and 4 channel phased array rat cardiac receiver coil. 
Anesthesia was induced with gas flow at 2–3 l/min, and the isoflurane delivered 
via a vaporizer (Vetamac, Rossville, IN) at 3–4%. The exhaust was connected to 
the Omnicon F/Air device (AM Bickford). After induction, animals were maintained 
at 2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) oxygen. An 
external water jacket was used to maintain a core temperature of 37°C. During 
all procedures, body temperature, ECG, and respiration were monitored (Echo: 
Indus Instruments, Houston, TX; MRI: SA Instruments, Stony Brook, NY; Cath: 
Powerlab, Ad instruments, Colorado Springs, CO). Long and short axis scout images 
were acquired so that short axis images could be planned using a segmented, 
cardiac – triggered FLASH sequence. The images were acquired with a slice 
thickness of 1.5mm ensuring the entire biventricular length is covered. The CMR 
parameters were as follows. Slice thickness-1.50mm, field of View-30.00mm x 
30.00mm, image matrix-192 x 192 pixels, image resolution-156μm x 156μm, Flip 
angle-15 degrees, Echo time-2.50ms, Rep. time-7.02ms, number of frames-25, 
number of averages-6, software version-Paravision 5.1. 
2.10.2 CMR imaging analysis  
Scans were coded by number and analysed in batches by the author who was 
blinded to the identity and haemodynamic results at the time of analysis. 
Trabeculations and papillary muscles were considered as part of the blood pool. 
The epicardial and endocardial borders were manually outlined in end-diastolic 
and end-systolic frames using Qmass (Medis medical imaging systems, Leiden, 
Netherlands). Stroke volume was determined from LVEDV and LVESV. Ejection 
fraction [(SV/EDV)*100%] was also determined. RV and LV masses were determined 
by manual planimetry at diastole. VMI was defined as the ratio between RV to LV 
mass, with the IVS considered part of the LV. LV eccentricity index (LVEI) was 
defined as the ratio between maximum anterior-posterior to septal lateral 
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diameters of the LV and was measured at both systole and diastole. All ventricular 
volumes and mass measurements were indexed to body surface area (171). 
2.11 In vivo hemodynamic measurements 
In the small animal CMR study, the in vivo haemodynamic measurements, RV 
hypertrophy and tissue harvest, gross anatomy and pulmonary vascular 
remodelling assessment was performed with the assistance of colleagues Dr. David 
Welsh and Dr. Kat Wilson at the University of Glasgow.  
Animals were anaesthetically induced with 3% (v/v) isoflurane and then 
maintained at 2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) 
oxygen. Hemodynamic measurements were taken using an ultra-miniature 
Polyimide Nylon catheter capable of measuring ventricular pressure continuously 
(AD instruments spr-869NR, Millar). The catheter was used as per the 
manufacturer’s instructions with the PowerLab 35 Series data acquisition system 
with LabChart Pro and the pressure volume (PV) Loop analysis module. For right 
heart pressure analysis, the catheter was inserted into the jugular vein and guided 
into the RV to measure RVSP.   
2.12 RV hypertrophy and tissue harvest 
Following hemodynamic assessment, animals were culled and hearts flushed with 
PBS using a blunt needle to clear peripheral blood cells. Euthanasia consisted of 
an overdose of anaesthetic followed by a schedule 1 kill (cervical dislocation). The 
heart was isolated, atria removed and tissue fixed with 10% (v/v) neutral buffered 
formalin (NBF) for 48 hours before paraffin processing for histological analysis by 
immunohistochemistry. Tissue was sectioned by microtome at width of 5µm and 
stained by Gomori's Trichrome staining kit (Atom Scientific, Manchester, UK) as 
per manufacturer’s instructions. 
2.13 Gross anatomy postpartum 
After the heart was isolated and atria removed, the RV and LV weights were 
obtained to determine RV hypertrophy. Interventricular septum was considered 
part of the LV.  
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2.14 Pulmonary vascular remodelling 
Vascular thickening was determined by smooth muscle actin antibody (ab5694, 
Abcam, Cambridge, UK) staining, thickening was characterized by an increase in 
the vessel wall diameter of more than 50% of the arterial wall or complete 
occlusion. The number of remodelled vessels over the total number of vessels 
present in a lung section was determined. Sections were analysed in a blinded 
manner. 
2.15 Data Storage 
In all the aforementioned studies, on completion of each CMR scan, the images 
were saved to the hard-drive of the scanner and backed up onto an encrypted 
portable device. All scans were coded by number and stored in a locked office 
until data analysis. 
2.16 Statistical analysis 
In survival analysis, survival was recorded from the date of diagnostic right heart 
catheterisation and endpoint was date of either death, lung transplantation or 
censoring. All-cause mortality was used for survival analysis and patients were 
censored if they were lost to follow-up or alive at last day of study.  Survival 
predictors were determined using a bivariate Cox proportional hazard regression 
analysis with age. Results were presented as hazard ratios with 95% confidence 
intervals. Variables that were significant were considered for multivariate 
analysis. Survival of patients were compared by a long rank test.  A p-value of 
greater than 0.05 indicated a lack of statistical significance. Statistical analysis 
was performed using SPSS (IBM SPSS Statistics, USA) and Graphpad Prism 
(Graphpad Software inc, USA). Additional statistical methodology pertaining to 
each study in this thesis is described separately, within the relevant chapters. 
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 Left ventricular strain 
and intra-ventricular 
dyssynchrony by CMR in 
idiopathic pulmonary arterial 
hypertension 
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3.1 Introduction 
A review of the existing literature on cardiac and pulmonary imaging was 
presented in chapter 1. CMR is the gold standard imaging investigation of 
biventricular structure and function (172). As described in chapter 1, many CMR 
measures have shown to be strongly predictive of mortality and survival in IPAH 
thus offering potential for monitoring and determining disease response to 
treatment (15).  Stroke volume, RVEF, RVEDVI are recognised as the key CMR 
prognostic measures in PAH patients. In a multicentre study prospectively using 
CMR before and during PAH disease specific treatment, Peacock et al 
demonstrated the importance of measuring both right sided and left sided 
variables when determining cardiac function (99). The concept of ventricular 
interdependency was also discussed, although in normal conditions the impact of 
the RV on LV function is negligible, in a pressure loaded RV, LV performance may 
be affected.  Chapter 1 also discussed that measurements of myocardial 
deformation and synchrony may provide additional and incremental information 
regarding ventricular function beyond conventional volume and ejection fraction 
assessment.  
The LV myocardium is organised into three layers (128). The sub-endocardial layer 
where fibres are orientated longitudinally from base to apex, the mid-wall layer 
where the fibres are orientated circumferentially and the sub-epicardial layer 
where fibres are orientated longitudinally from apex to base. Due to this complex 
architecture, LV deformation in systole is along different directions determining 
longitudinal shortening, circumferential shortening, radial thickening and torsion.  
Myocardial strain measures the degree of deformation of a myocardial segment 
from its initial length (108). If the initial length is termed L0 and the maximum 
length L, strain can be determined by the following formula. Strain = (L – L0) / L0. 
As mentioned above, due to the different directions of the myocardial 
deformation longitudinal, circumferential and radial strain can be calculated. 
Longitudinal strain represents the longitudinal shortening from base to apex and 
is expressed as a negative value. Circumferential strain represents myocardial 
shortening along the circular perimeter on a short axis view and is expressed as a 
negative value. Radial strain represents the radially directed myocardial fibres 
deformation towards the centre of the LV cavity and indicates LV thickening and 
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thinning during the cardiac cycle. As during systole there is thickening of the 
myocardium in this direction, this is expressed as a positive value. Strain rate 
(longitudinal, circumferential and radial) represent the rate at which myocardial 
deformation occur.  
Ventricular dyssynchrony can be observed at different levels (173). Inter-
ventricular dyssynchrony is the delayed activation of one ventricle with respect 
to the other. Intra-ventricular dyssynchrony refers to the late activation of 
different regions of a single ventricle compared to other regions of the same 
ventricle. This chapter will focus on intra-ventricular dyssynchrony assessment.  
Both echocardiography and CMR imaging are capable of measuring myocardial 
strain. Echocardiographic methods of strain imaging including speckle tracking are 
limited by noise interference, angle dependency and image quality. CMR derived 
myocardial strain measurement was first achieved by CMR tagging in the 1980s 
(174). However, CMR tagging requires prospective image acquisition and time 
consuming protocols. CMR-FT is based on optical flow technology (175). In CMR-
FT anatomic elements that are different along the cavity (blood pool) and 
myocardial tissue boundary are found by methods of maximum likelihood in 2 
regions of interest between 2 frames. This is initiated by manually tracing the 
endocardium or epicardium or both usually at end-diastole. The feature tracking 
proceeds by tracking each feature along the contour, based on a hierarchical 
algorithm and combining one-dimensional tracking with two-dimensional tracking 
(176). It is important to note there may be differences in strain between different 
CMR–FT solutions (177). All two-dimensional strain techniques can be affected by 
through plane motion. CMR-FT has been validated against myocardial tagging for 
strain analysis and also against RV speckle tracking imaging for RV longitudinal 
strain evaluation (178, 179). In practical terms, CMR–FT derived strain offers 
incremental clinical information beyond measurements of LV volumes and 
ejection fraction in patients with left heart disease. There are a large number of 
studies looking at CMR–FT derived LV strain in myocardial ischaemia and viability 
detection (180, 181), dilated cardiomyopathy (182) and arrhythmogenic RV 
cardiomyopathy (183).  
Assessment of intra-ventricular dyssynchrony is well established by both tissue 
Doppler and speckle tracking echocardiography. Cho et al assessed patients with 
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congestive heart failure with a normal QRS duration and concluded that 
mechanical dyssynchrony assessed by tissue Doppler imaging to be a significant 
predictor of mortality (184). In another study of 132 patients who had undergone 
cardiac resynchronisation therapy, patients who lacked both radial and transverse 
dyssynchrony had unfavourable clinical outcomes (185).   
RV strain has been studied by CMR–FT in PH patients. In a study by de Siqueira et 
al 116 patients who were referred for PH assessment were evaluated using CMR-
FT of the RV. They concluded that CMR-FT of the RV was feasible in a majority of 
patients, and RV longitudinal and circumferential strain variables correlated with 
disease severity and were associated with poor outcomes in PH (129).   
IPAH is a disease of the pulmonary vasculature and the RV. Conceptually the LV 
function should be normal. However as mentioned in chapter 1, the RV and LV do 
not function in isolation.  In PH, RV pressure overload causes paradoxical motion 
of the IVS towards the LV disturbing LV geometry and filling. LV preload is reduced 
due to decreased cardiac output from the RV. These series and parallel 
interactions from the RV to the LV affect LV performance. There is also the 
anatomical consideration of RV dilatation in a contained pericardial sac affecting 
LV geometry (149).In a study using echocardiography, Hardegree et al studied RV 
and LV function in patients with PAH (186). They demonstrated that despite 
normal LV size and normal conventional measures of LV systolic function (end-
diastolic dimension, ejection fraction, cardiac index by echo), patients had 
reduced LV free wall systolic strain. Reduced LV strain was associated with 
increased mortality in this study. They highlighted the significance of inter-
ventricular dependence in PAH. However, they did not study LV radial strain in 
this study and had not assessed intra-ventricular dyssynchrony.  
We conducted a comprehensive retrospective study of LV strain and intra-
ventricular dyssynchrony in patients with IPAH using CMR-FT. To the best of our 
knowledge, the significance of myocardial strain and dyssynchrony of the LV using 
quantitative analysis of CMR-FT in IPAH has not been investigated. The aims of the 
study were: 1) Assessment of feasibility of performing LV longitudinal, 
circumferential and radial strain and LV intra-ventricular dyssynchrony in IPAH. 2) 
Characterise the pattern of LV strain abnormalities and intra-ventricular 
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dyssynchrony. 3) Investigate the significance of these abnormalities on disease 
severity, prognostication and survival in IPAH. 
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3.2 Methods 
3.2.1 Patient recruitment 
We retrospectively identified all patients who were referred to a tertiary referral 
centre between 2010 to 2017 for investigations of PH and underwent right heart 
catheterisation and CMR. From these, we identified 76 treatment-naïve patients 
who were diagnosed of IPAH after a multidisciplinary evaluation including blood 
investigations (autoantibodies, HIV testing and NTProBNP), right heart 
catheterization, echocardiography (including TAPSE), pulmonary function testing, 
6-minute walk distance and CT scan of thorax (CTPA and High Resolution CT 
thorax). After exclusion of six patients due to inadequate image quality, presence 
of arrhythmia and a history of myocardial infarction, 70 patients with IPAH were 
included in the present analysis. All patients underwent invasive haemodynamic 
measurements and CMR within 72 hours from catheterisation, and gave informed 
written consent to undergo these procedures. An additional group of 40 healthy 
volunteers with no known history of arrhythmias, ischaemic heart disease and lung 
disease were used as controls. A composite end point of all-cause mortality and 
lung transplantation was recorded.  The study protocol was approved by the local 
research ethics committee. 
3.2.2 CMR imaging 
CMR imaging was performed in the supine position on a 1.5T MRI scanner (Avanto, 
Siemens, Erlangen, Germany). Images were acquired during end-expiratory breath 
holds. Long axis 4-chamber cine images and contiguous short axis cine images 
covering both ventricles from base to apex were acquired with cine SSFP imaging 
with following parameters: TR (repetition time)/ TE (echo time) 3.2-3.9/0.6-2 ms, 
flip angle 45-90, slice thickness 6 mm, temporal resolution 33-45 ms, spatial 
resolution 1.5-2 mm.  
3.2.3 Right heart catheterization 
Right heart catheterisation was performed during free breathing in the supine 
position with a 7 F quadruple lumen, flow directed balloon tipped Swan – Ganz 
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catheter using the internal jugular approach. Pressure measurements including 
RAP, mPAP, dPAP, sPAP and PAWP were obtained. Cardiac output was obtained 
by thermodilution and PVR data were obtained. Mixed venous saturations were 
also obtained during right heart catheterisation. Systemic blood pressures, heart 
rate and oxygen saturations were measured during right heart catheterisation. 
The method of right heart catheterisation is described in detail in section 2.5.  
3.2.4 CMR image analysis 
All CMR images were analysed by the author using the Medis suite analysis software 
(Medis medical imaging systems, Leiden, Netherlands). A second observer (AM) 
analysed 20 scans for inter-observer agreement analysis. Individual scans were 
anonymised and analysed by the author who was blinded to the identity and 
haemodynamic results of any given subject at the time of analysis. RV and LV 
volumes (RVEDV, RVESV, LVEDV, LVESV) were determined by manual planimetry 
of selected short axis images, as described previously. Particular methodological 
points of note included the deliberate inclusion of trabeculations and papillary 
muscles in all analyses, as discussed by previous authors(166, 167). Right and left 
ventricular stroke volume (RVSV and LVSV), ejection fraction (RVEF and LVEF), 
and mass (RVM and LVM) were determined as previously described. RV mass was 
determined as RV free wall mass, the IVS was considered part of the LV. 
Ventricular Mass index was determined as RV Mass: LV Mass. For correlation 
analyses, RV and LV variables were index to body surface area (BSA). Cardiac MR 
image analysis is described in detail in chapter 2.6.2. 
3.2.5 Strain analysis 
CMR feature tracking was performed using dedicated software (Qstrain, Medis 
medical imaging systems, Leiden, Netherlands). The 4-chamber view was used to 
calculate LV longitudinal strain (EllLV). LV short axis circumferential (EccLV) and 
radial strains (ErrLV) were derived from a mid-ventricular short axis view 
containing both papillary muscles. The horizontal long-axis SSFP cine series was 
used to identify the slice closest to the true mid cavity at end diastole (equidistant 
between apex and ring). The RV upper septal insertion of the left ventricle was 
manually defined to allow accurate segmentation according to AHA segmentation 
template. Endocardial values were calculated for longitudinal and circumferential 
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strain. Global as well as segmental peak systolic longitudinal, radial and 
circumferential strain and strain rates were derived. To minimize variability, user 
adjustments after the first attempt at tracking were kept to a minimum. RV 
longitudinal strain from the 4-chamber cine images were also derived. RV 
endocardium was divided in to the RV free wall and RV septum and average RV 
longitudinal strain was also calculated.  
3.2.6 Intra-ventricular dyssynchrony 
The strain software tracks 48 tissue segments throughout the cardiac cycle in 
radial, circumferential and longitudinal directions. The following dyssynchrony 
indices were calculated. 1) Radial dyssynchrony - Standard deviation of the time 
to peak (TTP-SD6) radial strain of six mid ventricular myocardial segments given 
as a percentage of the length of the cardiac cycle. 2) Circumferential 
dyssynchrony - Standard deviation of the time to peak circumferential strain of 
six mid ventricular myocardial segments given as a percentage of the length of 
the cardiac cycle. 3) Longitudinal dyssynchrony - Standard deviation of the time 
to peak of seven (TTP-SD7) longitudinal myocardial segments given as a 
percentage of the length of the cardiac cycle (168). Figure 3-1 demonstrates a 
healthy volunteer and a patient with IPAH short axis CMR assessment of 
circumferential synchrony. 
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Figure 3-1 Left ventricular circumferential intra-ventricular synchrony in health and IPAH 
The top row represents a healthy volunteer demonstrating a short axis showing synchronous contraction and relaxation of the left ventricle. The bottom row demonstrates 
a patient with idiopathic pulmonary arterial hypertension demonstrating LV intraventricular dyssynchrony. (Author’s own image)  
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3.2.7 Statistical analysis 
Continuous variables are summarised as mean ± SD, median (interquartile range) 
depending on their distribution. Categorical variables are summarised as n (%). 
Normality of groups was assessed using a Shapiro-Wilk test.  IPAH and healthy 
volunteer groups were compared using student t-tests, Mann-Whitney U tests and 
Fisher’s exact tests, where appropriate. Spearman correlation coefficients are 
used to assess association between continuous variables.  To test for inter-
observer variability in strain measurements intra-class correlation coefficient with 
a 2-way random model of absolute agreement was used. Survival was recorded 
from the date of diagnostic right heart catheterisation and endpoint was date of 
either death, lung transplantation or censoring. All-cause mortality was used for 
survival analysis and patients were censored if they were lost to follow-up or alive 
at the last day of study.  Survival predictors were determined using a bivariate 
Cox proportional hazard regression analysis with age. Results were presented as 
hazard ratios with 95% confidence intervals. Variables that were significant were 
considered for multivariate analysis. Survival of patients were compared by a long 
rank test. A p-value of greater than 0.05 indicated a lack of statistical significance. 
Statistical analysis was performed using SPSS (IBM SPSS Statistics) and Graphpad 
Prism (Graphpad Software inc). 
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3.3 Results 
3.3.1 Demographics 
70 patients with IPAH and 40 healthy volunteers were included in the study. There 
was no significant difference between the IPAH and the healthy volunteer groups 
in terms of gender, age, BSA or weight. Demographics of the study population are 
given in table 3.1.  
Table 3.1 Demographics of the study population. 
 
 
IPAH and the healthy volunteer groups in terms of gender, age, height, weight and BSA are shown. 
There was no significant difference between the IPAH and the healthy volunteer groups in terms of 
gender, age, BSA or weight. Continuous variables are summarised as mean ± SD, median 
(interquartile range) depending on their distribution. Categorical variables are summarised as n (%).  
IPAH and healthy volunteer groups were compared using student t-tests, Mann-Whitney U tests and 
Fisher’s exact tests, where appropriate. Normality of groups was assessed using a Shapiro-Wilk test. 
A p-value of greater than 0.05 indicated a lack of statistical significance. IPAH – idiopathic pulmonary 
arterial hypertension, BSA – body surface area  
 All   
 
IPAH Healthy 
volunteer 
P value 
n 110 70 40  
Gender 
(Female) 
75 45 23 0.5429 
Age 58 (45,67) 61(46,70) 53.5(42,63) 0.0605 
Height 1.65 +/-0.9 1.63 +/- 0.8 1.68 +/- 0.9 0.0015 
Weight 78.2 +/-15.5 78.6 +/- 15.8 77.5+/- 15.1 0.7220 
BSA 1.9 +/- 0.2 1.9 +/-0.2 1.9 +/- 0.2 0.6587 
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3.3.2 CMR variables and baseline haemodynamic characteristics 
of IPAH patients 
There were no significant differences between the patient group and healthy 
volunteers in terms of LV function measured by LV ejection fraction (LVEF) (66.1% 
vs 64.2% p= 0.6672). The RV function measured by RV ejection fraction (RVEF) was 
lower in the IPAH group as expected (34% vs 58.8% p<0.0001). There were 
significant differences in not only the right sided volume variables and VMI but 
also in the left sided volume variables (all p<0.0001). The baseline CMR 
characteristics of the IPAH and healthy volunteer groups are summarised in table 
3.2.  
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Table 3.2 The baseline CMR characteristics of the IPAH and healthy volunteer group  
 
 ALL  
 
IPAH Healthy p value 
n 110 70 40  
LVEF 65.2(60.3,71.2) 66.1(57.4,71.9) 64.2(61.3,67.9) 0.6672 
RVEF 44.6(30.3,57.2) 34.0(24.9,44.1) 58.8(54.6,64.3) <0.0001 
LVEDVI 62.5 (48.7,78.6) 50.6(43.7,62.4) 79.2(76.0,90.7) <0.0001 
LVESVI 22.4(14.9,28.2) 18.3(12.5,23.6) 27.7(24.7,34.2) <0.0001 
RVEDVI 97.9(85.8,118.7) 113.5(92.0,130.6) 86.3(75.8,95.8) <0.0001 
RVESVI 52.9(37.6,78.1) 73.2(53.0,93.5) 34.7(28.9,44.2) <0.0001 
LV Mass 
index 
49.0(42.9,57.3) 46.6(41.4,55.6) 52.7(46.4,61.0) <0.05 
RV Mass 
index 
23.1(14.3,31.3) 30.6(24.2,35.3) 12.7(10.9.14.9) <0.0001 
VMI 0.5(0.3,0.7) 0.6(0.5,0.8) 0.2(0.2,0.3) <0.0001 
 
IPAH and the healthy volunteer groups in terms of biventricular function, volume and mass are 
shown. There were no significant differences between the patient group and healthy volunteers in 
terms of LV function measured by LVEF. The RV function measured by RVEF was lower in the IPAH 
group as expected. There were significant differences in not only the right sided volume variables 
and VMI but also in the left sided volume variables. Continuous variables are summarised as median 
(interquartile range) due to their distribution. IPAH and healthy volunteer groups were compared 
using Mann-Whitney U tests. Normality of groups was assessed using a Shapiro-Wilk test. A p-value 
of greater than 0.05 indicated a lack of statistical significance. LVEDVI – LV end-diastolic volume 
index, LVESVI – LV end-systolic volume index, RVEDVI – RV end-diastolic volume index, RVESVI 
– RV end-systolic volume index, VMI – ventricular mass index  
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The baseline characteristics of the IPAH group are summarised in Table 3.3. The 
patients had a mPAP range of 25-79 mmHg. Of note is the normal PAWP in the 
patient group indicating normal LV filling pressures (median PAWP 8 mmHg, range 
0 – 14 mmHg).  
Table 3.3 The baseline characteristics of the IPAH group 
 
Variable Median (interquartile range) 
Log NT pro BNP 3.2 (2.7,3.6) 
DLCO (%) 45 (26,62) 
6-minute walk distance 250 (161,388) 
TAPSE 1.5 (1.2,1.9) 
Right atrial pressure 8 (4,13) 
Mean pulmonary artery pressure 50 (44,59) 
Pulmonary artery wedge pressure 8 (5,10) 
Cardiac output 3.6 (2.8,4.2) 
Cardiac index 1.9 (1.6,2.3) 
Stroke volume index 26.6 (19.8,30.9) 
Pulmonary vascular resistance 12.3 (8.5,16.1) 
Mixed venous saturations 63.2 (53.7,68.8) 
Heart rate 77 (68,88) 
Systolic blood pressure 127 (112,147) 
The IPAH patients had a mean pulmonary artery pressure range of 25-79 mmHg. Pulmonary artery 
wedge pressure was low indicating low LV filling pressures 8(5,10) mmHg. Continuous variables are 
summarised as median (interquartile range) due to their distribution. Normality of groups was 
assessed using a Shapiro-Wilk test. LOG NT pro BNP- N Terminal pro Brain Natriuretic Peptide, 
DLCO% - diffusion capacity, TAPSE – Tricuspid Annular Plane Systolic Excursion by 
echocardiography.  
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3.3.3 Inter-observer reproducibility 
Among the variables measured radial dyssynchrony demonstrated the best 
reproducibility (ICC = 0.9 95% CI 0.765 to 0.960).  All the other variables 
demonstrated good to very good reproducibility. The results are summarised in 
table 3.4. 
Table 3.4 Reproducibility of the strain, strain rate and dyssynchrony variables  
 
 
Among the variables measured radial dyssynchrony demonstrated the best reproducibility (ICC = 
0.900 95%CI 0.765 – 0.960).  All the other variables demonstrated good to very good reproducibility. 
To test for inter-observer variability in strain measurements, intra-class correlation coefficient with a 
2-way random model of absolute agreement was used. EccLV – LV circumferential strain, EllLV – LV 
longitudinal strain, ErrLV – LV radial strain.  
  
Variable Intraclass correlation 
coefficient  
95% CI lower 
bound 
95% CI upper 
bound 
EccLV .832 .630 .928 
EllLV .863 .622 .948 
ErrLV .703 .385 .873 
LV Circ. dyssynchrony .814 .581 .922 
LV Long. dyssynchrony .853 .663 .939 
LV Radial dyssynchrony .900 .765 .960 
LV Circ. strain rate .899 .764 .959 
LV Long. strain rate .794 .517 .916 
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3.3.4 Healthy volunteer vs IPAH:  strain, strain rate and 
dyssynchrony 
3.3.4.1 Left ventricle 
There were no significant differences between the two groups in ErrLV (65.3 vs 
70.7 p=0.1729). However, EccLV (-29.1 vs -32.1 p=0.0323) and EllLV (-16.6 vs -23.7 
p<0.0001) were significantly lower in the IPAH group compared to healthy 
volunteers. LV synchrony (SD-6 and SD-7 indices) was impaired in radial (0.59 vs 
0.25 p<0.0001), circumferential (0.93 vs 0.49 p<0.0001) and longitudinal (1.45 vs 
0.89 p<0.0001) directions in the IPAH group. LV Strain rate (radial, circumferential 
and longitudinal) were not significantly different between the two groups. (Table 
3.5)  
3.3.4.2 Right Ventricle 
In the RV, free wall (-14.1 vs -27.9 p<0.0001), septum (-8.6 vs -16.6 p<0.0001) and 
average strain (-10 vs -21.5 p<0.0001) as well as strain rates were impaired in the 
IPAH group compared to the healthy volunteer group.  (Table 3.6) 
3.3.4.3 Severe vs mild / intermediate disease 
Although there was no significant difference between the patient group and 
healthy volunteer group in terms of LV radial function, patients with more severe 
disease (classified according to cardiac index <2 at right heart catheterisation) 
demonstrated impairment of ErrLV compared to patients with less severe disease 
(50.9 vs 87.5 P<0.0001). In the same analysis, EccLV (-27.2 vs -32.1 p=0.0403) and 
EllLV (-14.9 vs -19.3 p=0.0021) were also different between the severe and mild 
disease groups. LV radial dyssynchrony was higher in patients with more severe 
disease (0.89 vs 0.39 p=0.0043). Table 3.7. shows the LV and RV strain and 
dyssynchrony variables between patients with severe disease (cardiac index <2) 
and patients with less severe (intermediate and mild disease – cardiac index >2). 
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Table 3.5 Healthy volunteer vs IPAH LV strain, strain rate and dyssynchrony.  
 
Strain parameter IPAH Healthy volunteer p value 
ErrLV 65.3 (41.3,92.2) 70.7 (61.4,83.9) 0.1729 
EccLV -29.1 (-35.1,-23.7) -32.1 (-34.0,-29.7) 0.0323 
EllLV -16.6(-21.4,-12.0) -23.7(-25.2,-21.0) <0.0001 
LV Radial dyssynchrony 0.59 (0.22,0.97) 0.25 (0.18,0.3) <0.0001 
LV Circ. dyssynchrony 0.93 (0.62,1.34) 0.49 (0.21,0.8) <0.0001 
LV Long. dyssynchrony 1.45 (1.02,2) 0.89 (0.71,1.42) <0.0001 
LV Radial strain rate 2.1(1.7,2.8) 2.4(2,2.7) 0.2576 
LV Circ. strain rate -1.8(-2.2,-1.4) -1.7(-1.9,-1.5) 0.5353 
LV Long. strain rate -1.1(-1.4,-0.8) -1.1(-1.3,-0.9) 0.6090 
 
There were no significant differences between the two groups in ErrLV (65.3 vs 70.7 p = 0.1729). 
However, EccLV (-29.1 vs -32.1 p = 0.0323) and EllLV (-16.6 vs -23.7 p <0.0001) were significantly 
lower in the IPAH group compared to healthy volunteers. LV was dyssynchronous in radial (0.59 vs 
0.25 o<0.0001), circumferential (0.93 vs 0.49 p<0.0001) and longitudinal (1.45 vs 0.89 p<0.0001) 
directions in the IPAH group. LV Strain rates were not significantly different between the two groups. 
Results are shown as mean (interquartile range). The IPAH group and healthy volunteer cohort were 
compared using Mann Whitney U test. Normality of groups was assessed using a Shapiro-Wilk test. 
A p-value of greater than 0.05 indicated a lack of statistical significance. EccLV – LV circumferential 
strain, EllLV – LV longitudinal strain, ErrLV – LV radial strain. 
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Table 3.6 Healthy volunteer vs IPAH RV strain, strain rate and dyssynchrony. 
 
Strain parameter IPAH Healthy volunteer p value 
RV Free wall strain  -14.1(-19.2,-9.6) -27.9(-31.9,-24.6) <0.0001 
RV Septum strain -8.6(-12.3,-5.8) -16.6(-20.3,-13.4) <0.0001 
RV Average strain  -10.0(-14.1,-7.4) -21.5(-24.4,-19.4) <0.0001 
RV Free wall strain rate -0.8(-1.1,-0.6) -1.5(-1.6,-1.3) <0.0001 
RV Septum strain rate -0.7(-0.8,-0.5) -0.8(-1.1,-0.7) 0.0031 
RV Average strain rate  -0.6(-0.8,-0.4) -1.1(-1.2,-1) <0.0001 
In the RV, free wall (-14.1 vs -27.9 p<0.0001), septum (-8.6 vs -16.6 p<0.0001) and average strain 
(-10 vs -21.5 p<0.0001) as well as strain rates were impaired in the IPAH group compared to the 
healthy volunteer group. Results are shown as mean (interquartile range). The IPAH group and 
healthy volunteer cohort were compared using Mann Whitney U test. A p-value of greater than 0.05 
indicated a lack of statistical significance.  
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Table 3.7 Strain, dyssynchrony and strain rate measurements in IPAH patients with severe 
vs intermediate / mild disease.  
 
Strain parameter Severe disease Intermediate and 
mild disease 
 
ErrLV 50.9 +/- 25.0 87.5 +/- 33.4 <0.0001 
EccLV -27.2 +/- 9.5 -32.1 +/- 9.6  0.0403 
EllLV -14.9 +/- 5.1 -19.3 +/- 6.4 0.0021 
LV Radial dyssynchrony 0.89 (0.30,1.17) 0.39 (0.17,0.67) 0.0043 
LV Circ. dyssynchrony 1.05 (0.74,1.29) 0.83 (0.53,1.73) 0.5970 
LV Long. dyssynchrony 1.52 (1.30,2.25) 1.33 (0.92,1.89) 0.0570 
LV Radial strain rate 2.0 +/- 0.7 2.6 +/- 0.7 0.0004 
LV Circ. strain rate -1.7 (-2.1, -1.3) -1.9 (-2.5,-1.5) 0.1610 
LV Long. strain rate -1.1 (-1.2,-0.8) -1.4 (-1.5,-0.8) 0.1577 
RV free wall strain -11.0 +/- 4.1 -17.9 +/- 6.0 <0.0001 
RV septum strain -7.4 +/- 3.3 -11.3 +/- 5.5 0.0006 
RV Average strain -8.0 +/- 2.9 -14.0 +/-5.2 <0.0001 
RV free wall strain rate -0.65 (-0.8, -0.5) -1.1 (-1.3,-0.8) <0.0001 
RV septum strain rate -0.65 (-0.8, -0.5) -0.7 (-0.9, -0.6) 0.3561 
RV average strain rate -0.5 (-0.6,-0.3) -0.8 (-0.9,-0.6) <0.0001 
 
Although there was no significant difference between the patient group and healthy volunteer group 
in terms of LV radial function, patients with more severe disease (classified according to cardiac 
index <2) demonstrated impairment of ErrLV compared to patients with less severe disease (50.9 vs 
87.5 p<0.0001). EccLV (-27.2 vs -32.1 p=0.0403) and EllLV (-14.9 vs -19.3 p=0.0021) were also 
different between the severe and mild disease groups. LV radial dyssynchrony was higher in patients 
with more severe disease (0.89 vs 0.39 p=0.0043).  Disease severity was classified by cardiac index 
derived from right heart catheterisation (cardiac index < 2). Results are shown as mean+/- SD or 
median (interquartile range) as appropriate. The two groups were compared using T test or Mann 
Whitney U test as appropriate. A p value greater than 0.05 demonstrated a lack of statistical 
significance. EccLV – LV circumferential strain, EllLV – LV longitudinal strain, ErrLV – LV radial strain. 
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3.3.5 Impaired LV ejection fraction in IPAH 
A small group of patients with impaired LV ejection fraction was studied to 
understand the mechanisms of LV impairment in IPAH patients. In the subgroup 
of patients with impaired LVEF (LVEF < 55%), EllLV (-9.9 vs -31.93 p<0.0001) and 
ErrLV (32.21 vs 76.2 p<0.0001) were significantly lower than patients with 
preserved LVEF. However, EccLV (-18.82 vs -18.82 p=0.8905) was similar in the 
two groups. The results are summarised in figure 3-2.  
 
 
 
Figure 3-2 IPAH patients with preserved LV ejection fraction vs impaired LV ejection fraction 
In the subgroup of patients with impaired LVEF (LVEF < 55%) (n=12), EllLV (-9.9 vs -31.93 p<0.0001) 
and ErrLV (32.21 vs 76.2 p<0.0001) were significantly lower than patients with preserved LVEF 
(n=58). However, EccLV was similar in the two groups. The two groups were compared for each 
variable by a t test.  A p value greater than 0.05 demonstrated a lack of statistical significance. LVEF 
– LV ejection fraction, EccLV – LV circumferential strain, EllLV – LV longitudinal strain, ErrLV – LV radial 
strain. 
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3.3.6 Association with markers of disease severity 
LV radial strain was significantly associated with known markers of disease 
severity including RVEF (r=0.66), RVESVI (r=-0.59), PVR (r=0.51) and SVI (r=0.44). 
(Figure 3-3) The association of longitudinal and circumferential strain with 
markers of disease severity was significant, however with a weaker strength. 
Among the LV dyssynchrony indices, radial dyssynchrony demonstrated the 
strongest association with known markers of disease severity (r values RVEF =-
0.44, RVESVI=0.46 respectively). The association of strain rate measurements 
were consistent with the aforementioned LV strain values. Considering the RV 
strain variables, RV average strain (average of septal and free wall strain) 
demonstrated strong association with RVEF (r=-0.7), RVESVI (r=0.63) and SVI (r=-
0.63). The LV and RV strain variables and association with markers of disease 
severity are summarised in appendix 1 and 2.  
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Figure 3-3 Association of LV radial strain with RV ejection fraction (A) and RV end-systolic 
volume index (B) and association of RV average strain with RVEF (C) by CMR.  
LV radial strain was significantly associated with known markers of disease severity including RV 
ejection fraction (r=0.66 p <0.0001) and RV end-systolic volume index (r=-0.59 p<0.0001). RV 
average strain (average of septal and free wall strain) demonstrated strong association with RVEF 
(r=-0.7 p<0.0001).  Spearmen correlations were used to assess association between continuous 
variables as appropriate. ErrLV – LV radial strain, RVEF – RV ejection fraction, RVESVI – RV end-
systolic volume index. 
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3.3.7 Baseline survival analysis 
In the cohort of 70 patients with IPAH, 25 deaths occurred during the follow up 
period. Median survival was 6.19 years. RVEF by CMR, cardiac index (right heart 
catheterisation), stroke volume index (right heart catheterisation), TAPSE by 
echocardiography, and CMR derived ErrLV, radial strain rate and radial 
dyssynchrony were predictive of death on bivariate cox proportional hazards 
regression with age. Right heart catheter derived mPAP was not a predictor of 
death in this model.  The results are summarised in table 3.8.  
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Table 3.8 Bivariate Cox proportional hazard regression analysis for survival in IPAH 
patients.  
 
Variable 
 
HR 95% CI P value 
LVEF 0.975 (0.937 – 1.015)  0.222 
RVEF 0.911 (0.866-0.959) <0.001 
RAP  1.002 (0.935-1.073) 0.956 
mPAP  0.997 (0.956-1.041) 0.900 
Cardiac index 0.397 (0.164-0.961) 0.041 
PVR 1.083 (0.997-1.176) 0.060 
SVI  0.936 (0.885-0.991) 0.023 
TAPSE 0.363 (0.145-0.908) 0.030 
ErrLV 0.967 (0.949-0.985) <0.001 
EccLV  1.001 (0.963-1.041) 0.952 
EllLV 1.001 (0.945-1.061) 0.971 
LV Radial dyssynchrony 3.329 (1.688-6.566) <0.001 
LV Circ. dyssynchrony 0.696 (0.453-1.070) 0.099 
LV Long. dyssynchrony 0.777 (0.453-1.331) 0.358 
LV Radial strain rate 0.396 (0.190-0.825) 0.013 
LV Circumferential strain rate 0.921 (0.605-1.402) 0.701 
LV Longitudinal strain rate 0.608 (0.216-1.715) 0.347 
RV free wall strain 1.070 (0.997-1.148) 0.059 
RV septal strain 1.013 (0.936-1.096) 0.754 
RV average strain 1.068 (0.982-1.161) 0.125 
RV free wall strain rate 1.446 (0.410-5.103) 0.567 
RV septal strain rate 0.399 (0.090-1.768) 0.226 
RV average strain rate 1.061 (0.211-5.348) 0.943 
 
In the cohort of 70 patients with IPAH, RVEF, cardiac index, stroke volume index, ErrLV, radial strain 
rate and radial dyssynchrony were predictive of death on bivariate cox proportional hazards 
regression with age. Data are shown as Hazard ratio with 95% confidence interval. All variables are 
analysed with age. A p value greater than 0.05 demonstrated a lack of statistical significance. LVEF 
– LV ejection Fraction, RVEF – RV ejection Fraction, RAP – right atrial pressure, mPAP – mean 
pulmonary artery pressure, PVR – pulmonary vascular resistance, SVI – stroke volume index, 
TAPSE – tricuspid annular systolic plane excursion, EccLV – LV circumferential strain, EllLV – LV 
longitudinal strain, ErrLV – LV radial strain. 
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In a multivariate model with age, SVI and PVR, ErrLV (HR 0.970 CI 0.952 – 0.989 
p=002) and radial dyssynchrony (HR 3.759 CI 1.745 8.097 p<0.0001) independently 
predicted survival. In the same multivariate model RVEF independently predicted 
survival (HR 0.902 CI 0.839-0.969 p=0.005), however TAPSE by echocardiography 
did not (HR 0.622 CI 0.205-1.887 p 0.402). These are shown in table 3.9.  
Table 3.9 Multivariate cox proportional hazard regression model for survival in IPAH 
patients  
 
a) 
b) 
 
Multivariate Cox proportional hazard regression model for survival in IPAH patients including a) radial 
strain as a prognostic variable b) radial dyssynchrony as prognostic variable. In a multivariate model 
with age, SVI and PVR, ErrLV (HR=0.970 p=0.002) and radial dyssynchrony (HR=3.759 p<0.0001) 
independently predicted survival. In the same multivariate model RVEF independently predicted 
survival however, TAPSE by echocardiography did not. A p value greater than 0.05 demonstrated a 
lack of statistical significance. SVI – stroke volume index, PVR – pulmonary vascular resistance, 
ErrLV – LV radial strain.  
  
 Hazard Ratio 95% Confidence Interval  p value 
Age 1.098 (1.052-1.146) <0.001 
SVI 0.955 (0.881-1.035) 0.259 
PVR 0.973 (0.858-1.103) 0.665 
ErrLV 0.970 (0.952-0.989) 0.002 
 Hazard Ratio 95% Confidence Interval  p value 
Age 1.019 (1.047-1.136) <0.001 
SVI 0.919 (0.841-1.004) 0.062 
PVR 0.970 (0.852-1.103) 0.639 
Radial 
dyssynchrony 
3.759 (1.745-8.097) <0.0001 
114 
 
The Kaplan-Meyer survival curves according to median value for ErrLV, RVEF and 
PVR are shown in Figure 3-4. Survival was worse in IPAH patients with LV radial 
strain < 65.3 (Logrank p=0.05), however low RVEF and low PVR at right heart 
catheterisation was not statistically significant. 
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Figure 3-4 Kaplan Meir curves demonstrating survival of IPAH patients 
Kaplan Meir curves demonstrating survival of IPAH patient with a) LV radial strain and b) RVEF and 
c) Pulmonary vascular resistance. Survival was worse in IPAH patients with low ErrLV, however low 
RVEF or high PVR was not statistically significant. The Kaplan-Meyer survival curves were 
determined by median values. A p value greater than 0.05 demonstrated a lack of statistical 
significance. ErrLV – LV radial strain, RVEF – RV ejection fraction. PVR – pulmonary vascular 
resistance. 
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3.4 Discussion  
The major findings of our study are as follows:  
1) Evaluation of LV strain in radial, circumferential and longitudinal directions is 
feasible in IPAH patients by CMR-FT.  
2) LV longitudinal strain and (LV circumferential strain to a lesser extent) is 
impaired in patients with IPAH compared to age matched healthy controls, and LV 
is dyssynchronous in radial, circumferential and longitudinal directions in IPAH.  
3) In more severe disease, LV radial strain is impaired compared to patients with 
less severe disease.  
4) LV strain variables especially radial strain and radial dyssynchrony indices are 
associated with markers of disease severity in IPAH  
5) LV radial dysfunction is associated with poor outcome in patients with IPAH and 
may provide incremental value to known CMR derived RV variables in IPAH.  
In IPAH there is progressive pulmonary vasoconstriction resulting in an increased 
afterload to the RV. Right ventricle initially adapts by increasing muscle thickness 
and contractility which is termed coupling. With advancing disease, the 
hypertrophy process will be halted and subsequently stroke volume will decrease. 
The RV dilates and the heart rate will increase to maintain RV cardiac output. 
Finally, RV uncoupling will occur with falling stroke volume. As uncoupling occur 
at a severe stage of the disease, the mechanisms of adaptations of the RV to 
prevent uncoupling/ maintain coupling become important in determination of 
survival of patients with PAH. Thus, traditionally measures of RV stroke volume, 
RV end diastolic and RV end systolic volume as well as RVEF and SV/ RVESV have 
been variables monitored during follow up of patients with PAH and have shown 
to be of high prognostic value (149).   
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Although it is well established that RV function, especially that relating to the 
dynamic function of the right heart is associated with outcome in PAH patients, 
some left heart variables are known to have better correlations with cardiac 
function in IPAH patients. LVEDV is more closely related to RV stroke volume than 
RVEDV in PH patients (16). Echocardiography studies had also demonstrated that 
LV eccentricity index but not RVEDV to be closely associated with outcome in PAH 
(36). Previous studies have also demonstrated that poor LV output in PH is related 
to poor LV filling and prolonged contraction time of the RV. These studies have 
therefore highlighted the importance of LVEDV as it reflected both reduced RV 
output and prolonged RV contraction time (187, 188). 
The LV myocardium is organized into three distinctive layers; the sub-endocardial 
layer formed by fibred orientated longitudinally from base to apex, the sub-
epicardial layer with fibres orientated from apex to base and the mid wall layer 
with fibres orientated along the circumferential axis. Due to this architecture the 
normal LV deforms along several different directions: longitudinal and 
circumferential shortening, radial thickening and torsion (128). After myocardial 
infarction it is known that both LV longitudinal and circumferential function are 
independent predictors of outcome, and circumferential function was predictive 
of LV remodelling, suggesting that the circumferential function serves to restrain 
ventricular enlargement after MI (189).  Although myocardial strain is most 
extensively studied in ischaemic heart disease, LV myocardial strain is also 
impaired in non-ischaemic heart diseases including dilated cardiomyopathy, 
hypertrophic cardiomyopathy and acute myocarditis providing prognostic 
information as well as pathophysiological insights in patients with left heart 
disease (190, 191).  
The impact of the RV on LV function is minimal under normal conditions. However, 
this does change when it comes to a pressure loaded RV. There are both parallel 
and series interactions of the RV on the LV. In PH, the direct effect of the 
paradoxical motion and the bowing of the interventricular septum impairs early 
diastolic filling of the LV. This is due to the prolonged isovolumetric contraction 
of the RV (150). The main mechanism appears to be increased RV wall tension; RV 
contraction continues while the LV is already in its diastolic phase.  LV filling is 
also affected by the low RV cardiac output. There is also the anatomical 
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consideration of RV dilatation with a geometrically restricted pericardial sac.  
Thus, measures of ventricular interaction and interdependency are extremely 
useful to assess disease severity as this not only contains information regarding 
stroke volume but also increasing RV wall tension. As mentioned in the 
introduction, several large studies in the past have shown the prognostic value of 
LV volume variables in PAH patients (99).  
LV strain measurements, especially LV radial and circumferential strain as well as 
LV intra-ventricular dyssynchrony, reflect the effects of parallel effect of RV 
septal bowing and the series effect of low RV cardiac output. Thus, it is not 
surprising that some of these measurements are coming out as superior prognostic 
markers compared to RV function/ volume. As discussed in the introduction, 
because of the ventricular interdependency, measures of ventricular interaction 
are clinically useful to measure disease state as they contain information on the 
stroke volume as well as wall tension. Parameters that incorporate post systolic 
isovolumetric time such as the myocardial performance index have also shown to 
be of clinical relevance (37).  
A small group of IPAH patients who had impaired LV ejection fraction (LVEF < 55% 
by CMR) were also studied to understand the mechanisms of LV impairment in this 
patient group. The LV longitudinal and radial function were significantly impaired, 
and LV circumferential function was preserved in IPAH patients who had impaired 
LVEF. We can hypothesise that LV maintains its ejection function initially by radial 
and circumferential contraction (in the setting of reduced longitudinal function) 
and subsequently LV radial function is impaired too as the disease progress.  
The alternative explanation for impaired LV mechanics in this study is the possible 
presence of intrinsic left heart disease in this population. All subjects included in 
this study met the conventional classification of group 1 with a mPAP of ≥25 mm Hg 
and a PAWP ≤15 mm Hg. Patients with raised PAWP were excluded and the patient 
population had a median PAWP of 8 mmHg. It is also important to note the 
diagnosis of IPAH was based on multiple imaging modalities discussed at a multi-
disciplinary meeting, including the absence of other features pointing to left heart 
disease, such as the presence of a dilated left atrium, pleural effusions, septal 
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lines etc. However, it is difficult to exclude that patients may have had elevations 
in left atrial pressure in the past.  
This study demonstrated that LV strain is significantly impaired in patients with 
IPAH compared to healthy volunteers. This is despite the conventional measure of 
LV function i.e. LVEF being preserved in a majority of the patients. In patients 
with more severe disease the LV strain impairment is more significant. LV lacks 
intra-ventricular synchrony in radial, circumferential and longitudinal directions 
in patients with IPAH compared to healthy volunteers. These abnormalities in 
strain and synchrony are associated with known markers of disease severity 
including haemodynamic markers, CMR markers and echocardiography derived 
TAPSE. Interestingly, both LV radial strain and dyssynchrony was superior to 
conventional markers of disease prognosis including stroke volume index derived 
at right heart catheterisation and RV ejection fraction measured by CMR in 
predicting survival.  
In the pan European EURO-MR study (99), patients with PH who were on disease 
targeted therapy demonstrated significant improvements not only in RV variables 
but in LVEF and LVEDV. Increases in 6-minute walk distance correlated with 
LVEDV. These results indicate that LV CMR-FT appear to be sensitive to the degree 
of disease severity than LVEDV, thus potentially providing a novel, sensitive 
marker of monitoring treatment response and disease progression in PAH patients. 
Previous studies had shown that under filling of the LV may also bring the LV 
myocytes into an atrophic state (17). Manders et al demonstrated substantially 
reduced contractile function in cardiomyocytes in a study of PAH patients using 
CMR and myocardial biopsy. Left ventricular dysfunction is also recognised as a 
post-operative complication in IPAH patients who have undergone lung 
transplantation (192). This is of importance as unloading the RV and improving LV 
preload might induce LV failure. Thus, the impact of pharmaceutical as well as 
mechanical interventions in PAH patients on the LV mechanics is of extremely 
importance and need to be explored in detail in a future study.  
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3.5 Conclusion 
Patients with IPAH had significant differences in LV strain and synchrony when 
compared to healthy volunteers despite the conventional measures of LV systolic 
function (LV ejection fraction) being normal in a majority. Furthermore, IPAH 
patients with more severe disease demonstrated worse LV strain and LV intra-
ventricular dyssynchrony when compared to patients with less severe disease. LV 
strain and intra-ventricular dyssynchrony, especially LV radial function, were 
associated with known markers of disease severity and predicted survival in 
patients with IPAH. These LV variables will provide incremental value to known 
RV CMR variables in terms of their ability to reflect disease severity and predict 
survival.  
3.6 Limitations 
There are several limitations to our study. This was a single centre retrospective 
observational study. There were patients who were diagnosed with IPAH who were 
not included in the study if they did not undergo cardiac MR imaging. This may 
exclude patients with severe breathlessness who probably did not manage CMR 
(breath holding difficulties) and may also exclude patients with mild disease who 
may not be diagnosed till they show significant symptoms. Survival analysis was 
done with a relatively small number of events (n= 25 deaths). A large-scale 
multicentre study is required to validate the findings of this study. Secondly, CMR 
feature tracking can be affected by through plane motion artefacts and also is 
limited by pixel size (175, 193). Previous feature tracking strain studies have 
demonstrated significant variability of strain values, mainly due to the lack of 
standardization in signal acquisition and image processing (177). In this study the 
interrater reproducibility of the variables was good to very good, however radial 
strain reproducibility demonstrated a wide confidence interval (Table 3.4). This 
study didn’t examine LV torsion and previous literature had proposed decreased 
LV torsion with delayed diastolic untwisting as a mechanism of LV diastolic 
dysfunction in PAH patients (130).  
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4.1 Introduction 
In the previous chapter, the study demonstrated impaired LV mechanics in 
patients with IPAH despite the conventional measures of LV function being normal. 
These LV variables were probably superior to known RV CMR variables in terms of 
their ability to reflect disease severity and predict survival in IPAH patients.  
In patients with PH, left atrial assessment has been limited to measuring the 
volume or area of the LA. PH due to heart failure with preserved ejection fraction 
(HFpEF) occurs as a result of impaired LV distensibility and relaxation. 
Distinguishing PH due to HFpEF (group 2 PH) from PAH is extremely important, as 
there is currently no evidence for using pulmonary vasodilators in the treatment 
of patients with group 2 PH. At present, right heart catheterisation is the definite 
investigation to confirm the diagnosis, a raised PAWP indicating group 2 disease. 
However, assessment of LA volume by CMR has been used to distinguish PAH from 
PH due to HFpEF. Crawley et al showed that left atrial volume of 43 ml/m2   to be 
a useful mean of distinguishing between PAH and group 2 PH, avoiding the need 
for invasive right heart catheterisation (18).   
Left atrial function is increasingly used to have a significant role in the prognosis 
and risk stratification in different cardiac diseases. The principal role of the LA is 
to modulate LV filling by three basic functions. They are reservoir function 
(collection of pulmonary venous return during LV systole), conduit function 
(passage of blood to the LV during early ventricular diastole) and booster pump 
function (during late diastole augmentation of LV filling) (153).  
When assessing LA function, it is important to recognise that there is significant 
interplay that exist between LA and LV performance during the cardiac cycle. 
Reservoir function is defined by atrial compliance during ventricular systole, 
however this is influenced by LV end-systolic volume. Conduit function is 
dependent on atrial compliance during ventricular diastole; however, is closely 
related to LV relaxation and stiffness and is reciprocally related to atrial reservoir 
function. Atrial booster function is dependent on the degree of venous return 
(atrial preload), magnitude and timing of atrial contractility and also on LV end-
diastolic pressure (atrial afterload) (153, 194).  
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Although LA volume has shown to correlate with cardiovascular outcomes there is 
an increasing amount of evidence suggesting that LA functional measurements will 
provide incremental and stronger evidence than LA volume alone. In a study using 
speckle tracking echocardiography by Mondillo et al, LA deformation mechanics 
were impaired in patients with systemic hypertension and diabetes with normal 
LA size (195). In another study by Kojima et al, where velocity encoded 
echocardiogram was used to assess LA function in patients with paroxysmal AF, LA 
functional impairment was observed before enlargement of LA (196).  
LA function is assessed by echocardiography using volumetric analysis, spectral 
Doppler analysis or by tissue Doppler analysis. Volumetric assessment of the LA is 
obtained by measuring LA volumes at their maximum (at end-systole before the 
opening of the mitral valve) and at their minimum (at end-diastole as the mitral 
valve closes) and immediately before the atrial systole (before the p wave on 
ECG). From these volumes, total ejection fraction, passive ejection fraction and 
active ejection fraction can be calculated. Spectral Doppler analysis uses trans-
mitral, pulmonary venous and left atrial appendage flows. Tissue velocities during 
ventricular systole (S’) and early diastole (E’) correspond to the atrial reservoir 
and atrial conduit function (194).  
There are a large number of studies using echocardiography derived LA function 
analysis in determining prognosis and risk stratification in different cardiac 
diseases. In the Dallas heart study of 1802 patients, LA emptying fraction but not 
the LA volume index was independently associated with mortality. It added 
incremental power to the Framingham risk score (197).  In a community-based 
cohort, LA emptying fraction was a predictor of cardiovascular events and its 
predictive ability was stronger than for LA volumes suggesting that LA dysfunction 
may represent a more advanced state of LA remodelling than LA enlargement 
(198).  
Echocardiography derived LA strain analysis has also been extensively studied in 
patients with left heart diseases. In patients HCM, echocardiography derived LA 
booster function was augmented while they observed impaired reservoir and 
conduit function. Kobayashi et al also observed that LA function was impaired 
even in patients with minimally symptomatic non obstructive HCM (199).  In 
patients who have suffered an acute coronary syndrome, LA function determined 
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by tissue Doppler imaging predicted adverse cardiac outcomes adding to 
prognostication of these patients (200).  
As mentioned in previous chapters’ CMR-FT is a new post-processing technique 
allowing the quantification of myocardial strain and strain rate using standard 
SSFP cine images. Kowallick et al demonstrated that CMR–FT to reliably quantify 
LA longitudinal strain and strain rate from standard SSFP cine images 
discriminating between patients with impaired LV relaxation and healthy controls 
(154). In the above study by Kowallick et al, they demonstrated significantly 
decreased passive strain in patients with HFpEF and HCM corresponding to 
impaired conduit function. As atrial conduit function is closely related to LV 
compliance, the authors suggested that this represented impaired LV relaxation. 
In the same study, total strain and peak positive SR which correspond to atrial 
reservoir function were decreased in HCM and HFpEF that might indicate impaired 
atrial compliance. They also showed increased active strain and peak late negative 
strain rate corresponding to booster pump function in HCM while decreased in 
HFpEF. They hypothesised that this may represent an initial increase in LA booster 
pump at early stages of impairment of LV relaxation followed by progressive 
decompensation of global LA performance. This was also demonstrated in a study 
by Murata et al using 3D echocardiography to study atrial function (155).  
Although PAH is partly defined by normal LV filling pressures, LV 
function/performance can be affected. RV pressure overload causes paradoxical 
motion of the inter-ventricular septum towards the LV disturbing LV geometry and 
filling. LV preload is reduced due to decreased cardiac output from the RV. These 
parallel and series interactions from the RV to the LV affect LV performance. 
There is also the anatomical consideration of RV dilatation in a contained 
pericardial sac (149). Considering the significant interplay that exist between LA 
and LV performance during the cardiac cycle, studying LA function may provide 
additional/ incremental information regarding cardiovascular performance in PAH 
patients.  
A comprehensive retrospective study of LA strain in patients with IPAH was 
conducted. To the best of our knowledge, the significance of LA strain has not 
been studied in patients with IPAH. The aims of the study were a) Determining the 
feasibility of performing LA strain in IPAH 2) To characterise the pattern of LA 
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strain abnormalities in IPAH 3) Investigate the significance of these abnormalities 
on disease severity in IPAH.  
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4.2 Methods 
4.2.1 Patient recruitment 
We retrospectively identified all patients who were referred between 2010 to 2017 
for investigations of PH and underwent right heart catheterisation and CMR. From 
these, we identified treatment-naïve patients who were diagnosed of IPAH after 
a multidisciplinary evaluation including blood investigations (autoantibodies, HIV 
testing), right heart catheterization, echocardiography, pulmonary function 
testing and CT scan of thorax (CT pulmonary angiogram and High Resolution CT 
thorax). After exclusion of patients due to inadequate image quality, presence of 
arrhythmia and a history of myocardial infarction, 56 patients with IPAH were 
included in the present analysis.  A majority of these patients as well as healthy 
volunteers were also included in the study described in chapter 3.   All patients 
underwent invasive haemodynamic measurements and CMR within 72 hours from 
catheterisation and gave informed written consent to undergo these procedures. 
An additional group of 30 healthy volunteers with no known history of arrhythmias, 
ischaemic heart disease and lung disease were used as controls. The study protocol 
was approved by the local research ethics committee. 
4.2.2 CMR imaging  
CMR imaging was performed in the supine position on a 1.5T MRI scanner (Avanto, 
Siemens, Erlangen, Germany). Images were acquired during end-expiratory breath 
holds. Long axis 4 chamber cine images and contiguous short axis cine images 
covering both ventricles from base to apex were acquired with cine SSFP imaging 
with following parameters: TR (repetition time)/ TE (echo time) 3.2-3.9/0.6-2 ms, 
flip angle 45-90, slice thickness 6 mm, temporal resolution 33-45 ms, spatial 
resolution 1.5-2 mm.  
4.2.3 Right heart catheterization 
Right heart catheterisation was performed during free breathing in the supine 
position with a 7 F quadruple lumen, flow directed balloon tipped Swan – Ganz 
catheter using the internal jugular approach. Pressure measurements including 
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RAP, mPAP, dPAP, sPAP and PAWP were obtained. Cardiac output was obtained 
by thermodilution and PVR data were obtained. Mixed venous saturations were 
also obtained during right heart catheterisation. Systemic blood pressures, heart 
rate and oxygen saturations were measured during right heart catheterisation. 
The method of right heart catheterisation is described in detail in chapter 2.5.  
4.2.4 CMR image analysis 
All MR images were analysed by the author using the Medis suite analysis software 
(Medis medical imaging systems, Leiden, Netherlands). Individual scans were 
anonymised and analysed by the author who was blinded to the identity and 
haemodynamic results of any given subject at the time of analysis. RV and LV 
volumes, mass and function were determined by manual planimetry as described 
in the methodology chapter 2.6.2.  
4.2.5 Strain 
LA myocardial feature tracking was performed using dedicated software (Qstrain, 
Medis medical imaging systems, Leiden, Netherlands). LA endocardial borders 
were manually traced using the 2-chamber and 4-chamber views using a point and 
click approach when the LA was at its minimum volume after atrial contraction. 
The atrial endocardial border surface was manually delineated and the automated 
tracking algorithm was applied. Subsequently this was visually reviewed to ensure 
accurate tracking of the LA. (Figure 2-3 and Figure 2-4) In case of insufficient 
automated border tracking, manual adjustments were made to the initial contour 
and the algorithm was reapplied. If the tracking quality was not sufficient, e.g. 
due to the presence of pulmonary veins or left atrial appendage, the 
corresponding segment was excluded from the analysis. Tracking was repeated for 
three times in both the 2- and 4-chamber view. LA longitudinal strain and SR 
results were averaged across all three repetitions in both views. Three aspects of 
atrial function / strain were analysed.  
1. εs, Reservoir function. (Total strain) 
2. εe, Conduit function (Passive strain) 
3. εa, Booster pump function (Active strain)  
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Accordingly, three strain rate parameters were evaluated.   
1. Peak positive strain rate (SRs, corresponding to atrial reservoir function),  
2. Peak early negative strain rate (SRe, corresponding to atrial conduit 
function)  
3. Peak late negative strain rate (SRa, corresponding to atrial contractile 
booster pump function) 
These strain rate and strain rate measurements are shown in figure 4-1. 
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Figure 4-1 Left atrial function compromises reservoir, conduit and contractile booster pump 
function.  
Total strain (εs) and peak positive strain rate (SRs) correspond to reservoir function. Passive strain 
(εe) and peak early negative strain rate (SRe) correspond to conduit function. Active strain (εa) and 
peak late negative strain rate (SRa) correspond to contractile booster pump function.  
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4.2.6 Statistical Analysis 
Continuous variables are summarised as mean ± SD, median (interquartile range) 
depending on their distribution. Categorical variables are summarised as n (%). 
Normality of groups was assessed using a Shapiro-Wilk test.  IPAH and healthy 
volunteer groups were compared using student t-tests, Mann-Whitney U tests and 
Fisher’s exact tests, where appropriate. Spearman correlation coefficients are 
used to assess association between continuous variables. A p-value of greater than 
0.05 indicated a lack of statistical significance. Statistical analysis was performed 
using SPSS (IBM SPSS Statistics) and Graphpad Prism (Graphpad Software inc).  
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4.3 Results 
4.3.1 Demographics 
Eighty-six patients were included in the analysis which included 56 patients with 
IPAH and 30 healthy volunteers. There was no significant difference between the 
IPAH and the healthy volunteer groups in terms of gender, age, or weight. 
Demographics of the study population are given in table 4.1. 
Table 4.1 Demographics of the study population 
 
 
There was no significant difference between the IPAH and the healthy volunteer groups in terms of 
gender, age, or weight. Continuous variables are summarised as mean ± SD, median (interquartile 
range) depending on their distribution. Categorical variables are summarised as n (%). Normality of 
groups was assessed using a Shapiro-wilk test.  PH and healthy volunteer groups were compared 
using student T tests, Mann-Whitney U tests and Fisher’s exact tests, where appropriate. A p-value 
of greater than 0.05 indicated a lack of statistical significance. 
  
 All IPAH Healthy volunteer p value 
n 86 56 30  
Gender (Female) 46 31 15 0.5429 
Age 58 (46,70) 62 (47,70) 50 (43,62) 0.0658 
BSA 1.65 +/-0.9 1.63 +/- 0.8 1.69 +/- 0.9 0.0007 
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4.3.2 CMR variables and baseline haemodynamic characteristics 
of IPAH patients 
There were no significant differences between the patient group and healthy 
volunteers in terms of LV function measured by LV ejection fraction (LVEF) (67.0% 
vs 63.8% p= 0.3890). The RV function measured by RV ejection fraction (RVEF) was 
lower in the IPAH group as expected (34.7% vs 63.8% p<0.0001). There were 
significant differences in not only the right sided volume variables and VMI but 
also in the left sided volume variables (all p<0.0001). The baseline CMR 
characteristics of the IPAH and healthy volunteer groups are summarised in table 
4.2.  
Table 4.2 The baseline CMR characteristics of the IPAH and healthy volunteer group 
 
 
 ALL IPAH Healthy p value 
LVEF 66.1(60.4,71.5) 67.0(59.7,72.3) 63.8(61.3,67.5) 0.3890 
RVEF 45.0(32.8,56.1) 34.7(28.0,45.1) 63.8(61.3,67.5) <0.0001 
LVEDVI 63.6 (48.9,77.5) 50.8(46.7,64.0) 78.4(75.0,90.6) <0.0001 
LVESVI 22.4(14.8,28.2) 18.2(12.4,23.3) 27.8(24.8,33.8) <0.0001 
RVEDVI 97.4(86.5,116.4) 106.5(90.1,129.7) 88.2(77.2,96.9) <0.0001 
RVESVI 50.4(38.1,75.1) 70.2(50.1,89.3) 37.4(31.5,44.5) <0.0001 
LV Mass index 50.0(43.0,58.1) 49.4(42.4,56.2) 55.0(45.6,61.3) 0.1022 
RV Mass index 23.1(13.7,31.3) 30.6(23.4,35.2) 12.7(11.1.14.8) <0.0001 
VMI 0.5(0.3,0.6) 0.6(0.5,0.7) 0.3(0.2,0.3) <0.0001 
 
There were no significant differences between the patient group and healthy volunteers in terms of 
LV function measured by LV ejection fraction (LVEF) (67 vs 63.8 p=0.3890). The RV function 
measured by RV ejection fraction (RVEF) was lower in the IPAH group (34.7 vs 63.8 p<0.0001). 
Results are shown as median (interquartile range). IPAH and healthy volunteer groups were 
compared using Mann-Whitney U test. A p-value of greater than 0.05 indicated a lack of statistical 
significance. LVEDVI – LV end-diastolic volume index, LVESVI – LV end-systolic volume index, 
RVEDVI – RV end-diastolic volume index, RVESVI – RV end-systolic volume index, VMI – ventricular 
mass index  
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The baseline characteristics of the IPAH group are summarised in Table 4.3. The 
patients had a mPAP of 51 (43,59) mmHg. As mentioned in the previous chapter 
of note again is the low PAWP of 8 (3,9) mmHg in the patient group ensuring that 
patients with intrinsic left heart disease are excluded.  
Table 4.3 The baseline characteristics of the IPAH group 
 
Variable Median (interquartile range) 
LogNTproBNP 3.1 (2.7,3.5) 
DLCO (%) 35 (26,57) 
6-minute walk distance 245 (140,365) 
TAPSE 1.3 (1.45,1.88) 
Right atrial pressure 7 (4,10) 
Mean pulmonary artery pressure 51 (43,59) 
Pulmonary artery wedge pressure 8 (3,9) 
Cardiac output 3.7 (3,4.3) 
Cardiac index 2 (1.5,2.4) 
Stroke volume index 27.6 (20.5,30.9) 
Pulmonary vascular resistance 12.1 (8.3,16.5) 
Mixed venous saturations 64 (56,69) 
Heart rate 75 (66,85) 
Systolic blood pressure 129 (113,148) 
The patients had a mPAP of 51 (43,59) mmHg and low PAWP 8 (3,9) mmHg. Continuous variables 
are summarised as median (interquartile range) due to their distribution. LogNTproBNP- N Terminal 
pro Brain Natriuretic Peptide, DLCO% - diffusion capacity, TAPSE – Tricuspid Annular Plane Systolic 
Extraction by Echocardiography.  
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4.3.3 Healthy volunteer vs IPAH:  left atrial strain and strain rate 
4.3.3.1 Left atrial strain 
Left atrial strain indices of εs (23.6 vs 32.8 p < 0.0001) and εe (6.1 vs 18.2 p < 
0.0001) corresponding to atrial reservoir function and conduit function 
respectively were impaired in IPAH patients compared to healthy volunteers. 
There was no significant difference in LA εa corresponding to booster pump 
function, however active strain was higher in IPAH patients compared to healthy 
volunteers (17.3 vs 13.9). The results are summarised in table 4.4.  
Table 4.4 Healthy volunteer vs IPAH Left atrial strain  
 
 
Left atrial εs corresponding to reservoir function (23.6 vs 32.8 p<0.0001) and εe corresponding to 
conduit function (6.1 vs 18.2 p<0.0001) was significantly lower in IPAH patients. Although εa wasn’t 
different between the two groups, was higher in IPAH patients (17.3 vs 13.9 p=0.4692). Results are 
shown as median (interquartile range). IPAH and healthy volunteer groups were compared using 
Mann-Whitney U test. A p-value of greater than 0.05 indicated a lack of statistical significance. εs = 
total strain corresponding to reservoir function, εe = passive strain corresponding to conduit function 
and εa = active strain corresponding to booster pump function of the left atrium.  
 
 
  
Strain parameter IPAH Healthy volunteer p value 
εs 23.6 (16.3,29.5) 32.8 (28.8,42.6) <0.0001 
εe 6.1 (3.4, 10.4) 18.2(14.9,24.9) <0.0001 
εa 17.3 (11.7, 21.2) 13.9 (12.1,19.1) 0.4692 
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4.3.3.2 Left atrial strain rate 
SRe (corresponding to conduit function) was significantly lower in IPAH patients 
compared to healthy volunteers (-0.39 vs -1.0 p < 0.0001). However, there were 
no significant differences between the IPAH and healthy volunteer group in SRs or 
SRa.  Results are summarised in table 4.5. 
Table 4.5 Healthy volunteer vs IPAH Left atrial strain rate  
 
 
SRe or peak early negative strain rate (corresponding to conduit function) was significantly lower in 
IPAH patients compared to healthy volunteers (-0.39 vs -1.0 p < 0.0001). Results are shown as 
median (interquartile range). IPAH and healthy volunteer groups were compared using Mann-
Whitney U test. A p-value of greater than 0.05 indicated a lack of statistical significance. SRs = peak 
positive strain rate corresponding to reservoir function, SRe = peak early negative strain rate 
corresponding to conduit function and SRa = peak late negative strain rate corresponding to booster 
pump function of the left atrium.  
 
4.3.3.3 Severe vs Intermediate / Mild disease  
Patients were categorised based on cardiac index derived by right heart 
catheterisation. Patients with more severe disease (cardiac index <2) 
demonstrated impairment of εe (5.4 vs 7.6 P=0.0473) and SRe (-0.3 vs -0.47 
p=0.024) compared to patients with less severe disease. Patients with severe 
disease had augmented SRa (-1.3 vs -1.00 p=0.0459). Results are summarised in 
table 4.6. 
  
Strain rate  IPAH Healthy volunteer p value 
SRs 0.99 (0.75,1.31) 1.05 (0.94,1.21) 0.4918 
SRe -0.39 (-0.57,-0.25) -1.0 (-1.2,-0.79) <0.0001 
SRa -1.08 (-1.38,-0.72) -0.97 (-1.24,-0.69) 0.3539 
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Table 4.6 Left atrial strain and strain rate measurements in IPAH patients with severe vs 
intermediate / mild disease.  
 
Strain 
parameter 
Severe disease Intermediate and mild 
disease 
p value 
εs 23.6 (15.8,29.6) 23.3 (17.1,28.4) 0.7701 
εe 5.4 (2.2,7.8) 7.6 (4.5,11.7) 0.0473 
εa 19.6 (12.0,23.5) 14.6 (11.2,20.1) 0.1371 
SRs 1.1 (0.75,1.50) 0.93 (0.73,1.22) 0.2131 
SRe -0.3 (-0.50,-0.17) -0.47 (-0.67,-0.32) 0.0240 
SRa -1.3 (-1.54,-0.80) -1.00 (-1.24,-0.65) 0.0459 
 
Patients with more severe disease demonstrated impairment of εe (5.4 vs 7.6 P=0.0473) and SRe (-
0.3 vs -0.47 p=0.0240) compared to patients with less severe disease. Patients with severe disease 
had augmented SRa (-1.3 vs -1.00 p=0.0459). Disease severity was classified by cardiac index 
derived from right heart catheterisation (cardiac index < 2). Results are shown as mean median 
(interquartile range). The two groups were compared using Mann Whitney U test. A p value greater 
than 0.05 demonstrated a lack of statistical significance. εs = total strain, εe = passive strain and εa 
= active strain, SRs = peak positive strain rate, SRe = peak early negative strain rate, SRa = peak 
late negative strain rate. 
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4.3.4 Association with markers of disease severity 
Left atrial εe demonstrated strongest correlations with known markers of disease 
severity including, RVEF (r=0.41 p=0.0017) and logNTproBNP (r=0.38 p=0.0071) 
and significant but weaker correlations with right heart catheter derived stroke 
volume index. Similarly, SRe demonstrated significant correlations with 
LogNTproBNP (r=0.54 p<0.0001), CO (r=-0.41 p<0.002) and RVEF (r=0.35 p<0.008). 
There were no significant correlations with εs or εa with known markers of disease 
severity. The results are shown in Table 4.7.  
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Table 4.7 Left atrial strain and association with markers of disease severity in IPAH patients 
 
 
 
 
 
 
 
 
 
Left atrial εe demonstrated strongest correlations with RVEF (r=0.64 p<0.0001), LVEDVI (r=0.41 
p=0.0017) and logNTproBNP ( r=0.38 p=0.0071) and significant but weaker correlations with right 
heart catheter derived stroke volume index. Similarly, SRe demonstrated significant correlations with 
LogNTproBNP (r=0.54 p<0.0001), CO (r=-0.41 p<0.002) and RVEF (r=0.35 p<0.008). There were 
no significant correlations with εs or εa with known markers of disease severity.  Spearmen 
correlations were used to assess association between continuous variables as appropriate. LVEF – 
LV ejection fraction, RVEF – RV ejection fraction, LVEDVI -  LV End-diastolic volume index, LVESVI 
– LV End-systolic volume index, RVESVI – RV end-systolic volume index, mPAP – mean pulmonary 
artery pressure, CO – Cardiac output, SVI – Stroke volume index.  
  
 
εs εe εa SRs SRe SRa 
LVEF 0.14 0.02 0.11 -0.05 -0.04 -0.2 
RVEF 0.2 0.41** -0.04 -0.1 -0.35** 0.15 
LVEDVI 0.01 0.28* -0.17 -0.14 -0.19 0.31* 
LVESVI -0.07 0.14 -0.14 -0.04 -0.07 0.28 
RVEDVI -0.25 -0.21 -0.13 -0.1 0.28* 0.08 
RVESVI  -0.24 -0.31* -0.06 0.01 0.32* -0.03 
mPAP -0.28 -0.06 -0.27* -0.18 -0.04 0.03 
CO -0.02 0.26 -0.2 -0.01 -0.41** 0.24 
SVI 0.06 0.37** -0.16 -0.18 -0.26 0.23 
LogNTproBNP -0.09 0.38** 0.09 -0.02 0.54*** -0.15 
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4.4 Discussion 
To best of our knowledge this is the first CMR study of LA function in patients with 
pulmonary arterial hypertension.  
This study demonstrates that the LA function is impaired in patients with PAH 
compared to healthy volunteers. Among the strain indices, conduit function was 
the most affected. Conduit function is the passage of blood to the LV during early 
diastole and is dependent on atrial compliance and related to atrial reservoir 
function but is also affected by LV relaxation. We also noted that in patients with 
more severe disease LV conduit function (and corresponding peak early negative 
strain rate) was affected compared to IPAH patients with less severe disease.   
To explain these findings, it is important to reiterate the significant interplay that 
exist between the LA and the LV and also the direct and series interaction of the 
RV to LV. Under normal conditions the impact of the RV on LV function is 
negligible. However ventricular independency plays an important role in the 
pressure loaded RV in PH. Ventricular interdependency can be affected both by 
parallel and series interaction. Leftward septal bowing hampers filling of the LV 
due to parallel interaction. Lowered RV stroke volume causes a decrease in LV 
filling due to series interaction (149).  
Evidence that inter-ventricular dyssynchrony might play a role in PAH is known. 
This is evidenced on an Electrocardiogram showing a complete or incomplete Right 
Bundle Branch Block (RBBB) pattern. Stojnic et al demonstrated a reduction in 
early diastolic filling of the LV in PH secondary to congenital cardiac disease (201). 
They also demonstrated a prolonged pressure decline in the RV compared to the 
LV. They concluded that early diastolic LV filling impairment is mediated by the 
deformation of the IVS towards the LV cavity in early LV diastole. The significantly 
reduced LA conduit function is likely to be related to impaired early LV relaxation. 
This study also demonstrated, albeit to a lesser extent, impaired LA reservoir 
function in IPAH patients compared to healthy volunteers. This is likely to reflect 
the increased RV afterload and the resultant reduced RV stroke volume. On further 
assessment of patients with severe disease vs intermediate or mild disease, LA 
conduit function was significantly different between the two groups, while LA 
reservoir function was not. Strain rate indices followed a similar pattern 
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demonstrating LA peak early negative strain rate, relating to LA conduit function 
to be the most significantly impaired. 
Interestingly although not statistically significant, LA booster pump function was 
augmented in IPAH patients. As LVEF is preserved, LV filling is maintained by 
increased LA booster pump function in these patients. As discussed earlier in this 
chapter patients with HCM demonstrated a similar increase in LA booster pump 
function and a reduced reservoir and conduit function. The authors in that study 
hypothesised that this may be a compensatory change that is likely to be followed 
by a progressive decrease in global LA performance.  
In PAH patients, series and parallel interaction occur concomitantly causing 
impairment of LV – LA mechanics. Although similar to previous studies focusing on 
LV, our results cannot confirm the dominant mechanism between these two, 
however from the results of our study we can conclude and hypothesise the 
following.  
1. This study demonstrates that the most significantly affected LA index is LA 
conduit function. LA conduit function is related to atrial compliance, 
however significantly affected by early LV relaxation / LV compliance.  
Considering atrial compliance is unlikely to be affected in the absence of 
left heart disease, impaired LA conduit function is likely related to LV 
relaxation. Early LV relaxation is affected by paradoxical septal motion of 
the RV during systole and prolonged RV contraction.  
2. LA conduit function, representing passive movement of blood during early 
diastole and not the LA reservoir function had the significant association 
with known markers of disease severity. LA conduit function was also the 
index that was significantly affected in the severe disease population 
compared to mild disease.   
3. The lack of early LV filling is to a degree compensated by LA booster pump 
function which is augmented in IPAH patients compared to healthy 
volunteers although did not reach a statistical significance. Whether this 
compensatory change is likely to be followed by a progressive decrease in 
global LA performance with disease progression is unknown.  
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Both pharmaceutical agents and mechanical resynchronisation therapy may 
improve inter-ventricular dyssynchrony. Whether these interventions that will 
improve left heart mechanics will improve the disease trajectory in PH patients is 
not completely explored (10).   
Lumens et al developed a computer simulation of severe PAH and showed 
improvements in cardiac pump function with simulated RV free wall pacing (152). 
Hardziyenka et al performed a study that included 14 patients with CTEPH who 
had diastolic inter-ventricular delay as assessed by tissue Doppler 
echocardiography. Temporary sequential RA-RV pacing at the RV apex at the 
optimal atrioventricular interval resulted in an increase in LV outflow tract 
velocity time integral, a reduction in diastolic inter-ventricular delay, reduced RV 
end-systolic area, increased LV end-diastolic area, and significant improvements 
in RV global and longitudinal contractility and LV longitudinal contractility (151). 
It is not yet known whether similar improvements would be seen in other forms of 
PH, or whether acutely improved haemodynamics and LA-LV mechanics would be 
maintained and translate to improved clinical outcomes in the long term. 
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4.5 Conclusion 
This study demonstrates that the left atrial function is impaired in patients with 
idiopathic pulmonary arterial hypertension compared to healthy volunteers. 
Among the strain indices conduit function was the most affected. Conduit function 
is the passage of blood to the LV during early diastole and is dependent on atrial 
compliance but is also affected by early LV relaxation. Parallel interaction from a 
prolonged RV contraction causing impaired early LV relaxation is the likely 
dominant mechanism in the absence of intrinsic left heart disease in this patient 
population. The lack of early LV filling is to a degree compensated by LA booster 
pump function which is augmented in IPAH patients compared to healthy 
volunteers. Further research is needed to explore the impact of pre-existing 
medical therapy and mechanical resynchronisation therapy on LV – LA mechanics.  
It is not yet known whether similar improvements would be seen in other forms of 
pulmonary hypertension, or whether acutely improved haemodynamics would be 
maintained and translate to improved clinical outcomes in the long term. 
4.6 Limitations 
There are several limitations to our study. This was a single centre retrospective 
observational study. There were patients who were diagnosed with IPAH who were 
not included in the study if they did not undergo CMR imaging. This may exclude 
patients with more severe disease who probably did not manage MR due to severe 
breathlessness (breath holding difficulties) and may also exclude patients with 
mild disease who may not be diagnosed till they show significant symptoms. CMR 
feature tracking can be affected by through plane motion artefacts and also is 
limited by pixel size (175, 193). Previous feature tracking strain studies have 
demonstrated significant variability of strain values, mainly due to the lack of 
standardization in signal acquisition and image processing(177). We also didn’t 
study inter-observer reproducibility of left atrial indices.  
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5.1 Introduction 
The differences in LV strain and the presence of LV intra-ventricular dyssynchrony 
in IPAH patients compared to healthy volunteers were discussed in Chapter 3. This 
was despite the conventional measure of LV function i.e. LVEF being preserved. 
Furthermore, IPAH patients with more severe disease demonstrated worse LV 
strain and LV dyssynchrony when compared to patients with less severe disease. 
Interestingly, LV mechanics were associated with known markers of disease 
severity and predicted survival in patients with IPAH and these LV variables were 
probably superior to known RV CMR variables in terms of their ability to reflect 
disease severity and predict survival.  
Many CMR measures have shown to be strongly predictive of mortality and survival 
thus offering potential for monitoring and determining response to treatment in 
PH.  Stroke volume, RVEF and RVEDVI are recognised as the key MR prognostic 
measures in PAH patients (91, 94). In a multicentre study prospectively using CMR 
before and during PAH disease specific treatment, Peacock et al demonstrated 
the importance of including both left sided and right sided variables when 
determining cardiac function (99). Swift et al demonstrated that CMR 
measurements reflecting RV structure and stiffness of the proximal pulmonary 
vasculature to be independent predictors of outcome in PAH (97).   
The advantage of CMR is the ability to achieve high resolution 3D imaging of the 
heart without using radiation. Recently, there have been significant focus on non-
invasive myocardial tissue characterisation.  Longitudinal relaxation time (T1) and 
transverse relaxation time (T2) are central properties of tissue which is 
determined by its molecular make up. T1 relaxation time is defined as the time 
when longitudinal proton magnetization recovers 63% of its equilibrium value 
(169).Late gadolinium enhancement has been the gold standard for determination 
of myocardial fibrosis. This is based on the difference in distribution of contrast 
between normal and fibrotic myocardium. The areas of fibrosis demonstrated a 
shorter T1 time than adjacent normal tissue. Conventionally this method is 
performed using inversion recovery gradient-echo sequences 10-15 minutes after 
gadolinium injection. Retention of contrast within the extracellular space results 
in shortening of the inversion time (T1) and hyper enhancement relative to normal 
myocardium. The main limiting factor when using LGE is that fibrotic process is 
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often a diffuse process thus lacking the normal non-fibrotic myocardium for 
reference. To ameliorate this issue, T1 mapping has been developed to quantify 
diffuse, non-ischemic myocardial fibrosis, as it does not rely on contrasting signal 
intensity.  
Blyth et al used contrast enhanced CMR imaging to determine the presence of LGE 
in PH. They hypothesised that myocardial abnormalities may exist in patients with 
PH, that they could be identified by contrast enhanced CMR imaging and that the 
severity of the contrast enhancement would relate to the severity of PH. LGE was 
present in almost all patients with PH and the extent of contrast enhancement 
was associated with RV volumes, RV function as well as mPAP derived at right 
heart catheterisation. The authors also found LGE to be associated with bowing of 
the interventricular septum and concluded that this may provide a novel marker 
for occult septal abnormalities directly relating to the haemodynamic stress 
experienced by these patients (133). McCann et al found similar results with the 
extent of LGE related to RV function and RV stroke volume. In two other patients 
who had post mortem histological analysis of the RV insertion regions, myocardial 
fibrosis was present suggesting this may be the causal mechanism, however there 
was also evidence of interstitial space expansion and a small increase in fat which 
may have contributed to late gadolinium enhancement. In a study by Freed et al, 
patients with RV insertion point LGE had larger RV volume index, lower RVEF and 
higher mPAP and LGE was a predictor for adverse outcomes (p=0.026) in this 
population (134). In a study by Shehata et al, LGE at RV insertion points were 
observed in almost all patients with PH and LGE was associated with pulmonary 
haemodynamics, reduced RV function and reduced eccentricity index (127). 
Reduced longitudinal strain of the basal anterior septal insertion point was 
independently associated with LGE although the same was not observed for the 
posterior insertion point. The authors suggested that the two insertion regions 
may behave differently as they are part of anatomically and functionally distinct 
regions i.e. RV outflow and inflow tracts. 
There have been numerous T1 based techniques for quantification of fibrosis. The 
modified Look Locker inversion recovery (MOLLI) technique was designed to 
overcome the limitations of motion and prolonged acquisition time (136). Specifics 
included an ability to acquire data within one breath-hold at a designated time 
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within the cardiac cycle and the capability of merging images from multiple Look 
Locker experiments at different consecutive inversion times into one data set. 
MOLLI sequencing employs a balanced steady-state free precession (SSFP) readout 
to achieve a higher signal to noise ratio with a narrow image acquisition period of 
less than 200 ms in end-diastole to minimize motion artefact. In a later study 
Messroghli et al demonstrated high reproducibility of this technique (137). 
Piechnik et al shortened MOLLI sequence (ShMOLLI) that generated immediate, 
high-resolution myocardial T1-maps in a short breath-hold with high precision. 
Other prototype vendor specific sequences have been developed including a 
modified Look-Locker FIESTA technique using saturation-recovery imaging, 
saturation-recovery single shot acquisition (SASHA), and saturation pulse prepared 
heart-rate-independent inversion recovery, which consists of a combination of 
saturation and inversion pulses (131). 
Typically, a series of short axis images are acquired pre contrast and 
approximately 12 minutes’ post gadolinium contrast with between 6 and 12 
consecutively longer inversion times depending on the protocol. Image acquisition 
is usually performed with ECG gating with breath holding at end-inspiration. 
Offline, standard basal, mid-ventricular and/or apical slices are then selected and 
can be further divided into conventional myocardial segments (or discrete regions 
of interest) and blood-pool for analysis if desired. A curve fitting technique is 
employed to reconstruct the consecutively acquired images into one data set from 
which a T1 map of voxels is generated.  
The signal intensity of each voxel directly represents the T1 relaxation time of the 
corresponding myocardial tissue. An exponential recovery curve of signal 
intensities at the different inversion times is then created for each designated 
region of interest (slice or segment) to determine the myocardial T1 relaxation 
time. These can be averaged to extrapolate T1 as an index of diffuse fibrosis, 
where shorter T1 time and higher signal intensity correspond to increased 
gadolinium contrast accumulation within the extra cellular matrix. 
Standardization of myocardial T1 values to non-myocardial tissue (blood) assists 
in minimizing the dynamic features of gadolinium contrast. The ratio of 
myocardial to blood post-contrast T1 values is expressed as the partition 
coefficient. By preceding post-contrast T1 mapping with pre-contrast T1 mapping, 
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myocardial extra-cellular volume (ECV) can similarly be derived (131, 169). This 
pseudo-equilibrium technique employs the reciprocals of myocardial and blood T1 
values pre-contrast and post-contrast and then adjusts for haematocrit to correct 
for the blood contrast volume of distribution. This ECV is expressed as a 
percentage of the total myocardial extracellular space. Gadolinium equilibrium 
between blood and myocardium must be achieved prior to image acquisition to 
enable accurate estimation of ECV.  
Native T1 mapping has the potential to identify both focal and diffuse myocardial 
fibrosis without the need for contrast administration and reflects myocardial 
disease involving the myocyte and interstitium.  
In a study by Sprujit et al, myocardium in IPAH, connective tissue disease 
associated PH and CTEPH patients were characterised using native T1 mapping. 
Native T1 values were determined using regions of interest in the RV and LV free 
wall, RV insertion points and the IVS. In PH patients, native T1-values of the 
interventricular insertion regions were significantly higher than the native T1-
values of the RV free wall, LV free wall and IVS and related to disease severity 
(138). Saunders et al also used regions of interest in the IVS, LV free wall and RV 
insertion points during T1 mapping assessment. Elevated myocardial native T1 was 
found to a similar extent in PH patient subgroups and was independently 
associated with IVS angle. The authors did not find an additive value of native T1 
mapping in the diagnostic and prognostic evaluation of PH patients(139).  In a 
study by Reiter et al, 58 patients with suspected PH were studied with right heart 
catheterisation and CMR imaging (132). LV global, segmental and ventricular 
insertion point (VIP) T1 times were evaluated manually and corrected for blood 
T1. The American Heart Association (AHA) LV segmentation technique was used to 
segment the LV myocardium including RV insertion points. Septal, lateral and 
global VIP T1 times were significantly higher in PH than in non-PH subjects. LV 
eccentricity strongly correlated with VIP T1 time, which in turn was strongly 
associated with T1 times in the entire LV myocardium. Although identification of 
raised native T1 times has been used to identify myocardial histological changes, 
success has been limited due to 
1. The need for visual assessment of the insertion points (Sprujt et al) or, 
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2. The existing AHA segmentation of the LV fails to isolate the regions of RV 
insertion for analysis (Reiter et al) 
The aims of our study were twofold: firstly, to avoid the use of contrast agent 
and, secondly to develop a novel method of myocardial segmentation during T1 
mapping, which isolated the regions of RV insertion points without requiring visual 
assessment. We hypothesised that the regional T1 values would identify 
myocardial abnormalities which relate to markers of disease severity and 
prognosis. Because this technique is non-invasive, we would then be able to use it 
in longitudinal studies. A validation cohort was also studied where ECV fraction 
following Gadolinium was used to dichotomise the T1 changes to cellular and 
interstitial changes. We hoped that this would provide insight into the 
pathophysiological processes underlying RV failure in PH. 
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5.2 Methods 
5.2.1 Patient recruitment 
We identified 130 treatment-naïve patients referred to the Scottish Pulmonary 
Vascular Unit between December 2014 and December 2016. As mentioned in the 
methods chapter, during the diagnostic admission patients underwent 
multidisciplinary evaluation based on right heart catheterisation, 
echocardiography, pulmonary function testing and CT scan of thorax. All patients 
underwent invasive haemodynamic measurements and CMR within 72 hours, gave 
informed consent to undergo these procedures and the study was reviewed by the 
local ethics reviewed committee.  
Five patients were excluded from the study due to previous myocardial infarction 
(which will have an impact on segmental T1 values) and four were excluded as a 
result of poor image quality of the cine images or/and the T1 maps. Of the 
remainder (121), 20 without PH (defined as mPAP < 25 mm Hg during right heart 
catheterisation) were used as controls and were included to provide reference 
values for T1 mapping. A second group (the Validation cohort) of 7 patients with 
known PAH on established treatment underwent CMR imaging with gadolinium 
contrast administration for the validation phase of the study. These subjects did 
not undergo right heart catheterisation. The study design is summarised in Figure 
5-1.  
The Subjects in the treatment naïve cohort were further categorised into WHO 
groups of PH. Idiopathic pulmonary arterial hypertension (IPAH), connective tissue 
disease, congenital heart disease (all group 1), left sided heart disease (group 2), 
hypoxic lung disease (group 3), chronic thromboembolic disease (group 4) and 
miscellaneous causes (group 5).  
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Figure 5-1 The study design.  
We identified 130 treatment-nai ̈ve patients referred to the Scottish Pulmonary Vascular Unit between 
December 2014 and December 2016. All patients underwent invasive haemodynamic 
measurements and CMR within 72 hours. Five patients were excluded from the study due to previous 
myocardial infarction and four were excluded as a result of poor image quality of the cine images 
or/and the T1 maps. Of the remainder (121), 20 without pulmonary hypertension (defined as mPAP 
< 25 mm Hg during right heart catheterisation) were used as controls and were included to provide 
reference values for T1 mapping. A second group (the Validation cohort) of 7 patients with known 
PAH on established treatment underwent CMR imaging with gadolinium contrast administration for 
the validation phase of the study. These subjects did not undergo right heart catheterisation.  
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symptomatic patients 
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PH
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No PH
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5.2.2 CMR imaging  
CMR imaging was performed in the supine position on a 1.5T MRI scanner (Avanto, 
Siemens, Erlangen, Germany). T1 maps were acquired using a MOLLI (Modified 
Look-Locker Inversion Recovery) sequence on a mid-ventricular short axis plane 
with a trigger delay to coincide with systole.  
As mentioned above, previous studies involving patients with PH has used the 
traditional AHA segmentation or visual analysis. However, this existing AHA 
segmentation of the LV fails to isolate the RV insertion regions for analysis. Figure 
5-1-A demonstrates the traditional AHA segmentation in a patient with PAH. The 
RV insertion regions with raised native T1 falls between segments making it 
difficult to identify, quantify and also to monitor longitudinal myocardial changes. 
Thus, a novel segmentation which isolate these regions is required specifically for 
the assessment of PAH patients.  
The LV was segmented using a novel modified AHA segmentation carefully 
excluding blood pool, papillary muscles and trabeculae. S6 was drawn with the 
inferior RV insertion point at its centre and S4 and S6 were defined as RV insertion 
regions (Figure 5-2-B).  
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Figure 5-2  CMR mid ventricular T1 map of a patient with pulmonary arterial hypertension 
The figure demonstrates raised native T1 at RV insertion points (arrows). The image A) uses 
traditional AHA segmentation. The attachment of the RV wall to the LV ( RV insertion points) is used 
to identify and separate the septum from the LV anterior and inferior free walls during the traditional 
AHA segmentation. Image B) demonstrates the novel segmentation proposed which encompasses 
the two insertion points into segments S4 and S6. T1 maps were generated from the individual motion 
corrected T1 relaxation images. The LV was segmented using our modified AHA technique carefully 
excluding blood pool, papillary muscles and trabeculae. Segment 6 was drawn with the inferior RV 
insertion point at its centre. Segment 4 and Segment 6 were defined as anterior and inferior RV 
insertion segments respectively. Segments 1, 2 and 3 represented the LV lateral wall.  
  
A B 
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In the validation cohort, subjects underwent native and post contrast T1 mapping. 
Extracellular volume fraction (ECV) values were calculated from T1 maps acquired 
pre and post contrast calibrated by blood haematocrit. ECV value was calculated 
as ECV = (1-hematocrit) (1/T1 myocardium post contrast – 1/T1 myocardium pre 
contrast) (1/T1 blood post contrast – 1/ T1 blood pre contrast).  
5.2.3 Right heart catheterisation 
Right heart catheterisation was performed during free breathing in the supine 
position with a 7 F quadruple lumen, flow directed balloon tipped Swan – Ganz 
catheter using the internal jugular approach. The method and the measurements 
taken during right heart catheterisation is described in detail in the Methods 
section 2.5.  
5.2.4 CMR imaging analysis 
All CMR images were analysed by the author using the Medis suite analysis software 
(Medis medical imaging systems, Leiden, Netherlands). A second observer (D.B) 
analysed twenty T1 mapping scans for inter-rater agreement. Individual scans 
were coded by number and analysed in batches by the author who was blinded to 
the identity and haemodynamic results of any given subject at the time of 
analysis. RV and LV volumes were determined by manual planimetry of selected 
short axis images, as described previously (166, 167). Particular methodological 
points of note included the deliberate inclusion of trabeculations and papillary 
muscles in all analyses, as discussed by previous authors (167). RV and LV volumes, 
RVEF and LVEF, and RV and LV mass were determined as previously described in 
the Methods section. RV mass was determined as RV free wall mass, the IVS was 
considered part of the LV. Ventricular Mass index (VMI) was determined as RV 
Mass/LV Mass. For correlation analyses, RV and LV volumes were indexed to BSA.  
5.2.5 T1 mapping analysis 
T1 maps were generated from the individual motion corrected T1 relaxation 
images using Qmap (Medis medical imaging systems,Leiden, Netherlands). The LV 
was segmented using our modified AHA technique carefully excluding blood pool, 
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papillary muscles and trabeculae. Segment 6 was drawn with the inferior RV 
insertion point at its centre. Segment 4 and Segment 6 were defined as anterior 
and inferior RV insertion segments respectively and in combination formed the RV 
insertion region. Segments 1, 2 and 3 represented the LV lateral wall (Figure 2). 
Definition of regions with the new myocardial segmentation using a modified AHA 
model is summarised in table 5.1.  
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Table 5.1 Definition of regions with the new myocardial segmentation using a modified AHA 
model. 
 
 
 
5.2.6 Statistical analysis 
All T1 values are given milliseconds. Continuous variables are summarised as 
median and interquartile range due to the small sample size in some groups. 
Categorical variables are summarised as n (%). Pearson or Spearman correlations 
are used to assess association between continuous variables. Normality of T1 
values was assessed using a Kolmogorov-Smirnov test. Inter-rater variability of 
determination of T1 times was calculated from paired measurements of the RV 
insertion regions using an interclass correlation coefficient with a two-way mixed 
model for absolute agreement. Kruskal-Wallis tests were used to compare 
Insertion region T1 values between the WHO groups and patients with no PH. PH 
and non PH patient groups were compared using Mann-Whitney U tests and Fisher’s 
exact tests, where appropriate. Multivariable linear regression models were used 
to determine whether any of haemodynamics, ventricular function, mass, or 
volume finding was independently associated with variations of T1 times.  
Statistical analysis was performed using SPSS (IBM SPSS Statistics) and Graphpad 
Prism (Graphpad Software inc). A p-value of greater than 0.05 indicated a lack of 
statistical significance.  
Segments Definition 
4 and 6 Right ventricular insertion region 
(anterior and inferior segment 
respectively) 
1, 2 and 3 LV lateral wall 
5 Septal segment 
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5.3 Results 
Demographics of the study population are given in table 5.2. There was no 
significant difference between the PH and the non-PH group in terms of gender, 
age, BSA, systemic blood pressure or heart rate.  
 
Table 5.2 Demographics of the study population.  
 
There was no significant difference between the PH and the non PH group in terms of gender, age, 
BSA, systemic blood pressure or heart rate. Results are shown as median (Interquartile range). P 
values are from Mann-Whitney U tests for continuous variables or Fisher’s tests for categorical 
variables. A p-value of greater than 0.05 indicated a lack of statistical significance. BSA – Body 
surface area, TRPG – tricuspid regurgitant pressure gradient, TAPSE – tricuspid annular systolic 
plane excursion, LVEF – LV ejection fraction, RVEF – RV ejection fraction 
 
 
  
 All PH No PH PH vs no 
PH 
n 121 101 20   
Male gender 59 (49%) 54 (54%) 5 (25%)  0.0269 
Age (years) 61(53,70.5)  61(54,70) 64.5(47.8,75) 0.5971 
BSA (m2) 1.9(1.8,2.1) 1.9(1.8,2.1) 1.8(1.6,2) 0.2409 
Systolic BP 129(113,147) 128(111,147) 133(120,152) 0.4542 
Heart rate 73(64,90.5) 73(64,91) 77(64,89)  0.8853 
TRPG(mmHg) 60(47,76) 64(54,80) 32(25,44) <0.0001 
TAPSE (cm) 1.7 (1.4,1.9) 1.7(1.3,2) 1.8(1.7,2) 0.1106 
LVEF 65.1(54.9,71.2) 64.2(54.4,71) 65.6(57.8,74.3) 0.6241 
RVEF  42.9(31.3,53.5) 38.9(28.7,48.6) 53.9(49.5,62.4) <0.0001 
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5.3.1 Treatment naive patient cohort - haemodynamics, ventricular 
volumes, mass and function 
 
Haemodynamics during right heart catheterisation and ventricular volumes, mass 
and function by CMR were evaluated in all subjects (Table 5.3). The PH group 
demonstrated higher pulmonary artery pressures, PVR, and RV chamber dilatation, 
hypertrophy and functional impairment as expected. However, the two groups did 
not differ in terms of cardiac output (and cardiac index) and left sided CMR 
variables.  
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Table 5.3 Haemodynamics during right heart catheterisation and biventricular volumes, 
mass and function determined by CMR for PH and for patients without PH.  
 
 
PH No PH PH vs no 
PH 
n (n=101) (n=20)  
RAP  7(3,10) 4(2.8,8) 0.1047 
mPAP 44(37,52) 18(16,21) <0.0001 
PAWP 8(5,10) 9(6,14) 0.4862 
Cardiac output 4.1(3.2,5.3) 4.2(3.6,5.5) 0.8039 
PVR 8.7(5.6,12.8) 2.5(1.5,3.4) <0.0001 
Cardiac Index 2.2(1.7,2.7) 2.3(1.9,2.8) 0.5873 
SVO2 65.3(57.7,71.8) 73.5(68.4,75.8) <0.01 
LVEDVI 57.5(49,77.7) 63.9(53.7,72.6) 0.3764 
LVESVI 21.7(14.9,28.1) 22.6(14.4,29) 0.7590 
LVEF 64.2(54.4,71) 65.5(57.8,74.3) 0.6241 
LV mass index 49.9(40.5,57.5) 41.5(35.8,46.3) <0.01 
RVEDVI 106(87.8,127.1) 77.6(67.7,105.9) <0.001 
RVESVI 67.3(45.1,90.5) 34.7(27.5,49.2) <0.0001 
RV ejection fraction 38.8(28.7,48.6) 53.9(49.5,62.4) <0.0001 
RV mass Index 28.1(22.9,35.1) 16.8(14.4,23.8) <0.0001 
VMI 0.5(0.3,0.6) 0.3(0.2,0.3) <0.0001 
 
Haemodynamics during right heart catheterisation and ventricular volumes, mass and function by 
CMR were evaluated in all subjects. The PH group demonstrated higher pulmonary artery pressures, 
PVR and RV CMR variables as expected. However, the two groups did not differ in terms of cardiac 
output (and cardiac index) and left sided CMR variables. Results are shown as median (interquartile 
range). PH and non PH patient groups were compared using Mann-Whitney U tests. A p-value of 
greater than 0.05 indicated a lack of statistical significance. RAP – Right atrial pressure, mPAP – 
mean pulmonary artery pressure, PAWP – Pulmonary artery wedge pressure, PVR – Pulmonary 
vascular resistance, SvO2 – mixed venous saturations, LVEDVI – LV end-diastolic volume index, 
LVESVI – LV end-systolic volume index, RVEDVI – RV end-diastolic volume index, RVESVI – RV 
end-systolic volume index, VMI – ventricular mass index 
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5.3.2 T1 analysis Inter-rater variability 
There was excellent agreement between the two observers GJ and DB for RV 
insertion region T1 values (Interclass correlation 0.995; 95%CI 0.992 to 0.999) and 
for global myocardial T1 values (Interclass correlation 0.991; 95%CI 0.975 to 0.996) 
using the novel AHA segmentation proposed earlier in this chapter. The Bland – 
Altman plots for the RV insertion region T1 values as well global myocardial T1 
values are shown in Figure 5-3.  
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A 
 
B 
 
Figure 5-3 Bland Altman plots for interobserver agreement for A) RV insertion region T1 
times and B) global myocardial T1 values using the novel segmentation proposed in the 
thesis.  
There was excellent agreement between the two observers for RV insertion region T1 values 
(Interclass correlation 0.995; 95%CI 0.992 to 0.999) and for global myocardial T1 values (Interclass 
correlation 0.991; 95%CI 0.975 to 0.996) using the novel AHA segmentation proposed earlier in this 
chapter.  Inter-rater variability of determination of T1 times was calculated from paired measurements 
of the RV insertion regions using an interclass correlation coefficient with a two-way mixed model for 
absolute agreement. 
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5.3.3 Relationship between global T1 values, regions and 
segments 
 
The anterior insertion segment T1 values were strongly associated with global 
(r=0.855), inferior insertion segment (r=0.732) and septal segment (r=0.740) T1 
values. The Inferior insertion segment was strongly associated with global 
(r=0.890) and septal segment (r=0.822). Anterior and inferior insertion segments 
showed moderate associations with lateral region values (r=0.628 and r=0.621 
respectively). The Insertion Region T1 values correlated very strongly with global 
T1 values (r=0.935) (Figure 5-4). 
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Figure 5-4 The association between a) anterior insertion segment and inferior insertion 
segment, b) RV insertion region and global myocardial T1 values of the LV. 
The anterior insertion segment T1 values were strongly associated inferior insertion segment 
(r=0.732) T1 values. The Insertion Region T1 values correlated very strongly with global T1 values 
(r=0.935). The Insertion region consists of both anterior and inferior insertion segments. Pearson 
correlations were used to assess association between continuous variables. Normality of insertion 
region T1 values was assessed using a Kolmogorov-Smirnov test. A p-value of greater than 0.05 
indicated a lack of statistical significance. 
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5.3.4 Global, regional and segmental T1 times 
The global T1 times were higher in the PH population compared to non PH controls 
(990.5 vs 960.3, p=0.0022). There was no significant difference between LV lateral 
wall regional T1 times (972.7 vs 958.3, p=0.344) between the PH and non PH 
groups. The Insertion region T1 values was higher in PH compared to non PH (1012 
vs 962.9, p<0.0001). Anterior Insertion segment (1002 vs 948.2, p<0.0001), inferior 
insertion segment (1020 vs 970.2, p<0.0001) and septal segment T1 values (995.2 
vs 962, p=0.0008) were higher in PH compared to No PH (Table 5.4, Figure 5-5. 
and Figure 5-6).  
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Table 5.4 Global, regional and segmental T1 values between PH and non PH patients 
 
 
 
Anterior Insertion segment (1002 vs 948.2, p<0.0001), inferior insertion segment (1020 vs 970.2, 
p<0.0001) and septal segment T1 values (995.2 vs 962, p=0.0008) were higher in PH compared to 
No PH There was no significant difference between LV lateral wall regional T1 times (972.7 vs 958.3, 
p=0.344) between the PH and non PH groups. The LV was segmented using our modified AHA 
technique carefully excluding blood pool, papillary muscles and trabeculae. The inferior insertion 
segment was drawn with the inferior RV insertion point at its centre. Anterior and Inferior insertion 
segments were combined to define the RV insertion region. The septal region completed the 
interventricular septum. Lateral region was defined to contain the LV lateral wall. The PH and no PH 
group for each region or segment is compared by Mann Whitney U test. **** represents p < 0.0001 
and *** represents p<0.001.   
 
  
 
PH No PH PH vs no 
PH 
n (n=101) (n=20)  
Global myocardial  991 (960,1021) 960 (931,986) 0.0022 
RV Insertion Region [(S4 + 
S6)/2] 
1012 (974, 1054) 963 (940,983) <0.0001 
LV Lateral Wall 
[(S1+S2+S3)/3] 
972 (940, 995) 958 (924,994) 0.3444 
Anterior Insertion Segment 
(S4) 
1002 (954,1045) 948 (928,971) <0.0001 
Inferior Insertion Segment 
(S6) 
995 (956,1024) 962 (934,980) 0.0008 
Septal Segment (S5) 1020 (979,1021) 970 (946,998) <0.0001 
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Figure 5-5 Boxplots demonstrating a) Global myocardial T1 values between PH and no PH 
patients b) Insertion region T1 values between PH and non PH groups. 
The global T1 times were higher in the PH population compared to non PH controls (990.5 vs 960.3, 
p=0.0022). The Insertion region T1 values was higher in PH compared to non PH (1012 vs 962.9, 
p<0.0001). The LV was segmented using our modified AHA technique carefully excluding blood pool, 
papillary muscles and trabeculae. The inferior insertion segment was drawn with the inferior RV 
insertion point at its centre. Anterior and Inferior insertion segments were combined to define the RV 
insertion region. The two groups were compared by a Mann Whitney U test. A p-value of greater 
than 0.05 indicated a lack of statistical significance. **** represents p < 0.0001 and ** represent 
p<0.01.  
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Figure 5-6 Boxplots of T1 values between PH and no PH groups grouped according to 
regional and segmental values.  
Anterior Insertion segment (1002 vs 948.2, p<0.0001), inferior insertion segment (1020 vs 970.2, 
p<0.0001) and septal segment T1 values (995.2 vs 962, p=0.0008) were higher in PH compared to 
No PH There was no significant difference between LV lateral wall regional T1 times (972.7 vs 958.3, 
p=0.344) between the PH and non PH groups. The LV was segmented using our modified AHA 
technique carefully excluding blood pool, papillary muscles and trabeculae. The inferior insertion 
segment was drawn with the inferior RV insertion point at its centre. Anterior and Inferior insertion 
segments were combined to define the RV insertion region. The septal region completed the 
interventricular septum. Lateral region was defined to contain the LV lateral wall. The PH and no PH 
group for each region or segment is compared by Mann Whitney U test. **** represents p < 0.0001 
and *** represents p<0.001.   
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5.3.5 WHO groups of PH  
The patients were classified according to the WHO group of PH (1- PAH, 2 – PH 
due to left heart disease, 3 – PH due to hypoxic lung disease, 4- CTEPH, and no 
pulmonary hypertension). There were no patients with group 5 disease in the study 
population. There were significant differences between the groups in global T1 
times (p = 0.0214), however on post hoc analysis the only significant difference 
was found between group 1 and no PH groups (p=0.018). Insertion region T1 times 
were different between the groups (p<0.0001), and significant differences were 
observed in group 1 vs no PH (p<0.0001) and Group 3 vs no PH (p=0.0361). 
However, there were no differences between groups in LV lateral regional T1 
times (Figure 5-7).  
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Figure 5-7 Boxplots of global myocardial T1 values and insertion region T1 values between 
different WHO groups of pulmonary hypertension and symptomatic patients with no PH.  
There were significant differences between the groups in global T1 times (p = 0.0214), however on 
post hoc analysis the only significant difference was found between group 1 and no PH groups 
(p=0.018). Insertion region T1 times were different between the groups (p<0.0001), and significant 
differences were observed in group 1 vs no PH (p<0.0001) and Group 3 vs no PH (p=0.0361). 
Kruskal-Wallis tests were used to compare Insertion region T1 values between the WHO groups and 
patients with no pulmonary hypertension and post hoc analysis was done using a Dunns multiple 
comparison test. A p-value of greater than 0.05 indicated a lack of statistical significance. **** 
represents p < 0.0001 and * represents p<0.05.   
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5.3.6 Haemodynamics at right heart catheterisation and CMR 
findings  
Insertion region T1 values demonstrated moderate correlation with mixed venous 
saturations obtained at right heart catheterisation (r=-0.622), pulmonary vascular 
resistance (r=0.530) and right atrial pressure (r= 0.483). The relationship with 
invasive pressure measurements (sPAP, dPAP, mPAP) was weaker. There were no 
significant correlations between insertion region T1 times and LV volume, mass or 
function measurements by CMR. However, insertion region T1 times correlated 
significantly with RVESVI (r = 0.693), RVEDVI (r =0.632, p<0.0001), RV mass index 
(r=0.619) and RVEF (r=-0.599) measured by CMR (Figure 5-8) (table 5.5 and table 
5.6). 
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Figure 5-8 Associations between a) right ventricular end systolic volume index measured by 
CMR and b) mixed venous saturations obtained during right heart catheterisation and RV 
insertion region T1 values.  
RV insertion region T1 values demonstrated moderate correlation with mixed venous saturations 
obtained at right heart catheterisation (r=-0.622). The relationship with invasive pressure 
measurements (sPAP, dPAP, mPAP) was weaker. RV insertion region T1 times correlated 
significantly with RVESVI (r = 0.693) measured by CMR. Pearson or Spearmen correlations were 
used to assess association between continuous variables as appropriate. Normality of insertion 
region T1 values was assessed using a Kolmogorov-Smirnov test. A p-value of greater than 0.05 
indicated a lack of statistical significance. 
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Table 5.5 Correlation between RV insertion region and global myocardial T1 values and 
haemodynamics during right heart catheterisation.  
 
Pearson or Spearmen correlations were used to assess association between continuous variables 
as appropriate. Normality of insertion region T1 values was assessed using a Kolmogorov-Smirnov 
test. **** represents p < 0.0001 and *** represents p<0.001. RA – right atrial pressure, mPAP – mean 
pulmonary artery pressure, CO – cardiac output, PVR – pulmonary vascular resistance, SvO2 – 
mixed venous saturations.  
 
Table 5.6 Correlation between RV insertion region and global myocardial T1 values and RV 
CMR variables.  
 
Pearson or Spearmen correlations were used to assess association between continuous variables 
as appropriate. Normality of insertion region T1 values was assessed using a Kolmogorov-Smirnov 
test. **** represents p < 0.0001. RVEDVI – right ventricular end-diastolic volume index, RVESVI – 
right ventricular end systolic volume index, VMI – ventricular mass index 
  
 
RA  mPAP  CO PVR Cardiac 
Index 
SvO2 
RV insertion 
Region T1 
.483**** .392**** -.524**** .530**** -.515**** -.622**** 
Global T1 .456**** .351*** -.432**** .439**** -.427**** -.591**** 
 
RVEDVI RVESVI RVEF RV Mass 
Index 
VMI 
RV insertion 
Region T1 
.619**** .693**** -.599**** .619**** .495**** 
Global T1 .535**** .578**** -.497**** .571**** .435**** 
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5.3.7 Subgroup analysis of IPAH  
In patients with IPAH, the association of Insertion region T1 times with markers of 
disease severity including cardiac Index, RV volumes and function were more 
apparent. RV insertion region T1 changes were not associated with pulmonary 
artery pressure in this population (Figure 5-8) (Table 5.7). 
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Figure 5-9 Correlation between a) RV insertion region T1 values and mixed venous 
saturations at right heart catheterisation and b) RV insertion region T1 values and RV end 
systolic volume index by CMR in IPAH patients.  
In patients with IPAH, the association of Insertion region T1 times with markers of disease severity 
including cardiac Index, right ventricular volumes and function were more apparent. RV insertion 
region T1 values were not associated with pulmonary artery pressure in this population. Spearman 
correlations were used to assess association between continuous variables as appropriate  
.  
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Table 5.7 Association between Insertion region T1 times, haemodynamics during right heart 
catheterisation and CMR variables in IPAH patients.  
 
 
RA  mPAP PVR CI SvO2 RVESVI RV Mass 
Index 
RV insertion 
Region T1 
.654**** .189 .569*** -.704**** -.734**** .770**** -.621**** 
 
In patients with IPAH, the association of RV insertion region T1 times with markers of disease severity 
including cardiac Index, RV volumes and function were more apparent. RV insertion region T1 values 
were not associated with pulmonary artery pressure in this population. Spearman correlations were 
used to assess association between continuous variables as appropriate. **** represents p < 0.0001 
and *** represents p<0.001. RA – right atrial pressure, mPAP – mean pulmonary artery pressure, 
PVR – pulmonary vascular resistance, CI – cardiac index, SvO2 – mixed venous saturations, 
RVESVI – right ventricular end-systolic volume index 
 
5.3.8 Multivariable linear regression 
A multivariable linear regression model was used to assess the association between 
RV volume and insertion region T1 times, independently of haemodynamics during 
right heart catheterisation. A model containing RA pressure, pulmonary vascular 
resistance and RVESVI gave an adjusted R-squared value of 0.554 determining 
insertion region T1 values. All were significant predictors of Insertion region T1 
values (Table 5.8). 
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Table 5.8 Multivariable linear regression analysis showing associations between 
haemodynamics during right heart catheterisation, RV structure and insertion region T1 
times. 
 
Variable Regression 
coefficient 
95% CI P-value 
RAP .207 .537 to 3.940 0.010 
PVR .233 0.915 to 4.472 0.003 
RVESVI .407 .595 to 1.2 <0.001 
 
A multivariable linear regression model was used to assess the association between RV volume and 
insertion region T1 times, independently of haemodynamics during right heart catheterisation. A 
model containing RA pressure, pulmonary vascular resistance and RVESVI gave an adjusted R-
squared value of 0.554 determining insertion region T1 values. All were significant predictors of 
Insertion region T1 values.  RAP -  right atrial pressure, PVR – pulmonary vascular resistance, 
RVESVI – right ventricular end-systolic volume index.  
 
5.3.9 Validation cohort 
In the validation cohort of patients with established PAH T1 values were measured 
pre and post Gadolinium enhancement as a measure of ECV fraction. ECV values 
were significantly higher in the RV Insertion region compared to lateral region 
(36.97± 4.4 vs 28.2 ± 5.1, p< 0.05, 95%CI -14.8 to -2.7) (Figure 5-9). ECV values 
demonstrated very good correlation with native T1 values (r=0.71).  
  
176 
 
 
 
  
Figure 5-10 a) ECV map demonstrating raised ECV values in the RV insertion regions, b) 
boxplot of the ECV values in the RV insertion regions in patients with established PAH.  
In the validation cohort of patients with established PAH using Gadolinium enhancement a) ECV 
map demonstrating raised ECV values in the RV insertion regions, b) boxplot of the ECV values in 
the RV insertion regions demonstrating significantly higher values compared to the LV lateral region. 
In the validation cohort, subjects underwent native and post contrast T1 mapping. Extracellular 
volume fraction (ECV) values were calculated from T1 maps acquired pre and post contrast 
calibrated by blood haematocrit. ECV value was calculated as ECV= (1-hematocrit) (1/T1 
myocardium post contrast – 1/T1 myocardium pre contrast) (1/T1 blood post contrast – 1/ T1 blood 
pre contrast). ECV values were significantly higher in the RV Insertion region compared to lateral 
region (36.97± 4.4 vs 28.2 ± 5.1, p< 0.05, 95%CI -14.8 to -2.7). The two groups were compared by 
a Mann Whitney U test. ****represents p<0.0001. (Author’s own image) 
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5.4 Discussion 
This is the first study using a novel myocardial segmentation to identify T1 changes 
from CMR in PH. We believe there are a number of reasons to use this novel 
segmentation rather than the pre-existing AHA segmentation in the focused 
assessment of patients with PH. Firstly, the pre-existing segmentation technique 
fails to isolate the RV insertion points /regions which are the most susceptible to 
deformation in PH. Secondly, the visual assessment of the insertion regions fails 
to identify subtle myocardial changes because it requires manual contouring of a 
region of interest. Finally, myocardial changes may have a prognostic significance 
in PH, and a methodology that is reproducible and not reliant on visual assessment 
is paramount for this use. Thus, we introduced a novel segmentation of the 
myocardium that is feasible, reproducible and, because it does not rely on the use 
of potentially harmful contrast, can be used in longitudinal assessment of this 
population.  
In our study, global native T1 times were significantly higher in patients with PH 
compared to symptomatic patients without PH. However, LV lateral wall regional 
T1 values were not raised in our PH population compared to patients with no PH 
in contrast to Reiter et al (132).  It is important to note that Reiter et al used a 
healthy volunteer cohort as their control population.  
We did not identify significant differences between RV insertion region T1 times 
in different groups of pulmonary hypertension, however, the trend demonstrated 
highest native T1 changes in group 1 followed by group 3 disease, with lower 
native T1 times in the insertion regions in patients with CTEPH. We believe that 
PH independent of its cause, result in changes in RV insertion regions.  
We showed that native T1 changes at the RV insertion regions are associated with 
invasive measurements of disease severity including right atrial pressure, PVR and 
mixed venous saturations. However, the relationship with pulmonary artery 
pressure measurements was weak. In the subgroup of patients with IPAH these 
relationships were more apparent with a lack of association with pulmonary artery 
pressure.  The RV insertion region T1 times were significantly associated with 
changes in RV volume, mass and function measured by CMR. Raised native T1 was 
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an independent predictor of an increased right ventricular systolic index, 
suggesting reduced myocardial contractility resulted by changes in myocardial 
architecture, although the order of the two events isn’t clear. We suggest the 
most likely mechanism to be of progressive RV dilatation and reduced RV 
contractility, shifting the interventricular septum towards the LV, which in turn 
results in increased stress at the interventricular regions; this leads to changes in 
myocardial architecture leading to myocardial fibre disarray and fibrosis.  
We showed that in a subgroup of patients with IPAH, native T1 changes are 
strongly associated with markers of disease severity, including cardiac Index, PVR, 
mixed venous saturations, RV volumes and function but not with mPAP. These 
findings are consistent with previous literature of LGE and its association with 
disease severity in PH.  
Extracellular volume fraction is a marker of myocardial tissue remodelling. Apart 
from amyloid, an increased ECV is most likely due to excessive collagen deposition 
and is a more robust measure of myocardial fibrosis. In the validation cohort of 
patients with established PAH, we identified raised ECV values in the RV insertion 
regions which were consistent with native T1 changes we identified in our 
treatment-naive study population. 
5.5 Conclusion 
We conclude that, 
1. Raised T1 times in RV insertion regions were associated with RV volume, 
mass and function by cardiac MR as well as markers of disease severity 
during right heart catheterisation,  
2. Native T1 mapping (which does not use contrast) is an alternative to late 
gadolinium enhancement in assessment of severity of damage to the heart 
in pulmonary hypertension. Native T1 mapping allows myocardial tissue 
characterisation without the need for a reference area or contrast 
administration and hence can be repeated without concern, for example in 
the long term evaluation of treatment.   
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The main problem with previous attempts to use T1 mapping in PH patients is that 
they used visual regions of interest which do not allow precise repetition. We 
therefore further conclude that this novel myocardial segmentation described in 
our study will identify myocardial histological changes in patients with pulmonary 
hypertension. This will provide an opportunity to use myocardial histological 
characterisation in longitudinal studies in patients with PH and to identify 
treatment related changes in the myocardial tissue architecture in this disease 
population.  
 
5.6 Limitations 
We applied a non-contrast CMR protocol in our treatment-naïve study population, 
thus we were not able to determine LGE of the insertion regions. Post contrast T1 
and ECV values as well as LGE in this patient group, would have provided further 
insight into pathophysiology behind CMR changes in the RV insertion points. 
However, in our validation cohort of patients where T1 mapping was used post 
Gadolinium, we identified similar ECV changes to native T1 changes seen in our 
study population thus suggesting the native T1 changes are likely due to 
myocardial fibrosis rather than an alternate pathology.  
We used a patient population with no pulmonary hypertension, albeit with 
symptoms requiring admission and right heart catheterisation as our control group. 
Although this may be viewed as a study limitation, we PH rather than healthy 
volunteers will be an ideal to way optimise and use T1 mapping techniques during 
clinical use. 
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 Longitudinal cardiac 
changes by CMR in a Sugen-
hypoxia small animal model of 
pulmonary arterial 
hypertension 
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6.1 Introduction 
Small animal (rodent) models are increasingly used to identify pathophysiology as 
well as therapies for PAH with the intention of translating the findings to humans. 
Accurate monitoring of disease in rodents with emphasis on ventricular function 
and with the ability to monitor the disease state without killing the animal is 
needed. The careful categorisation to distinguish PAH from other groups of PH 
(especially PH due to left heart disease) is often overlooked in rodent studies. 
Various small animal models to recapitulate human PH have been produced. Rats 
have the advantage that they display a more profound pulmonary vascular 
response to angiogenic stimuli, although mice have the advantage of being 
genetically modifiable.  
Various rodent models to recapitulate human PAH have been produced. 
Taraseviciene-Stewart et al described the Sugen-hypoxia (SuHx) rat model in 2001 
(156). Based on the fact that VEGF is an important maintenance and 
differentiating factor for vascular endothelial cells, they designed an experiment 
to inhibit VEGF signalling in rats exposed to chronic hypoxia and normoxia. They 
showed that a selective VEGF Receptor-2 (VEGFR-2) inhibitor, SU5416 (Sugen) to 
cause mild PH and pulmonary vascular remodelling in rats exposed to normoxia. 
However, in rats exposed to chronic hypoxia, Sugen caused severe PH associated 
with pulmonary arterial endothelial cell proliferation. The VEGFR-2 blockade 
caused endothelial cell apoptosis, which under chronic hypoxic conditions 
triggered luminal obliterative endothelial cell proliferation.  
Subsequently in 2010, Abe et al showed that SuHx rats demonstrated evidence of 
severe pulmonary arteriopathy including concentric neo-intimal and complex 
plexiform-like lesions which closely resemble plexiform lesions seen in humans 
(157). Subsequently, other groups have attempted to characterize hemodynamics 
in a SuHx model beyond right heart catheterization alone. Vitali et al evaluated 
longitudinal changes in a SuHx mouse model of PH. In this study, 
echocardiographic and invasive measurements were performed after 3 weeks of 
hypoxia and after 10 weeks of recovery in normoxia. Ten weeks in recovery after 
hypoxic exposure, RV systolic pressure had decreased, but remained elevated 
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compared to normoxic controls. However, RV hypertrophy had resolved. They 
observed very few angio-obliterative lesions at the 10 week follow up (158). De 
Raaf et al used telemetry to characterise haemodynamic response in SuHx rats 
and associated these with serial histology. There was severe PH observed in 
response to SuHx but the RV systolic pressure decreased upon return to normoxia 
(however remained elevated compared to controls). There was progressive 
vascular remodelling characterised by progressive intima obstruction (159). Jones 
et al demonstrated a good correlation between M-mode and Doppler Echo vs. right 
heart catheterisation in the monocrotaline rat model (161). In a study by 
Urboniene et al assessing validation of high resolution echocardiography and 
cardiac MR vs high fidelity catheterisation in experimental PH monocrotaline rat 
model, non-invasive measures of RV free wall thickness/mass correlated well with 
post-mortem measurements (160).  
Our group has a proven track record in using CMR imaging to evaluate RV function 
in humans with PAH (99, 104, 133). The same non-invasive and repeatable 
measurements would be of great advantage for the study of rodent models to 
allow a detailed understanding of bi-ventricular structural and functional changes 
that occur during disease progression, to enhance efficacy in translational 
medicine. We investigated whether CMR is feasible in a SuHx rat model of PH. 
Subsequently we investigated the structural and functional changes associated 
with the model during disease progression. Finally, we discussed the suitability of 
the SuHx model for translational studies of the mechanisms of RV dysfunction in 
PAH. 
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6.2 Method 
6.2.1 Ethics 
All experimental procedures were carried out in accordance with the United 
Kingdom Animal Procedures Act (1986) and with the US NIH publication No. 85-23, 
revised 1996, and ethical approval was also granted by the University of Glasgow 
Ethics Committee. Rodents were housed in a 12-hour light dark cycle with access 
to food and water ad libitum. 
6.2.2 Study design 
Male Sprague Dawley rats (three weeks) (n=32) were divided into two groups (n=16 
in each group). Group 1) Sugen-hypoxia - a single dose of subcutaneous Sugen-
5416 (Sigma, UK) suspended in vehicle (20mg/kg)), before being placed in a 
hypobaric chamber (atmospheric pressure 550 mbar) for 2 weeks and then placed 
in normal room pressure (1013 mbar) for 3 weeks whilst PH developed. Group 2) 
Normoxia maintained at normal room pressure for 5 weeks. In each group (n=16) 
half the animals entered the CMR arm of the study (n=8) while the other half 
underwent right heart catheterization for hemodynamic assessment (n=8). 
Animals were assessed at five weeks and eight weeks from the beginning of the 
study. The study design is summarized in Figure 6-1.  
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Figure 6-1 Study design 
Male Sprague Dawley rats (n=32) were divided into two groups (n=16 in each group). Group 1) 
Sugen hypoxia (SuHx) - a single dose of Sugen-5416, before being placed in a hypobaric chamber 
for two weeks and then placed in normal room pressure for three weeks whilst PH developed, 
animals receive control chow throughout. Group 2) normoxic maintained at normal room pressure 
for 5 weeks. In each group half the animals entered the cardiac MRI arm of the study (n=8) while the 
other half underwent right heart catheterization for hemodynamic assessment (n=8). Animals were 
assessed at 5 weeks and 8 weeks from the beginning of the study with right heart catheterization, 
CMR and gross anatomy at autopsy.  
 
6.2.3 In vivo hemodynamic measurements 
Animals were anaesthetically induced with 3% (v/v) isoflurane and then 
maintained at 2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) 
oxygen. Hemodynamic measurements were taken using an ultra-miniature 
Polyimide Nylon catheter capable of measuring ventricular pressure continuously 
(AD instruments spr-869NR, Millar). The catheter was used as per the 
manufacturer’s instructions with the PowerLab 35 Series data acquisition system 
with LabChart Pro and the pressure volume (PV) Loop analysis module. For right 
heart pressure analysis, the catheter was inserted into the jugular vein and guided 
into the RV to measure RVSP.   
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6.2.4 RV hypertrophy and tissue harvest 
RV hypertrophy and tissue harvest was performed as described in the Methods 
section 2.11 
6.2.5 Gross anatomy postpartum 
Gross anatomy postpartum was performed as described in the Methods section 
2.12. 
6.2.6 Pulmonary vascular remodelling 
Pulmonary vascular remodelling assessment was performed as described in the 
methods section 2.13.  
6.2.7 CMR imaging 
CMR imaging was performed in a Bruker Biospec 7-T/30-cm (Bruker Biospin, 
Ettlingen, Germany) system with a gradient coil insert (400 mT/m). Using a 72mm 
transmit birdcage resonator and 4 channel phased array rat cardiac receiver coil. 
Anaesthesia was induced with gas flow at 2–3 l/min, and the isoflurane delivered 
via a vaporizer (Vetamac, Rossville, IN) at 3–4%. The exhaust was connected to 
the Omnicon F/Air device (AM Bickford). After induction, animals were maintained 
at 2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) oxygen. An 
external water jacket was used to maintain a core temperature of 37°C. During 
all procedures, body temperature, ECG, and respiration were monitored (Echo: 
Indus Instruments, Houston, TX; MRI: SA Instruments, Stony Brook, NY; Cath: 
Powerlab, Ad instruments, Colorado Springs, CO). Long and short axis scout images 
were acquired so that short axis images could be planned using a segmented, 
cardiac – triggered FLASH sequence. The images were acquired with a slice 
thickness of 1.5mm ensuring the entire biventricular length is covered. The CMR 
parameters were as follows. Slice thickness-1.50mm, field of View-30.00mm x 
30.00mm, image matrix-192 x 192 pixels, image resolution-156μm x 156μm, Flip 
angle-15 degrees, Echo time-2.50ms, Rep. time-7.02ms, number of frames-25, 
number of averages-6, software version-Paravision 5.1. 
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6.2.8 CMR analysis 
Scans were coded by number and analysed in batches by the author who was 
blinded to the identity and hemodynamic results at the time of analysis. A second 
observer (A.U) analysed 5 scans for inter-rater agreement analysis. Trabeculations 
and papillary muscles were considered as part of the blood pool. The epicardial 
and endocardial borders were manually outlined in end-diastolic and end-systolic 
frames using Qmass (Medis medical imaging systems, Leiden, Netherlands). Stroke 
volume was determined from LVEDV- LVESV. Ejection fraction [(SV/EDV)*100%] 
was also determined. RV and LV masses were determined by manual planimetry 
at diastole. Ventricular mass index was defined as the ratio between RV to LV 
mass, with the IVS considered part of the LV. LV eccentricity index (LVEI) was 
defined as the ratio between maximum anterior-posterior to septal lateral 
diameters of the LV and was measured at both systole and diastole. All ventricular 
volumes and mass measurements were indexed to body surface area (171). 
6.2.9 Statistical analysis 
Ventricular volumes and mass are given as µlcm-2 and mgcm-2 respectively indexed 
for body surface area. Statistical analysis was performed using SPSS (IBM, SPSS 
Statistics, USA) and Graphpad Prism (Graphpad, USA). A significance level of 0.05 
was employed for statistical tests. An analysis of variance test was used to 
compare RV and LV mass, volumes and function between normoxic animals and 
different stages of SuHx. If there was statistical significance a Tukey test was used 
for post hoc analysis. To compare different methods of ventricular mass index 
measurement (CMR vs autopsy) a spearmen correlation was used.  Inter-rater 
variability for determination of LV and RV function were calculated from paired 
measurements of the LVEF and RVEF of two readers as intra-class correlation 
coefficient with a two-way mixed model for absolute agreement. Results are 
shown as mean +/- SD unless otherwise stated. 
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6.3 Results  
6.3.1 Right heart catheterisation and RV hypertrophy  
Compared to normoxic rats (23.87 ± 4.1 mmHg) RVSP was significantly elevated in 
SuHx rats at both five and eight weeks (40.95 ± 15.5 mmHg p=0.03, 48.89 ± 9.6 
mmHg p=0.002 respectively). There were no significant differences in RVSP 
between SuHx rats at five and eight weeks. Similarly, relative RV mass measured 
at autopsy by RV / (LV + septum) was significantly elevated at five week (0.36 ± 
0.1 p=0.021) and eight week (0.4 ± 0.04 p=0.004) SuHx compared to controls (0.25 
± 0.04). Immunohistochemical analysis of α-smooth muscle actin staining in the 
smooth muscle layer of small pulmonary arteries of the lungs demonstrated 
vascular thickening and remodelling at both 5 and 8 weeks of SuHx. Although there 
was statistically significant difference between the percentage of remodelled 
vessels between normoxia and SuHx groups (57.4% ± 7.3 vs 77.6% ± 10.3 p=0.02, 
57.4% ± 7.3 vs 78.5% ± 9.4 p=0.02), there was no significant difference observed 
between SuHx rats at five and eight weeks. (Figure 6-2) 
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Figure 6-2 Right ventricular systolic pressure measured by right heart catheterization (A), 
RV/(LV + septum) by gross weight (B), the percentage of remodelled vessels in a lung 
section (C) and immunohistochemical analysis of α-smooth muscle actin (α-SMA) staining 
in the smooth muscle layer of small pulmonary arteries of the lungs (D - G).   
For right heart pressure analysis, the catheter was inserted into the jugular vein and guided into the 
RV to measure RV systolic pressure (RVSP). Animals were culled, the heart was isolated, atria were 
removed and RV/(LV + septum) were measured to assess RV hypertrophy. Although there are 
significant differences between the normoxic group (n=8) and Sugen hypoxic groups at 5 (n=4) and 
8 weeks (n=4), there were no significant differences in RVSP nor RV/(LV + septum) at autopsy 
between Sugen hypoxia 5 and 8 weeks. Vascular thickening was determined by smooth muscle actin 
antibody (ab5694, Abcam, Cambridge, UK) staining, thickening was characterized by an increase in 
the vessel wall diameter of more than 50% of the arterial wall or complete occlusion. The number of 
remodelled vessels over the total number of vessels present in a lung section was determined. 
Results are shown as mean +/- SEM. ANOVA test was used to compare the three groups, and if 
there was statistical significance a Tukey HSD test was used for post hoc analysis.  * represents p < 
0.05 and ** represents p < 0.01. For immunohistochemical analysis of α-smooth muscle actin (α-
SMA) staining in the smooth muscle layer of small pulmonary arteries of the lung sections were 
viewed at ×200. D and F demonstrate normoxic animals at 5 and 8 weeks while E and G demonstrate 
vascular thickening and remodelling of the pulmonary vasculature (black arrows) in Sugen hypoxic 
rats at 5 and 8 weeks respectively.  
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6.3.2 CMR 
A representative long axis image (A) and a short axis cine stack (B-F) are shown in 
Figure 6-3. The LV and the RV demonstrated good spatial and temporal resolution 
allowing manual planimetry. All of the images in normoxic or SuHx animals were 
suitable for analysis. Initial scout images were acquired to identify the cardiac 
chambers.  
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Figure 6-3 Cardiac MRI short axis image taken from a long axis (A) and a short axis cine 
stack (B – F) of a normoxic Sprague Dawley rat.  
CMR imaging was performed in a Bruker 7T (Bruker, Biospin, Germany) system. Anaesthesia was 
induced by placing the rat in an anaesthesia induction chamber with gas flow at 2–3 l/min, and the 
isoflurane was delivered via a vaporizer (Vetamac, Rossville, IN) at 3–4%. After induction, animals 
were then maintained at 2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) oxygen. 
An external water jacket was used to maintain a core temperature of 37°C. During all procedures, 
body temperature, ECG, and respiration were monitored using a rodent monitoring system (Echo: 
Indus Instruments, Houston, TX; MRI: SA Instruments, Stony Brook, NY; Cath: Powerlab, Ad 
instruments, Colorado Springs, CO). Long axis and short axis scout images were acquired so that a 
true short axis images could be planned using a segmented, cardiac – triggered FLASH sequence. 
The short axis images were acquired with a slice thickness of 1.5 mm ensuring the entire biventricular 
length is covered.  
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6.3.3 Inter-rater variability 
There was excellent agreement between the two observers (ICC 0.97, 95%CI 0.74 
to 1.0) for LVEF as well as for RVEF (ICC 0.96, 95%CI 0.64 to 1.0).  
6.3.4 Right ventricle 
RVESVI was significantly increased in SuHx rats at 8 weeks (0.28 ± 0.04 p=0.003) 
compared to normoxic rats (0.18 ± 0.03). There were no significant differences 
between normoxia and SuHx at five weeks. Compared to normoxic rats (0.17 ± 
0.03), RV mass index was increased in the SuHx rats at five weeks (0.28 ± 0.04 
p=0.002) and eight weeks (0.27 ± 0.04 p=0.002). RV demonstrated progressive 
dilatation (increasing RVEDVI) at eight weeks of SuHx compared to normoxic rats 
(0.75 ± 0.13 vs 0.56 ± 0.1 p=0.022). In RVEF, there were no significant differences 
between normoxic rats and 5 and 8 week SuHx rats however demonstrating trends 
towards impairment (RVEF = 68.3 ± 5.1%, 69.4 ± 6.9% and 62.6 ± 6.1 % 
respectively). SVI was preserved in the SuHx model at five and eight weeks 
compared to normoxia (0.44 ± 0.1 vs 0.5 ± 0.04 vs 0.49 ± 0.1). VMI after five weeks 
(0.34 ± 0.06 p=0.003) and eight weeks of SuHx (0.34 ± 0.06 p = 0.002) were 
significantly higher than normoxic rats (0.21 ± 0.04). (Figure 6-4)  
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Figure 6-4 RV end systolic volume index (RVESVI) (A), RV end diastolic volume index 
(RVEDVI) (B), RV mass index (C), RV ejection fraction (RVEF) (D), Ventricular mass index 
(VMI) (E) and Stroke volume index (SVI) (F).  
Graphs show comparison in normoxia (n=8), 5 week Sugen hypoxia (n=4) and 8 week Sugen hypoxia 
(n=4). RV end diastolic and end systolic volumes and RV mass were determined by manual 
planimetry and indexed to body surface area. RVEF was determined by [(RVEDV-
RVESV)/RVEDV]*100%. A demonstrates progressive increase in RV end systolic volume index 
during the course of sugen hypoxia, while B demonstrates RV dilatation at eight weeks. RV mass 
index (C) was significantly increased in 5 week and 8 week Sugen hypoxia compared to normoxic 
rats. RVEF (D) was preserved however trending towards deterioration at eight weeks. Ventricular 
mass index (VMI) was calculated as the ratio between RV mass to LV mass. Interventricular septum 
was considered as part of the LV. VMI maybe an alternative to RV/(LV + septum) measured at 
autopsy as discussed. Results demonstrated increased VMI at 5 weeks and 8 weeks of Sugen 
hypoxia compared to normoxic rats (E). There were no significant differences in stroke volume index 
(SVI) between normoxia, 5 week Sugen hypoxia and 8 week Sugen hypoxia (F).  Results are shown 
as mean +/- SEM. The groups were compared by ANOVA and if there was statistical significance a 
Tukey HSD test was used for post hoc analysis. * represents p < 0.05 and ** represents p < 0.01. 
 
6.3.5 Left ventricle 
No differences were observed between the normoxic and SuHx groups (normoxia, 
5 and 8 weeks respectively) in terms of LVEDVI (0.73 ± 0.08 vs 0.74 ± 0.06 vs 0.75 
± 0.16), LVESVI (0.29 ± 0.05 vs 0.24 ± 0.04 vs 0.25 ± 0.03), LV mass index (0.79 ± 
0.07 vs 0.82 ± 0.09 vs 0.8 ± 0.15) or LVEF (60.3 ± 7.03 vs 67.8 ± 3.16 vs 66.5 ± 
3.12). (Figure 6-5)  
6.3.6 LV eccentricity index (LVEI) 
LVEI measured at systole was significantly higher in SuHx rats at five weeks (1.2 ± 
0.07 p=0.006) and in SuHx rats at eight weeks (1.22 ± 0.14 p=0.004) compared to 
normoxic rats (0.98 ± 0.08).  There were no differences between LVEI at diastole 
between normoxia and SuHx at 5 or 8 weeks (1.06 ± 0.05 vs 1.14 ± 0.04 vs 1.1 ± 
0.06).  (Figure 6-5)  
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Figure 6-5 LV end systolic volume index (LVESVI) (A), LV end diastolic volume index 
(LVEDVI) (B), LV mass index (C), LV ejection fraction (LVEF) (D), LV eccentricity index (LVEI) 
in systole (E) and LV eccentricity index in diastole (F)  
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Graphs are shown in normoxia (n=8), Sugen hypoxia at 5 weeks (n=4)  and  Sugen hypoxia at 8 
weeks (n=4).  LV end diastolic and end systolic volumes and LV mass were determined by manual 
planimetry and indexed to body surface area. LVEF was determined by [(LVEDV-
LVESV)/LVEDV]*100%. There were no significant differences between the normoxic group and 
different stages of sugen hypoxia in LVESVI, LVEDVI, LV mass index and LVEF. Left ventricular 
eccentricity index (LVEI) was defined as the ratio of the anterior-inferior and septal-posterolateral 
cavity dimensions at the mid-ventricular level and was measured at both systole (E) and diastole (F). 
Although there were no significant differences between the three groups in the LVEI in diastole, LVEI 
was higher in both sugen hypoxic groups compared to normoxia in systole. Previous human studies 
had demonstrated LVEI in systole to correlate with pulmonary hypertension. The groups were 
compared by ANOVA and if there was statistical significance a Tukey HSD test was used for post 
hoc analysis. Results are shown as mean +/- SEM. ** represents p < 0.05. 
 
6.3.7 Autopsy vs CMR in the measurement of RV hypertrophy 
CMR images taken from a normoxic and SuHx animal and light microscopy images 
of the same animals at autopsy were compared. Although both techniques could 
visually demonstrate ventricular size and wall thickness (hypertrophy), CMR 
demonstrated functional aspects of RV contraction including septal flattening and 
paradoxical septal motion during systole in SuHx animals. Figure 6-6 demonstrates 
short axis CMR images (A, B and C) and light microscopy images (D and E) of short 
axis sections of the same rat hearts at autopsy. B and C demonstrates a SuHx 
animal at the same short axis at diastole (B) and systole (C). The SuHx animal 
demonstrated a significantly dilated and hypertrophied RV with paradoxical septal 
motion at systole. There was very good correlation between VMI measured by CMR 
vs autopsy (Spearmen r = 0.8328 95% CI 0.5633 to 0.9422 p < 0.0001). However, 
CMR images demonstrate functional aspects of RV contraction including septal 
flattening and paradoxical septal motion during systole due to RV pressure 
overload.   
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Figure 6-6 Cardiac MR images (A – C) and light microscopy images (D and E) of short axis 
sections of rat hearts.  
A and D demonstrate a normoxic rat. B, C and E demonstrate a Sugen hypoxic rat. B and C 
demonstrates the same animal short axis at diastole (B) and systole (C).  F demonstrates the 
correlation between RV hypertrophy assessed by weighing RV and LV+S at autopsy and by 
ventricular mass index by CMR in normoxic rats and sugen hypoxic rats. There was very good 
correlation between VMI measured by CMR vs autopsy (Spearman r = 0.8328). However, CMR 
images demonstrate functional aspects of RV contraction including septal flattening and paradoxical 
septal motion during systole (C) due to RV pressure overload.  
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6.4 Discussion 
To best of our knowledge, this is the first study demonstrating longitudinal 
biventricular mass, volume and function in a PH animal model using CMR. Previous 
studies had used echocardiography to examine biventricular function and 
structure in small animal models of PAH (158). Previous CMR studies used phase 
contrast imaging but did not explore LV and RV volume and functional variables 
known to be prognostic in PH, nor look at longitudinal changes (160).  
Our study demonstrated the feasibility of CMR in a small animal model of PAH with 
good spatial and temporal resolution and excellent inter-observer reproducibility. 
The future advantage of CMR over cardiac catheterization and autopsy is the 
ability to perform imaging serially on the same animal to look at disease 
progression and response to treatment without killing the animal.  
The main cause of morbidity and mortality in patients with PAH is RV failure. It 
had been assumed that the cause of RV dysfunction was alterations to the 
pulmonary vasculature and therefore treatment focus had been centred on 
improving pulmonary haemodynamics, with the assumption that improvement in 
RV would follow. However, it is now evident that cardiac response to a given level 
of pulmonary hemodynamic overload is variable but important in the subsequent 
prognosis of these patients (95).  Although traditionally right heart catheterization 
and post mortem studies have been used, there is a need for non-invasive tests of 
RV function in animal models of PAH. In addition, we need to have a better 
understanding of the longitudinal changes in ventricular function in animal models 
of PAH.  Although the RV is the obvious focus of attention, LV dysfunction can 
occur through cardiac interaction as I have discussed in previous chapters thus 
simultaneous evaluation of the LV is important. Echocardiography is widely 
available and can be used to estimate RVSP, however imaging of the RV with its 
complex geometry is difficult.  
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6.4.1 The SuHx small animal model – PH  
Plexiform lesions in the pulmonary vasculature are known to be the hallmark of 
PAH and attempts have been made to establish an animal model that closely mimic 
human disease. The major limitation of other animal models of PH such as chronic 
hypoxia and the monocrotaline rat model is that they do not develop occlusive 
neotintimal and plexiform lesions that are seen in human disease. The SuHx model 
has been shown to cause severe PH with the development of plexiform lesions. 
We used a SuHx model consisting of an injection of Sugen, 2 weeks of hypobaric 
hypoxia and 3 weeks or normoxia. Dean et al explored the effects of Metformin 
on the development of PH via Aromatase inhibition, a similar SuHx model was used 
(Sugen + 2 weeks of hypobaric hypoxia and 3 weeks of normoxia)(202). The study 
demonstrated similar haemodynamics and RV hypertrophy compared to our study 
population after 8 weeks. In a longitudinal study looking at effects of exercise in 
a small animal model of PH, SuHx rats (sugen + 3 weeks normobaric hypoxia + 
normobaric normoxia), underwent echocardiography and RV/ (LV + septum) 
assessment. Sedentary PH and exercised PH animals had relatively similar RV/ 
(LV+ septum) (0.47+/-0.03 and 0.47+/-0.05) ratio as to our study (203). In a study 
by Long et al, investigating the effects of BMP ligands targeting the BMPR2 
signalling pathway, using a sugen hypoxia rat model, similar RVSP was observed 
at 8 weeks from sugen injection, however demonstrating higher RV/ (LV + 
septum). Abe et al investigated the longitudinal hemodynamic and histological 
changes in the model.  At 13 to 14 weeks after Sugen, the rats had very high RVSP 
(96+/- 11 vs 21) and  severe RV hypertrophy (0.76 at five weeks, 0.74 at 8 weeks 
and 0.74 at 13-14 weeks)(157). In another study by Al-Husseini et al looking at the 
effects of diethylcarbamazine (DEC) on PH, SuHx rats (sugen + 3 weeks hypobaric 
hypoxia + 2 weeks normoxia) demonstrated RVSP of around 60 mmHg (204). Our 
study demonstrated persistent PH as measured by RVSP during right heart 
catheterisation in the SuHx model. The varying degrees of RVSP and RV 
hypertrophy in these studies, is likely related to the duration of exposure to 
hypoxia, however, could also be related to the animal strain, gender and age at 
exposure.  
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6.4.2 The SuHx small animal model – RV function 
In humans with PAH, progressive narrowing of the pulmonary vasculature causes 
increased load to the RV. The RV adaptation results in increasing wall thickness 
(hypertrophy) and contractility (coupling). Ventriculo-arterial coupling preserves 
stroke volume and ventricular efficiency. The RV then dilates, increasing wall 
stress and oxygen consumption per gram resulting in uncoupling and reduced 
stroke volume (149). In our study, RV hypertrophy was followed by subsequent 
dilatation. However, stroke volume and RVEF were relatively preserved.  This was 
despite the presence of persistently elevated RVSP. We believe this study 
represents the natural history of RV hypertrophy and failure, demonstrating 
compensated RV hypertrophy (adaptive remodelling) before progression into 
maladaptive remodelling with further RV dilatation and RV failure, with reduction 
of RV output.  
6.4.3 Adaptive vs maladaptive remodelling 
Wang et al hypothesized that a SuHx mouse model may capture the transition 
from adaptive to maladaptive RV remodelling including impairment in RV function 
by studying pressure volume measurements in vivo. The results suggested that RV 
remodelling may begin to shift from adaptive to maladaptive with increasing 
duration of SuHx exposure. However, for the duration of SuHx exposure used in 
their study, no drop in cardiac output was observed (205). Similarly, Sutendra et 
al studied the natural history of RV failure from a compensated RV hypertrophy to 
decompensated RV hypertrophy in a monocrotaline rat model of PH by serially 
assessing clinical variables (weight loss, mortality, ascites) (206). We believe that 
our study demonstrates a period of adaptive remodelling of the RV with 
compensated hypertrophy with minimal RV dilatation at later stages of the study. 
By lengthening the exposure to SuHx we may be able to identify the transition 
from adaptive to maladaptive remodelling and identify decompensated right heart 
failure in this model. Most patients present to clinical assessment when there are 
signs of more severe RV dysfunction and in contrast pre-clinical SuHx model 
demonstrate adaptive remodelling at least early in its disease progression. This is 
of importance in the design of pre-clinical studies as intervention with 
experimental therapeutics is likely to occur at this early adaptive stage of disease 
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progression where RV function/stroke volume seem to be preserved despite the 
presence of PAH.   
6.4.4 Small animal model - LV function 
In PAH, impaired LV performance is explained by series interaction of low RV 
cardiac output and direct ventricular interaction due to inter-ventricular 
dyssynchrony and paradoxical septal motion (130, 187). Previous human studies 
have demonstrated that patients with progressive illness demonstrated LV volume 
changes compared to stable patients. Previous echocardiography studies have also 
demonstrated impaired LV strain and torsion in PAH patients (130). We observed 
preserved LV systolic function with preserved LV mass and volume variables in this 
small animal model of PAH. Although PAH animals demonstrated paradoxical 
septal motion of the septum in our study, preserved RV output probably explains 
the preserved LV function. Further studies are required to study LV mechanics in 
detail in small animal models of PAH.  
6.5 Conclusion 
CMR is feasible in a small animal model of PAH and could be used in pre-clinical 
animal studies to explore bi-ventricular structural and functional changes during 
the course of illness. It is likely that the SuHx model demonstrates adaptive 
remodelling to persistently elevated pulmonary pressures which is demonstrable 
by preserved RV function and stroke volume with hypertrophy of the RV. Further 
longitudinal studies are required to assess this model in detail, especially focusing 
on longitudinal RV response. We observed preserved LV systolic function with 
preserved LV mass and volume variables in this small animal model of PAH. 
Although PAH animals demonstrated paradoxical septal motion of the septum in 
our study, preserved RV output probably explains the preserved LV function. The 
search for better animal models of PH continues because our understanding of the 
pathobiology of disease and the development of new therapeutic strategies 
depends on robust animal models, but at present no single model has all the 
features of human disease.  
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6.6 Limitations 
The study assessed rats at 5 and 8 weeks from Sugen exposure, while assessment 
later may have demonstrated worsened haemodynamics and RV variables 
mimicking disease presentation in humans. The rats were anaesthetized with 
Isoflurane, previous studies using halogenated anaesthetics have been shown to 
impair RV-PA coupling, however these effects were seen both in hypoxia and 
hyperoxia (207). Future studies with late gadolinium enhancement data will 
provide further insights into myocardial remodelling in PAH.  
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 General Discussion 
and Conclusions 
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Treatment of pulmonary arterial hypertension has significantly advanced over the 
recent years. A various combination of drugs as well as surgical and interventional 
procedures has improved morbidity and survival in patients with PH (10). The 
hemodynamic diagnosis of PH requires direct measurement of the pulmonary 
artery pressure by right heart catheterisation. However, right heart 
catheterisation is an invasive test and does carry a small risk of morbidity and 
mortality. Diagnostic algorithms have been devised that combines clinical history 
and examination, cardio- respiratory assessment by non-imaging techniques and 
subsequently imaging techniques in patients suspected of having PH (7). The aim 
of these investigations is to establish a probable diagnosis of PH and also to 
identify the likely underlying aetiology. The initial non-invasive tests provide 
information regarding disease severity, prognosis and can also be used to assess 
response to disease modifying treatment. Advancing imaging techniques may also 
help us to understand mechanisms responsible for the pathophysiology of PH in 
both the pulmonary circulation and the RV.   
As pulmonary hypertension is a disease of the pulmonary vasculature and as the 
mortality is associated with RV failure, RV has been the widely studied chamber 
in PH. Although a disease of the pulmonary circulation and the RV, there is now 
evidence demonstrating LV abnormalities in PH (16, 17). The left atrial volume 
has been used in identifying patients with HFpEF (18), however whether the left 
atrial function provides any incremental or addition information regarding cardiac 
function in patients with PAH is unknown. Pulmonary arterial hypertension is a 
rare disease and small animal models are increasingly used to identify 
pathophysiology and therapies for PH with the intention of translating these 
findings to the human disease (19). So far studies involving small animals have 
focused on cardiac catheterisation and less frequently echocardiography to 
monitor disease. Accurate monitoring of disease in rodents with emphasis on 
ventricular function and with the ability to monitor the disease state without 
killing the animal is needed. 
The overall aim of the thesis was to determine if CMR could be used to address 
current issues in the assessment of patients with PAH.  
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7.1 Left ventricular strain and intra-ventricular 
dyssynchrony by CMR in idiopathic pulmonary 
arterial hypertension 
Traditionally measures of RV volumes and function and LV volumes (especially LV 
end-diastolic volume) have been variables monitored during follow up of patients 
with PAH (99). Myocardial strain which is a measure of myocardial deformation 
and measures of ventricular synchrony both by echocardiography and by CMR have 
shown to provide incremental prognostic information in various cardiac diseases 
(181-183).  
Although the impact of the RV on LV function is minimal under normal conditions, 
this does change when it comes to a pressure loaded RV (149). There are both 
parallel and series interactions of the RV on the LV. In PH, the direct effect of the 
paradoxical motion and the bowing of the IVS impairs early diastolic filling of the 
LV. This is due to the prolonged isovolumetric contraction of the RV. The main 
mechanism appears to be increased RV wall tension; RV contraction continues 
while the LV is already in its diastolic phase.  LV filling is also affected by the low 
RV cardiac output. There is also the anatomical consideration of RV dilatation with 
a geometrically restricted pericardial sac. Thus, measures of ventricular 
interaction and interdependency are extremely useful to assess disease severity 
as this not only contains information regarding stroke volume but also increasing 
ventricular wall tension. As mentioned in the introduction, several large studies 
in the past have shown the prognostic value of LV volume variables in PAH 
patients.  
Chapter 3 explored LV mechanics including longitudinal, circumferential and 
radial myocardial deformation and LV intra-ventricular synchrony in patients with 
IPAH to assess the LV mechanics beyond LV volume and function measured by 
LVEF. CMR-FT was used in this study to assess LV strain and intra-ventricular 
synchrony with the advantage being that there is no requirement for additional 
image acquisition or time consuming protocols.  In this study patients with IPAH 
had significant differences in LV strain and demonstrated intra-ventricular 
dyssynchrony of the LV compared to healthy volunteers. This was despite the 
conventional measures of LV function i.e., LVEF being normal. Furthermore, IPAH 
patients with more severe disease demonstrated worse LV strain and LV 
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dyssynchrony when compared to patients with less severe disease. Interestingly 
some of these LV markers of myocardial deformation were superior to known RV 
CMR variables in terms of their ability to reflect disease severity and predict 
survival. The study concluded that LV strain measurements do provide incremental 
and additional prognostic information in IPAH probably as they reflect both RV 
cardiac output and RV wall tension/ septal bowing. The proposed mechanism of 
impairment of LV mechanics is shown in Figure 7-1.   
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Figure 7-1 The proposed mechanism of impaired LV mechanics in pulmonary arterial 
hypertension 
There are both parallel and series interactions of the RV on the LV. In PAH, the direct effect of the 
paradoxical motion and the bowing of the interventricular septum impairs early diastolic filling of the 
LV. This is due to the prolonged isovolumetric contraction of the RV. The main mechanism appears 
to be increased RV wall tension; RV contraction continues while the LV is already in its diastolic 
phase.  LV filling is also affected by the low RV cardiac output. There is also the anatomical 
consideration of RV dilatation within a geometrically restricted pericardial sac. 
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7.2 Left atrial strain by CMR in idiopathic pulmonary 
arterial hypertension 
Left atrial assessment in PH has been limited to measuring the volume or area of 
the left atrium. This is to distinguish PAH from HFpEF (18). There is increasing 
evidence showing LA function assessment providing stronger evidence determining 
cardiovascular outcomes in patients with left sided heart diseases (195, 197). 
Although PAH is partly defined by normal LV filling pressures, LV function/ 
performance can be affected as discussed in detail in Chapter 3. Considering the 
significant interplay that exist between LV and LA, studying LA function will 
provide further insight into left heart dysfunction in PAH.  
Chapter 4 explored LA function assessment in patients with IPAH using CMR-FT. 
This study demonstrated impaired LA strain indices in patients with IPAH 
compared to healthy volunteers. The most significantly affected LA index is LA 
conduit function. LA conduit function is related to atrial compliance, however 
significantly affected by early LV relaxation / LV compliance.  Considering atrial 
compliance is unlikely to be affected in the absence of intrinsic left heart disease, 
impaired LA conduit function is likely related to impaired LV relaxation. Early LV 
relaxation is affected by paradoxical septal motion of the RV during systole and 
prolonged RV contraction.  
LA conduit function, representing passive movement of blood during early 
diastole, demonstrated significant association with known markers of disease 
severity, however, LA reservoir function (related to LV preload) did not. LA 
conduit function was also the index that was significantly affected in the severe 
disease population compared to mild / intermediate disease.  The lack of early LV 
filling is to a degree compensated by LA booster pump function which is 
augmented in IPAH patients compared to healthy volunteers. Whether this initial 
compensatory mechanism subsequently fails and progress into global LA 
impairment is to be explored. The study concluded that future research is needed 
to explore the impact of pre-existing medical therapy and mechanical 
interventions on LV – LA mechanics.  Figure 7-2 shows the proposed mechanism of 
impaired LA mechanics in PAH.  
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Figure 7-2 The proposed mechanism of impaired LA mechanics in pulmonary arterial 
hypertension 
This study demonstrates that the most significantly affected LA index is LA conduit function. LA 
conduit function is related to atrial compliance, however significantly affected by early LV relaxation 
/ LV compliance.  Considering atrial compliance is unlikely to be affected in the absence of intrinsic 
left heart disease, impaired LA conduit function is likely related to LV relaxation. Early LV relaxation 
is affected by paradoxical septal motion of the RV during systole and prolonged RV contraction. LA 
conduit function, representing passive movement of blood during early diastole, demonstrated 
significant association with known markers of disease severity, however, LA reservoir function 
(related to LV preload) did not. LA conduit function was also the index that was significantly affected 
in the severe disease population compared to mild disease.  The lack of early LV filling is to a degree 
compensated by LA booster pump function which is augmented in IPAH patients compared to 
healthy volunteers although did not reach a statistical significance 
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7.3 Non-invasive measurement of myocardial damage in 
pulmonary hypertension by CMR 
Recently there has been significant focus on non-invasive myocardial tissue 
characterisation by CMR. LGE has been the gold standard in determining 
myocardial fibrosis. Although identification of native T1 times has been used to 
identify myocardial changes in PH, this has been limited to the need for visual 
assessment of RV insertion regions as well as due to the failure of the pre-existing 
AHA segmentation in isolating these for analysis (132, 138).  
In Chapter 5, a novel myocardial segmentation to identify T1 changes in PH was 
introduced. There are a number of reasons to use this novel segmentation rather 
than the pre-existing AHA segmentation in the focused assessment of patients with 
PH. Firstly, the pre-existing segmentation fails to isolate the RV insertion points 
/regions which are the most susceptible to deformation in PH. Secondly, the visual 
assessment of the insertion regions fails to identify subtle myocardial changes 
because it requires manual contouring of a region of interest. Finally, myocardial 
changes may have a prognostic significance in PH, and a methodology that allows 
longitudinal assessment is required.  
In this study, RV insertion region native T1 times were significantly higher in 
patients with PH compared to symptomatic patients without PH. The study showed 
that native T1 changes at the RV insertion regions are associated with invasive 
measurements of disease severity including right atrial pressure, PVR and mixed 
venous saturations. Raised native T1 was an independent predictor of an increased 
right ventricular systolic index, suggesting reduced myocardial contractility 
resulted by changes in myocardial architecture, although the order of the two 
events isn’t clear. It is suggested that the most likely mechanism to be of 
progressive RV dilatation and reduced RV contractility, shifting the 
interventricular septum towards the LV, which in turn results in increased stress 
at the interventricular regions; this leads to changes in myocardial architecture 
leading to myocardial fibre disarray and fibrosis.  
In a small group of patient who had ECV mapping, the findings were consistent 
with native T1 mapping. This suggest that the RV insertion region changes seen in 
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native T1 mapping are likely due to myocardial fibrosis. The study concluded that 
native T1 mapping with the novel myocardial segmentation allows myocardial 
tissue characterisation and can be used in the longitudinal assessment of PH 
patients.  
The proposed mechanism of native T1 changes at the RV insertion regions in PAH 
patients is shown in Figure 7-3.  
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Figure 7-3 The proposed mechanism of native T1 changes at the RV insertion regions in 
pulmonary arterial hypertension 
Raised native T1 was an independent predictor of an increased right ventricular systolic index, 
suggesting reduced myocardial contractility resulted by changes in myocardial architecture, although 
the order of the two events isn’t clear. It is suggested that the most likely mechanism to be of 
progressive RV dilatation and reduced RV contractility, shifting the interventricular septum towards 
the LV, which in turn results in increased stress at the interventricular regions; this leads to changes 
in myocardial architecture leading to myocardial fibre disarray and fibrosis.  
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7.4 Longitudinal cardiac changes by CMR in a sugen-
hypoxia small animal model of pulmonary arterial 
hypertension.  
Finally, we studied the feasibility of CMR in a small animal model of PAH and 
explored whether this could be used in pre-clinical animal studies to explore bi-
ventricular structural and functional changes during the course of illness. We also 
investigated the suitability of the Sugen-hypoxia model for translations studies of 
the mechanism of RV dysfunction and ventricular interdependence in PAH. Based 
on the findings, it is likely that the Sugen-hypoxia model demonstrates adaptive 
remodelling to persistently elevated pulmonary pressures which is demonstrated 
by preserved RV function and stroke volume with hypertrophy of the RV. The 
search for better animal models of PH continues because our understanding of the 
pathobiology of disease and the development of new therapeutic strategies 
depends on robust animal models, but at present no single model has all the 
features of human disease.  
7.5 Future Directions 
Further research is needed to explore the impact of pre-existing medical therapy 
and mechanical interventions on LV – LA mechanics in patients with PAH. This is 
of importance as unloading the RV and improving LV preload might induce LV 
failure. Thus, the impact of pharmaceutical as well as mechanical interventions 
in PAH patients on the LV mechanics need to be explored in detail in a future 
study. Both the left heart studies discussed in this thesis were retrospective 
studies conducted in a heterogeneous population of patients. A multicentre study 
is required in a carefully selected patient group to confirm the findings in this 
thesis but also more importantly to identify changes in the LV strain variables with 
disease progression and treatment.  
Non-invasive myocardial tissue characterisation is a unique advantage of CMR over 
other imaging modalities. Future studies should focus on exploring myocardial 
mechanics contributing to tissue changes that was seen at RV insertion regions. 
Although not explored in the study, feature tracking CMR could be used to assess 
whether LV / RV strain is associated with these changes in the RV insertion regions. 
Also of interest in a future study would be to identify longitudinal changes that 
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occur in the RV insertion regions with disease targeted pharmaceutical therapy as 
well as mechanical interventions.  
The advantage of CMR in translational research is the ability to accurately monitor 
disease in rodents with emphasis on ventricular function and with the ability to 
monitor the disease state without killing the animal. After peer-reviwed 
publication of the small animal CMR study, colleagues at the SPVU have since 
embarked on a study involving small animal CMR and assessing response to disease 
targeted therapy (170). The study is exploring Macitentan treatment and its 
impact on the dysfunctional right ventricle in a sugen-hypoxia rat model of 
pulmonary hypertension using longitudinal repeated CMR in the same animal. It 
would also be of interest to study LV mechanics (LV strain and dyssynchrony) in 
animal models of PH to understand the degree of ventricular interaction compared 
to humans with PH.  
7.6 Limitations 
I have discussed the limitations of individual studies at the end of each chapter. 
It is also important to note that it was not possible to perform sex differences 
analysis in any of the studies performed both in humans and small animals. 
Considering the importance of the topic, future studies on the subject is 
warranted.  
7.7 Final comment 
Non-invasive imaging provides information regarding disease severity, prognosis 
and can also be used to assess response to disease modifying treatment in PH. 
Advancing imaging techniques may also help us to understand mechanisms 
responsible for the pathophysiology of PH in both the pulmonary circulation and 
the RV.  However, focus in this thesis was on measures of ventricular interaction 
and interdependency that are extremely useful to assess disease severity and 
prognosis in PH. The search for better animal models of PH continues because our 
understanding of the pathobiology of disease and the development of new 
therapeutic strategies depends on robust animal models.  
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Appendix 1 LV Strain variables and association with known markers of disease severity.  
 
 
ErrLV was significantly associated with known markers of disease severity including RVEF (r=0.66), RVESVI (r=-0.59), PVR (r=0.51) and SVI (r=0.44). The association 
of longitudinal and circumferential strain with markers of disease severity was significant, however with a weaker strength. Among the LV dyssynchrony indices, radial 
dyssynchrony demonstrated the strongest association with known markers of disease severity (r values RVEF =-0.44, RVESVI=0.46 respectively). Spearman 
correlations are used to assess association between continuous variables. *, **, *** and **** indicates p <0.05, <0.01, <0.001 and <0.0001 respectively. EccLV – LV 
circumferential strain, EllLV – LV longitudinal strain, ErrLV – LV radial strain, RVEF- RV ejection fraction, RVEDVI - RV end-diastolic volume index, RVESVI – RV end 
Systolic Volume, TAPSE – tricuspid annular systolic plane excursion, NTPBNP- N Terminal Brain Natriuretic Peptide RAP – right atrial pressure, mPAP – mean 
pulmonary artery pressure, CO – cardiac output, CI – cardiac index, PVR- pulmonary vascular resistance, SVI- stroke volume index, SvO2- mixed venous saturations 
 
 RVEF RVEDVI RVESVI TAPSE NTPBNP RAP mPAP CO CI PVR SVI SvO2 
ErrLV 0.66**** -0.43*** -0.59**** 0.51**** -0.40** -0.05 -0.15 0.54**** 0.47**** -0.51**** 0.44*** 0.43*** 
EccLV -0.43 0.45 0.49 -0.40 0.16 -0.04 0.18 -0.31 -0.25 0.37 -0.26 -0.28 
EllLV -0.49**** 0.45*** 0.51**** -0.61**** 0.24 0.19 0.27* -0.37** -0.42*** 0.45**** -0.42*** -0.46**** 
Radial dyssynchrony -0.44*** 0.39*** 0.46*** -0.33** 0.40** 0.15 0.07 -0.33** -0.32** 0.28* -0.24* -0.35** 
Circ. dyssynchrony -0.07 0.25* 0.20 -0.37** 0.14 0.10 0.02 -0.12 -0.12 0.14 -0.02 -0.20 
Long. dyssynchrony -0.01 0.22 0.16 -0.30* 0.27* 0.07 -0.06 -0.24* -0.25* 0.15 0.03 -0.27* 
Radial strain rate 0.5**** -0.38** -0.47**** 0.47*** -0.36** -0.03 -0.10 0.46**** 0.40*** -0.41*** 0.31** 0.38** 
Circ.  strain rate -0.30* 0.41*** 0.41*** -0.39** 0.12 -0.07 0.21 -0.28* -0.23 0.36** -0.17 -0.24* 
Long. strain rate -0.32** 0.31** 0.34** -0.45*** 0.02 0.01 0.20 -0.24* -0.31** 0.31** -0.24* -0.30* 
231 
 
 
Appendix 2 RV strain variables and association with known markers of disease severity 
 
 
RV average strain (average of septal and free wall strain) demonstrated strong association with RVEF (r=-0.7), RVESVI (r=0.63) and SVI (r=-0.63). Spearman 
correlations are used to assess association between continuous variables. *, **, *** and **** indicates p <0.05, <0.01, <0.001 and <0.0001 respectively. RVEF- RV 
ejection fraction, RVEDVI - RV end-diastolic volume index, RVESVI – RV end-systolic volume index, TAPSE – tricuspid annular systolic plane excursion, NTPBNP- N 
Terminal Brain Natriuretic Peptide, mPAP – mean Pulmonary Artery Pressure, RAP – Right atrial pressure, CO – cardiac output, CI – cardiac index, PVR- pulmonary 
vascular resistance, SVI- stroke volume index, SvO2- mixed Venous Saturation 
 RVEF RVEDVI RVESVI TAPSE NTPBNP RAP mPAP CO CI PVR SVI SvO2 
Free wall 
strain 
-0.62**** 0.37** 0.56**** -0.68**** 0.38** 0.21 0.08 -0.56**** 0.62**** 0.51**** -0.62**** -0.55**** 
Septum strain -0.53**** 0.32** 0.46**** -0.38** 0.22 0.14 0.02 -0.37** -0.40*** 0.38** -0.45**** -0.48**** 
Average strain -0.70**** 0.44*** 0.63**** -0.64**** 0.41*** 0.22 0.08 -0.59**** -0.60**** 0.57**** -0.63**** -0.59**** 
Free wall 
strain rate 
-0.55**** 0.43*** 0.56**** -0.57**** 0.36** 0.15 0.10 -0.59**** -0.63**** 0.55**** -0.46**** -0.51**** 
Septum strain 
rate 
-0.10 0.13 0.13 -0.16 0.13 -0.13 -0.13 -0.20 -0.22 0.13 -0.09 -0.22 
Average strain 
rate 
-0.55**** 0.38** 0.52**** -0.54**** 0.34** 0.09 0.02 -0.49**** -0.57**** 0.44*** -0.46**** -0.48**** 
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